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Abstract
The flow of genetic information starting from DNA passing through RNA, finally leads
to the formation of protein which have important and inevitable roles in metabolism and
anabolism. Damaged DNA and or RNA developed either due to oxidation, virus, cancer,
mutation, and infection lead to severe undesired side reactions (diseases). Several
methods were developed affecting on protein synthesis all over its stages of synthesis,
from these candidates the antisense methodology which have been observed to bind to
DNA and RNA and inhibit their functions. Another candidate is the use of the strategy
of enzyme inhibitors which have been attracted much attention in medicinal chemistry.
In this thesis we tried to use both mechanisms, the antisense strategy through preparing
novel PNAs, and the strategy of enzyme inhibitors through developing of new
topoisomerase inhibitors.
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In order to assess the hybridization properties of these monomers to complementary
DNA and RNA, thymine isogaPNA monomers 1 (TR) and 2 (TS) were designed and
synthesized. The two monomers were individually introduced into aegPNA sequences
in different positions to form different thymine dodecamers. The results illustrated in
Table 1, show good binding properties to both DNA and RNA.  
Table 1. Tm values of some complexes formed between various PNA oligomers and its
complementary DNA and RNA. 　 
Tm (oC) Tm (oC)
PNA sequences Complex
with　dA12
Complex
with rA12
PNA sequences Complex
with
dA12
Complex
with rA12
H-T12-Lys-NH2
H-T11-TR-Lys-NH2
H-TR-T11-Lys-NH2
H-T9-TRTRTR-Lys-NH2
65
65
65
60
73
67
67
67
H-T11-TS-Lys-NH2
H-TS-T11-Lys-NH2
H-T9-TSTSTS-Lys-NH2
H-TSTSTS-T9-Lys-NH2
61
64
56
58
67
68
63
64
 
Various acetylgalloylbenzamides 3a-f, galloylbenzamides 4a-f, acetylgalloylamino-
Vbenzothiazoles 5a-b, galloylaminobenzothiazoles 6a-b, acetylgalloylaminothiazole 7
and galloyl- aminothiazole 8 derivatives were prepared. Most of these compounds
showed high inhibitory activity against topoisomerase I and topoisomerase II (Table 2).
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Table 2. Topoisomerases I and II inhibitory activities of compounds 3a-f, 4a-f, 5a-b,
6a-b, 7 and 8.
Comp.
#
# of
acetyl
position topo I
inhibition
(IC50, mM)
Comp.
#
# of
hydroxy
topo I inhibition
(IC50, mM)
(topo II)
3a (o)
3b (o)
3
2
3,4,5-
3,4-
4.7
88.0
4a (o)
4b (o)
3
2
0.9 (0.09)
6.4
3c (m)
3d (m)
3
2
3,4,5-
3,4-
11.2
43.2
4c (m)
4d(m)
3
2
1.6 (0.08)
10.0
3e (p)
3f (p)
3
2
3,4,5-
3,4-
8.6
> 100.0
4e (p)
4f (p)
3
2
1.4 (0.08)
2.6 (0.14)
5a
5b
7
3
2
3
3,4,5
3,4-
7.7
> 100.0
> 100.0
6a
6b
8
3
2
3
8.2
16.9
34.4
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I. General Introduction
1The information that enables a cell to live and to divide, giving rise to two identical
daughter cells, is coded on genes. The chemical material of a gene is deoxyribonucleic
acid (DNA) (in some viruses it is RNA). The genetic information for the synthesis of a
particular protein is contained in a gene, a specific stretch of nucleotide sequence in
DNA. DNA must be duplicated in a process called replication before a cell divides. The
replication of DNA allows each daughter cell to contain a full complement of
chromosomes (Fig. 1). DNA replication occurs at polymerization rates of about 500
nucleotides per second in bacteria and about 50 nucleotides per second in mammals.
Several enzymes can affect on the process of replication including DNA polymerase I,
DNA polymerase III and some helicases enzymes such as DNA ligase. For the genetic
information to be expressed, a DNA sequence must first be copied into a strand of RNA.
In this process called transcription in which the antisense (nontemplate) strand used as a
Fig. 1. The central dogma of molecular biology.
2template for the synthesis of a messenger RNA (mRNA) strand that is complementary
to the antisense strand but identical to the information in the sense (template) strand.
Each gene gives rise to many identical mRNA molecules. The mRNA is then
transported from the nucleus to the cytoplasm, where it is translated into the amino acid
sequence of a protein in a process called translation. This unidirectional flow of genetic
information transfer is sometimes called central dogma of molecular genetics(1-3) and
this lead to the formation of protein which have important and inevitable roles in
metabolism and anabolism. Gene expression can be regulated at many of the steps in the
pathway from DNA to RNA to protein(4) as shown in Fig. 2.
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Fig. 2. Control of gene expression.
Damaged DNA and / or RNA caused by either oxidation, virus, cancer, mutation, and
infection have received much attention of medicinal chemistry in order to repair the
undesired side reactions (diseases) caused by these damage agents. The RNA
component of ribosomes (rRNA) is essential for protein synthesis(5) and therefore is an
attractive target for antimicrobial drugs. Indeed, many natural antibiotics disrupt protein
synthesis and most of these appear to act by binding rRNA.(6) Several methods were
developed affecting on protein synthesis all over its stages of synthesis including;
antisense strategy (e.g. PNAs), intercalator (e.g. actinomycin D), alkylating agents of
nucleobase (e.g. nitrosoureas) and inhibition of enzymes (e.g. topoisomerase I and II
inhibitors), etc….especially in the antisense methodology, there is a potent ability for
various genetic therapy because of the direct inhibition of abnormal nucleic acid
sequences by antisense molecules with the complementary sequences. Peptide nucleic
3acid (PNA) which is one of the artificial antisense molecules, is a DNA mimic that has
shown considerable promise as a lead compound for developing gene therapeutic drugs.
PNA is characterized by its ability to block DNA and RNA polymerases and ribosome
progression when bound to DNA or RNA templates(7-9) as well as its high potency to
inhibit the activity of telomerase by binding to its RNA component.(10) Antisense has
been observed to bind to DNA and RNA and inhibit their functions. Some of them have
been showed to inhibit cell growth of cancer and to give effect on cancer mouse and rat
in vivo. A few of them has been applied clinically to cancer patients under phase II.
When artificial antisense agents show no effect on such diseases, the next candidates
come to the strategy of enzyme inhibitors. Inhibition of enzyme functions have been
received much attention so far and many types of such drugs have been developed and
explored to lead to various kinds of inhibitors which are commercially available. On the
other hand, topoisomerases I and II are essential nuclear enzymes that catalyze the
concerted breaking and rejoining of DNA strands. In addition to their normal cellular
functions, both topisomerase I and II enzymes have recently emerged as important
cellular targets for chemical intervention in the development of antitumor drugs.
Examples of these topoisomerase inhibitors are camptothecin, etoposide and
doxorubicin. This year the human genome project has been sequenced and become
more clear.(11) From these background we started our research which was focused on
targeting at DNA, RNA and protein, and inhibit their functions. One is to inhibit the
expression of DNA and RNA by artificial antisense, through developing of new PNA
antisense. Another way is inhibition of enzymatic function by binding small molecules
to them, through the preparation of galloyl derivatives as new topoisomerase inhibitors.
By these two ways we can develop potent drugs which can inhibit the replication of
DNA, transcription of DNA into RNA, translation of RNA and certain enzymes.     
4II. Development of Novel PNAs
52.1. Introduction
6The antisense and antigene strategy for treatment of diseases at the level of gene
expression has attracted wide attention in medicinal chemistry. On transcription, every
gene gives rise to a relatively large number of copies of messenger ribonucleic acid
(mRNA), which is translated into a large number of protein molecules. This is why
inhibition of gene expression ought to be more efficient than inhibition of the resulting
protein product. There are already a number of drugs on the market whose activity is
based on direct interaction with deoxyribonucleic acid (DNA). Many of these
compounds, which are mainly used for chemotherapy, intercalate or bind specifically
only to DNA. On the other hand, it is possible to achieve sequence-specific recognition
of nucleic acids using synthetic oligonucleotides that bind specifically by hydrogen
bonding to complementary nucleic acids. These compounds are called antisense
oligonucleotides based on their binding to the target sequence (sense strand). Zamecnik
and Stephenson were the first to propose in 1978, the use of synthetic antisense
oligonucleotides for therapeutic purposes.(12) With a 13-mer oligonucleotide that was
complementary to the RNA of Rous sarcoma virus they were able to inhibit the growth
of this virus in cell culture. The specific inhibition is based on the specific Watson-Crick
base pairing (Fig. 3) between the heterocyclic bases of the antisense oligonucleotide and
of the viral nucleic acid. The process of binding of the oligonucleotides to a
complementary nucleic acid is called hybridization.
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Various cellular processes can be inhibited depending on where the oligonucleotide
hybridizes on single stranded regions of the DNA or mRNA. A simple model describes
the inhibition of protein biosynthesis by an antisense oligonucleotide being bound to the
mRNA (Fig. 4).  
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Fig. 4. Schematic illustration of (a) Normal gene expression. DNA is transcribed into
mRNA followed by translation to give multiple copies of the protein gene
product; (b) Antisense inhibition. An antisense oligonucleotide binds specifically
to mRNA via Waston-Crick hydrogen bonding whereby it inhibits translation of
mRNA into protein; (c) Antigene inhibition. Transcription is inhibited by the
binding of an antigene oligonucleotide to DNA.
Several requirements needed for the antisense oligonucleotide to be able to inhibit
translation including; (1) stability of the oligonucleotide toward extra- and intra- cellular
enzymes, (2) specific interaction between the oligonucleotide and its target sequences,
(3) stability of the complex formed between the oligonucleotides and its complementary
target sequences under physiological conditions and (4) the ability to penetrate through
the cell membrane.
Once it has reached the cytoplasm, it must bind specifically and with sufficient affinity
to the target mRNA to inhibit its translation into the corresponding protein. Natural
oligonucleotides have been shown to exhibit both antisense and antigene properties in
vitro.(13-15) However, both DNA and RNA are rapidly degraded by nucleases in vivo and
in attempts to overcome this serious obstacle an impressive number of oligonucleotide
analogues have been synthesized during the last two decades including; backbone
modification(16-28), base modification(29-34) and sugar modification.(35-40) Chemical
modifications generally improve the biological stability of oligonucleotides to nucleases
and improve the passage through membranes. On the other hand, these chemical
modifications have an adverse effects on the specificity and binding affinity.
Three practical problems block the application of a modified oligonucleotide as a
therapeutic agent:-
1) Poor uptake into cells.
2) Digestion by cell nucleases.
3) Short life time of the duplex formed.
The recent invention of peptide nucleic acids, PNAs(41), as strong and specific DNA and
RNA binding agents has attracted much attention because of the ease and simplicity of
the scale-up methods for peptide chemistry, in comparison with the synthetic
procedures used for other modified sugar-phosphate backbones. The N-
8aminoethylglycine backbone of the polyamide a gPNA (Fig. 5), carrying nucleobases
through an acetyl linker, was designed from molecular modeling studies as the result of
atom-by-atom replacement of the sugar-phosphate DNA backbone by a polyamide
backbone.(42) PNAs act as excellent structural mimics of DNA/RNA and exhibit strong
sequence specific binding with complementary oligonucleotide sequences following
Watson-Crick base pairing rules, and thus fulfill the primary condition for their
biological application. The relatively high binding affinity of PNAs towards the natural
oligonucleotides is attributed to the lack of the electrostatic repulsion between the
uncharged PNA backbone and the negatively charged sugar-phosphate backbone of the
DNA and RNA(42) and the rigidity of the peptide backbone of PNA which arises from
the SP2 hybridization as well as the presence of tertiary amide linkage.
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Fig. 5. Sugar-phosphate DNA/RNA and aminoethylglycyl PNA backbones.
The main drawbacks of aegPNA are; the relatively poor water solubility(43), poor
cellular uptake of PNAs(44), and that the mixed purine/pyrimidine PNA oligomers bind
to both parallel and antiparallel DNA target sequences with almost equal ability(45,46),
but with the antiparallel binding mode slightly preferred over the parallel mode (the C-
terminus of the PNA is conventionally taken to be analogous to the 3’ end of
DNA/RNA). PNA oligomers bind strongly with highest sequence discrimination to
complementary oligomers of DNA, RNA or PNA itself, and in general the hybrid
thermal stability (Tm) for identical sequences in the following order; PNA-PNA > PNA-
RNA > PNA-DNA (> RNA-DNA) > DNA-DNA.       
 
2.1.1. Strategies for chemical modification of aegPNA
Various attempts for the modifications/substitutions in the PNA backbone, in the
aminoethyl, glycyl or the acetyl segment carrying the nucleobase have been made,
results in chiral PNA and is aimed to achieve selective binding with target
DNA/RNA.(47)　PNAs are suffixed with negatively charged DNA or positively charged
polypeptide sequences at either the C- or the N-terminus. This modification results in
PNA-DNA(44) or PNA-peptide chimeras(48) that have favorable aqueous solubility,
cellular uptake and DNA binding/recognition properties. The PNA sequences have also
9been appended with polyamines(49) to increase the aqueous solubility and improve
binding to the target DNA. Some of these modified PNAs show improved water
solubility, cellular uptake and/or directional binding selectivity relative to pure
aegPNAs, but in most cases exhibit a reduced binding towards the target sequences.
2.1.2. Construction of bridged PNA structures
The reduced entropy loss upon complex formation, can be achieved if the
conformational freedom in aegPNA is constrained by bridging the aminoethyl or glycyl
acetyl linker arms (Fig. 6) to give rise to cyclic analogues with pre-organized structures
without affecting the nucleobase recognition ability through hydrogen bonding.
Additionally, the introduction of chemical bridges into aegPNA to provide cyclic
structures may help in controlling the rotameric populations by fixing the nucleobase
orientation and also in directional selective binding by virtue of the chirality in the
backbone. Such a structural pre-organization approach using additional conformational
constraint has been extremely successful in the case of DNA analogues. Prominent
examples are conformationally locked nucleic acids(50) or conformationally frozen
hexitol(51) and altritol nucleic acids(52) (Fig. 7), which have pre-organized 3’-endo sugar
conformations as prevalent in highly stable DNA-RNA duplexes.      
N
O
B
NH
O
Fig. 6. Possible positions for introduction of methylene or ethylene bridges.
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Fig. 7. a) Locked 3’-endo conformation in LNA; b) Frozen 3’-endo conformation in
hexitol and altritol nucleic acids.  
2.1.3. PNA with five-membered nitrogen heterocycles
Many researchers have exploited trans-4-hydroxy-L-proline for the synthesis of wide
variety of chiral, constrained and structurally pre-organized PNAs (Fig. 8). Depending
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on the construction strategy and the presence or absence of tertiary amine group in the
monomers, the modifications afford either positively charged or uncharged cyclic PNA
analogues.
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Fig. 8. PNA analogues with five-membered pyrrolidine rings.
2.1.3.1. Aminoprolyl PNA
The introduction of a methylene bridge between the b -carbon atom of the aminoethyl
segment and the a ’’-carbon atom of the glycine segment of the aegPNA resulted in 4-
aminoprolyl PNA, with the introduction of two chiral centers (Fig. 9).(53) The
incorporation of single chiral D-trans- and L-trans-prolyl PNA monomeric units in the
PNA oligomers at the N-terminus resulted in discrimination in parallel/antiparallel
binding orientation preferences towards the target DNA sequences. A backbone
combining aegPNA alternating with L-trans-4-aminoprolyl PNA was later shown to
bind to the target sequences with higher affinity than the pure aegPNA oligomers.(54)
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Fig. 9. Prolyl PNA with a ’’- b -methylene bridge.
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2.1.3.2. Gly-pro-peptide PNA
4-Hydroxyproline was used by Lowe et al. for the synthesis of a novel chiral
prolylglycyl PNA. The methylene bridge was inserted between the a ’’-carbon atom of
the glycine unit and the b ’-carbon atom of the nucleobase linker of aegPNA (Fig. 10).(55-
57) The tertiary amide bond in the backbone between proline and glycine units replaced
the aminoethylglycyl backbone. The backbone thus comprised alternate glycine-proline
units, the nucleobase was directly attached to the proline ring by alkylation through the
4-hydroxy function. The oligomer with such a backbone did not bind to the target
sequences and this may be due to the rigidity of the system which may lead to
disfavored recognition for the target sequences. The sequences with aegPNA alternating
with the proline-glycine PNA unit showed reduced binding to the target sequences,
unlike the 4-aminoproline PNA.(54)   
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aegPNA gly-pro-peptide PNA
Fig. 10. Prolylglycyl PNA with a a ’’- b ’-methylene bridge.
2.1.3.3. Aminoethylprolyl PNA, aepPNA
In this type of PNA the a ’’-carbon atom of the glycine unit and the b ’-carbon atom of
the nucleobase linker were joined through a methylene bridge (Fig. 11).(58) The
flexibility in the aminoethyl segment of aegPNA was retained, unlike that in the
proline-glycine PNA. The nucleobase attachment to the pyrrolidine ring was fixed by
virtue of the chirality of C-4, thus removing the possibility of any rotameric populations.
The oligomers comprising 4-(S)-2-(S/R) aepPNA thymine units showed very favorable
binding properties towards the target sequences without compromising the specificity.
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Fig. 11. Aminoethylprolyl PNA with a a ’’- b ’-methylene bridge.
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2.1.3.4. Pyrrolidinone PNA
Another conformationally restricted cyclic PNA analogue was derived from a
pyrrolidinone ring system.(59) A methylene bridge was inserted between the a -carbon
atom of the aminoethyl segment and the b ’-carbon atom of the acetyl linker to the
nucleobase of aegPNA (Fig. 12). The carbonyl group of the nucleobase linker was
retained and was forced to point towards the carboxy terminus of the backbone. The
bridge prevented rotation around the C-N bond of the acetyl segment connecting the
nucleobase residue to the backbone, and pre-organized PNA in a rotameric
conformation prevailing in complexes of PNA with nucleic acids.(60) The oligomers
incorporating the (3S,5R) isomer carrying adenine as a base were shown to have highest
affinity towards RNA in comparison with DNA.   
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aegPNA Pyrrolidininone PNA
Fig. 12. Pyrrolidinone PNA with a - b ’-methylene bridge.
2.1.3.5. Pyrrolidine PNA-II with - ’-methylene bridge
Introduction of a b - a ’-methylene bridge, resulting in another pyrrolidine based PNA
modification (Fig. 13).(61) This should probably ease the rigidity of the direct attachment
of the nucleobase to the pyrrolidine ring, as in the case of the a - b ’-methylene-bridged
pyrrolidine PNA-I or aepPNA. Incorporation of (2R,4S) pyrrolidine PNA monomer in
the center of the aegPNA T8 sequence, was able to bind to the target DNA better than
pure aegPNA, while incorporation of the other isomer (2S,4S) was found to make
destabilization with DNA.    
N
O
NH
B
N
O
B
HN
HN
O
B
HN
O
a '
b
*
*
+
Pyrrolidine PNA-IIaegPNA
Fig. 13. Pyrrolidine PNA-II with a ’- b -methylene bridge.
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2.1.3.6. Aminomethylthiazolidine PNA, amtPNA
A thiomethylene bridge was inserted between the a -carbon atom in the aminoethyl
segment and the a ’’-carbon atom of the glycine segment of the aegPNA, providing
aminomethylthiazolidine PNA, amtPNA.(62) The amtPNA thus constructed restricts
movement in both the aminoethyl and the glycyl segments of the aegPNA (Fig. 14).
The syn and anti isomers of the amtPNA were incorporated into aegPNA sequences in
the central position, the triplex formed with this PNA with both DNA and RNA were
significantly destabilized.
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Fig. 14. Aminomethylthiazolidine PNA, amtPNA.
2.1.4. PNA with six-membered ring structures
2.1.4.1 Glucosamine nucleic acids, GNAs
The binding affinities and selectivities of the oligomers containing GNAs indicated
selective recognition of RNA, the entropy changes were found to be smaller for GNA-
DNA/RNA than for DNA-DNA/RNA(63) (Fig. 15).
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Fig. 15. A six-membered cyclic PNA derived from glucosamine.
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2.1.4.2. Piperidinone PNA
Introduction of an ethylene bridge between the a - and b ’-carbon atoms in the
ethylenediamine and acetyl linkers resulting in a six-membered ring structure as in
pipridinone PNA (Fig. 16).(64) Incorporation of these monomers containing adenine
nucleic acid base into the aegPNA resulted in a large decrease in the duplex stability.
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Fig. 16. Piperidinone PNA with a - b ’-methylene bridge.
2.1.4.3. Morpholino PNA
The attractive morpholino antisense oligomers(65), with high sequence specificity, water
solubility and low production cost, have sparked research into further modifications in
morpholino-based DNA analogues. Set of morpholino analogues with phosphonate ester,
amide or ester linkages between the morpholino nucleoside residues was synthesized
(Fig. 17).(66) Preliminary evaluation indicated that the uridine homo- oligomer with
either amide or ester linkage stabilized the complex with the DNA targets relative to the
DNA-DNA complexes. The adenine homo-oligomers showed destabilizing effects when
complexed with the target homo-thymidine DNA sequences. The amide-linked
morpholino PNAs were better accommodated in the complexes than the ester- or the
phosphonate-linked oligomers.  
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Fig. 17. PNA with morpholino amide and ester backbones.
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2.1.5. APNA and PNA-APNA chimera
An aromatic PNA analogue in which the backbone o-aminophenylbutanoic acid
derivative carries the nucleobase through an ether linkage has been synthesized (Fig.
18).(67) These analogues were designed in order to investigate possible p  stacking
interactions and their stabilizing effects on duplex-triplex structures.(68)
O
B
NH
O
*
Fig. 18. Aromatic peptide nucleic acid, APNA-I.
The aromatic PNA was subjected to further modification by replacing it with another
aromatic N-(2-aminobenzyl)glycine backbone (Fig. 19).(69) The optimum distance of six
s  bonds between the nucleobases along the backbone was extended to seven s  bonds in
this modification. The direct incorporation of aromatic rings in the backbone renders at
least three bonds in the backbone coplanar. Furthermore, the internucleobase distance
was altered by additional methyl substitution in the glycyl segment, affording N-(2-
aminobenzyl)-(R-or S)-alanine or by replacing it with b -alanine, as in N-(2-amino-
benzyl)- b -alanine backbones. The incorporation of these modified units in aegPNA
produced PNA-APNA chimera. The modified oligomers exhibited decreased binding
affinities relative to the pure PNA.
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Fig. 19. APNA-II-PNA chimera.
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2.2. Scope of Investigation
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A large variety of structural modifications of oligonucleotides have been investigated as
an exciting new concept for drug design to modulate the expression of genetic
information by antisense and antigene oligonucleotide. Aminoethylglycine peptide
nucleic acids (aegPNAs) developed by Nielsen and co-workers are oligonucleotide
analogues in which the sugar phosphate backbone is replaced by a peptide
chain.(41,43,45,70a-c) PNA is a very potent DNA mimic capable of hybridization to
complementary DNA, RNA or PNA itself. Therefore many types of nucleotides with
peptide backbone have been synthesized in order to improve the limited solubility and
to investigate the structural flexibility and requirements for nucleic acid recognition
(e.g., introduction of a certain side chain(60a-c) and double bond(72) to peptide backbones,
conversion of carbonyl group to sulfonyl group(73), and construction of ethereal and /or
cyclic structural peptide backbones).(58,74a-c) However, there is no report on the peptide
nucleic acids corresponding to the ‘non-genetic’ 2’,5’-linked oligonucleotide (2’,5’-
isoDNA)(75), which is one of the important candidates to search the effective antisense
oligonucleotides due to the intrinsic selective RNA-binding activity of 2’,5’-isoDNA
(although the hybridization affinity of 2’,5’-DNA or -RNA/ 3’,5’-RNA is somewhat
inferior to that of the 3’,5’-DNA/ 3’,5’-RNA duplex, despite 2’,5’-DNA or -RNA shows
binding selectivity for 3’,5’-RNA over 3’,5’-ssDNA) (Fig. 20). The favorable RNA- and
DNA- binding properties of PNA and the selective binding affinity of 2’,5’-isoDNA to
RNA have led us to design 2’,5’-isoDNA mimic chiral PNAs (isoPNAs) in order to
develop novel PNAs with higher affinity to complementary RNA sequences. An
antisense strategy in which the antisense molecules binding strongly and more
selectively to RNA seems to be one of the most effective gene targeting therapy. This is
attributed to that the selective binding to a specific region in the RNA sequences can
alter several characters in the structure of RNA such as loop and turn forms of the RNA.    
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Fig. 20. Design of 2’,5’-isoDNA mimic peptide nucleic acids.
The sugar phosphate backbone of 2’, 5’-isoDNA consists of a repeating unit of seven
atoms, configurationally and conformationally constrained by the 3’-deoxy-D-ribose
ring. If these seven atoms could be replaced by an isostructural dipeptide unit that
consists of repeating of six atoms glycyl-glycine isoPNA (isoggPNA) or seven atoms
glycyl- b -alanine isoPNA (isogaPNA) (Fig. 20), the new backbone would be amenable
for preparation by automated peptide synthesizer and this may be lead to structural
analogues of isoDNA. In this context, we examined the synthesis and hybridization
properties of PNAs containing novel isogaPNA monomers with glycyl- b -alanine
backbone derived from D and L-aspartic acid, together with the synthesis of isoggPNA
monomer with glycyl-glycine backbone derived from L-serine (Fig. 21).
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Fig. 21. Various isoPNA monomers.
We also studied on the strategy to antiviral agents from some derivatives of PNA
monomers, which are potent isosters of natural nucleoside, in our effort of developing
new PNAs (Fig. 22).
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Fig. 22. Structures of some derivatives of isogaPNA tested as antiviral agents.
2.3. Results and Discussion
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2.3.1. Synthesis of glycyl- -alanine isoPNA (isogaPNA) monomers
The synthesis of glycyl- b -alanine isoPNA (isogaPNA) monomers proceeds through D-
or L-aspartic acids protected with Boc and benzyl groups.
Thymine monomers were prepared as follows (Scheme 1). Compounds 1 and 7 could be
reduced in a rapid and convenient method under mild conditions to its corresponding
alcohols 2 and 8.(76) Treatment of compounds 1 and 7 with equimolar amounts from N-
methylmorpholine and ethylchloroformate in dry THF at –10oC for 5-10 minutes under
argon gas gave the corresponding mixed anhydrides as intermediate. Treatment of these
mixed anhydrides with sodium borohydride in MeOH at 0oC for 10 minutes followed by
another 10 minutes at room temperature gave the corresponding alcohols 2 and 8 in
60% and 62% yields, respectively. Coupling between alcohols 2 and 8 with N3-
benzoylthymine under Mitsunobu condition(77,78) in the presence of N,N-diethyl
azodicarboxylate and triphenylphosphine in dry THF under argon gas at 0oC for 1 hour
followed by overnight stirring at room temperature afforded compounds 3 and 9 in 45%
and 44% yields, respectively. Treatment of compounds 3 and 9 with 3N HCl in EtOAc
at room temperature for 2 hours(79) afforded the HCl salt of compounds 4 and 10,
respectively. In this reaction removal of both Boc and benzoyl groups was observed,
neutralization of the HCl salt with 5% NaHCO3 gave compounds 4 and 10 in 70% and
75% yields, respectively. Coupling between compounds 4 and 10 with equimolar
equivalent from Fmoc-glycine, in the presence of TBTU, HOBt and DIEA in DMF
afforded compounds 5 and 11 in 65% and 66% yields, respectively. Finally deprotection
of the benzyl group of compounds 5 and 11 was carried out using 1,4-cyclohexadiene
and 10% Pd/C in MeOH successfully gave Fmoc-glycyl-b -alanine(thymine) PNA
monomers (R and S form) 6 and 12 in 65% and 62% yields, respectively (Scheme 1).(80)
Adenine monomer was also prepared in a similar method for the preparation of thymine
monomer 6 (Scheme 2). Coupling of the alcohol 2 with N6-benzoyladenine under
Mitsunobu condition in the presence of N,N-diethyl azodicarboxylate and triphenyl-
phosphine in dry THF under argon gas at 0oC for 1 hour followed by overnight stirring
at room temperature afforded compound 13 in 45% yield.(77) Removal of the Boc moiety
from compound 13 was carried out by stirring with TFA/CH2Cl2 (1:1) at 0
oC for 1 hour
followed by stirring at room temperature for 6 hours.(81) Neutralization of the TFA salt
with 5% NaHCO3　gave a crude compound which was used directly for the next step
without purification. Coupling between this crude compound and Fmoc-glycine in the
presence of TBTU and TEA in CH3CN afforded compound 14 in 65% yield.
(82) Finally
debenzylation of compound 14 was carried out using hydrogen gas and 10% Pd/C
provided the Fmoc-glycyl-b -alanine(adenineBz) PNA monomer 15 in 50% yield
(Scheme 2).(83)
All of the prepared compounds were identified by their melting points, IR, 1H-NMR,
13C-NMR, mass spectrum, elemental analysis and angle of optical rotation.
21
COH
BocHN
OMeN , ClOEt
BocHN
COEt
NaBH 4, MeOH
BocHN
OH
BzN
N
H
O
O
Ph 3P, THF BocHN H2N
HN
N
O
O
Fmoc-Gly, TBU
HN
N
O
O
N
H
HN
N
O
O
MeOH
BocHN
COH
OMeN
, ClOEt
BocHN
COEt
NaBH 4, MeOH
BocHN
OH
BzN
N
H
O
O
Ph 3P, THF
BocHN
N
BzN
O
O
H2N
HN
N
O
O Fmoc-Gly, TBU
HN
N
O
O
HN
N
O
O
MeOH
(44% ) HOBt, D IEA, DM F
THF, -10oC
, DEAD
(60% )
(45% )
 3N  HCl, E tOAc1)
2) 5%  NaHCO 3
(70% ) (65% )
, 10%  Pd-C
(65% )
1 2
3 4
5 6
THF, -10oC
, DEAD
(62% )
 3N  HCl, E tOAc
2) 5%  NaHCO 3
(75% ) (66% )
, 10%  Pd-C
(62% )
7
8
9 10
11 12
1)
HOBt, D IEA, DM F
O
FmocHN
N
H
O
FmocHN COHCOBn
N
H
O
FmocHN COH
N
H
O
FmocHN COBn
COBnCOBn
COBnCOBnCOBn
COBnCOBn
COBnCOBnCOBn
N
BzN
O
O
Scheme 1. Synthesis of thymine isogaPNA monomers (R and S).
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2.3.2.　Synthesis of glycyl-glycine isoPNA (isoggPNA) monomer
The synthesis of thyminylmethylglycine 21 is the key step for the preparation of
thymine isoggPNA monomer 24. Attempts for the coupling of L-serine with N3-
benzoylthymine(84) under the Mitsunobu conditions, previously applied to the coupling
between hydroxymethylalanine and N3-benzoylthymine in the preparation of isogaPNA
monomers, were proven to be unsuccessful (the starting material N3-benzoylthymine
was recovered). The coupling using the tosylated compound 19, prepared by the
reaction of 18 with p-toluenesulfonyl chloride in pyridine(85) and N3-benzoylthymine
under basic conditions but unfortunately, did not proceed well (tosylation of Boc-ser
methyl ester underwent facile b  elimination at the tosylated position to give methyl
acrylate compound). To this extent, compound 19 was converted to the corresponding
iodide 20 using sodium iodide in dry acetone.(85) The iodide compound 20 was further
reacted with N3-benzoylthymine under basic conditions, afforded compounds 21 and 22
in 68 % and 11 % yields successfully after flash silica gel chromatography and
subsequent recrystallyzation. Removal of the Boc group of 21 using conc. HCl in
dioxane(86) followed by coupling with Fmoc-glycine in the presence of TBTU gave
compound 23 in 74% yield. Finally reductive cleavage of the benzyl ester of 23 was
carried out using H2 gas and 10% Pd-C gave thymine isoggPNA monomer 24 in 87%
yield (Scheme 3).(83)
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2.3.3.　Solid-phase synthesis of thymine isogaPNA oligomers
In order to assess the hybridization properties of thymine isogaPNA monomers 6 and 12
to complementary DNA and RNA, the two monomers were individually introduced into
aegPNA sequences in different positions to form various thymine dodecamers, in
addition to another two thymine dodecamers that consist only from complete isogaPNA
monomers 6 and 12 (Table 1). The preparation of these oligomers was carried out using
automated synthesis on an expedite 8909 (Applied Biosystems, Foster city, CA, USA)
(Fig. 23) which can offer a routine method for producing PNAs on relatively small (2
m M) scale and standard Fmoc chemistry on Fmoc–XAL PEG-PS resin. L-Lysine was
introduced at the C-terminus of the PNAs to reduce their self aggregation and to ensure
adequate water solubility.(41) The monomers were coupled by activation with HATU in
DMF/NMP (1/1). After the final coupling, Fmoc-group was removed by 20% piperidine
in DMF and cleavage of the PNAs from the resin was performed using TFA/m-cresol
(4/1).
Table 1. Various oligomers of aegPNA and isogaPNA thymine monomers.
PNA sequences
25
26
27
28
29
30
31
32
33
34
35
36
37
38
H-T12-Lys-NH2
DNA T12
H-T11-TR-Lys-NH2
H-TR-T11-Lys-NH2
H-T9-TRTRTR-Lys-NH2
H-TRTRTR-T9-Lys-NH2
H-T6-TR-T5-Lys-NH2
H-TR12-Lys-NH2
H-T11-TS-Lys-NH2
H-TS-T11-Lys-NH2
H-T9TSTSTS-Lys-NH2
H-TSTSTS-T9-Lys-NH2
H-T6TS-T5-Lys-NH2
H-TS12-Lys-NH2
25
T = thymine aegPNA monomer; TR = thymine isogaPNA monomer (6); TS =thymine
isogaPNA monomer (15).
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 D M F
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  deprotect
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 20% piperidine
       in DMF
    7  minutes
W a sh
 D M F
  5 eq.  DIEA,  7.5 eq. lutidine,
5 eq. monomer and  4.5 eq. HATU
          in NMP /DMF  (1/1)
               15 minutes
W a sh
 D M F
  acetic anhydride,
2,6-lutidine in DMF
        5 minutes
The preparation of these monomers was carried out using 
automated synthesis on an  Expedite 8909
                                        (Applied B iosys tems)
Fig. 23. PNA synthesis cycle.
The crude products were purified by C18-reverse-phase HPLC using gradients of 0.1%
TFA in acetonitrile. The purity of the oligomers was rechecked by HPLC and
characterized by Mass specteral analysis (matrix-assisted laser desorption ionozation
time-of-flight mass spectrometry) (MALDI-TOF)(87), which gave a signal for the
expected molecular weight (3338.90 (observed) versus 3338.34 (calculated)) (Fig. 24).
Fig. 24. MALDI-TOF mass analysis
of PNA oligomers.
2.3.4. 　 Hybridization property of
thymine isogaPNA oligomers
The hybridization properties of PNA
oligomers 27-38 with its
complementary DNA and RNA were
investigated by UV thermal melting
experiments (Tm) at 260 nm and the
Tm results of these oligomers was compared with those formed with an unmodified
thymine aegPNA 25 (Table 2. entry 1) and with those which formed with DNA T12 26
(Table 2. entry 2). These results show that; aegPNA T12-Lys-NH2 control strand 25 gave
Tm values of 65 and 73oC when hybridized to complementary dA12 and rA12,
respectively (Table 2, entry 1). Natural DNA T12 26 gave Tm values of 32 and 27
oC
26
when hybridized to dA12 and rA12, respectively (Table 2, entry 2). PNA dodecamer 27,
28 with a single isogaPNA (TR) unit in either the C- or the N-terminus of the PNA
dodecamer gave the same Tm values of 65 and 67oC when hybridized to complementary
dA12 and rA12, respectively (Table 2, enteries 3 and 4). PNA dodecamer 29 which
contains three units of isogaPNA (TR) towards C-terminus of the PNA dodecamer gave
Tm values of 60 and 67oC when hybridized to dA12 and rA12, respectively (Table 2,
entry 5). While the PNA dodecamer 30 which contains three units of isogaPNA (TR)
towards the N-terminus of the PNA dodecamer gave Tm values of 59 and 62oC when
hybridized to dA12 and rA12, respectively (Table 2, entry 6). Incorporation of a single
isogaPNA (TR) unit in the middle of the PNA dodecamer, PNA dodecamer 31 gave Tm
values 53 and 56oC when hybridized to complementary dA12 and rA12, respectively
(Table 2, entry 7). Unfortunately no thermal melting transition was observed with the
PNA dodecamer which consists mainly from 12 units of isogaPNA (TR) 32 when
hybridized either with the complementary dA12 and rA12, respectively (Table 2, entry 8).
The above data of the PNA dodecamers 27-32 imply decreased Tm values of 1.5oC, 2oC
and 12oC for fragments 29, 30 and 31, respectively, calculated from the unmodified
aegPNA dodecamer 25 complex with DNA (see Table 2 enteries 5, 6, 7 vs. 1), and
decreased Tm values of  6oC, 6oC, 2oC, 3.5oC and 17oC) for fragments 27, 28, 29, 30
and 31, respectively, calculated from the unmodified aegPNA dodecamer 25 complex
with RNA (see Table 2 enteries 3, 4, 5, 6, 7 vs. 1). However, the incorporation of one
and three isogaPNA (TR) into the dodecamers 27-31 resulted in significant close Tm
values (_ _Tm 2-3oC) observed between the PNA dodecamers 27-31 DNA complexes
and the corresponding PNA dodecamers 27-31 RNA complexes, contrary to the
characters that aegPNA and isoDNA hybridize with RNA preferentially.
Table 2. UV thermal melting data (Tm values) of complexes between PNAs 25-38 and
complementary DNA and RNA.
                        Tm (oC)a
Entry Compound
#
Complex
with dA12
Complex
with rA12
D Tm (RNA
vs.DNA) (oC)
D Tm/mod. (oC)
1
2
3
4
5
25
26
27
28
29
65
32
65
65
60
73
27
67
67
67
8.0
-
2.0
2.0
7.0
-, (-6.0)f
-, (-6.0)f
(-1.5)e, (-2.0)f
27
6
7
8
9
10
11
12
13
14
30
31
32
33
34
35
36
37
38
59 (50)b
53 (44)c
ndd
61
64
56
58 (56)b
46 (39)c
nd
62
56
nd
67
68
63
64
53
nd
3.0
3.0
-
6.0
4.0
7.0
6.0
7.0
-
(-2.0)e, (-3.5)f
(-12.0)e, (-17.0)f
-
(-4.0)e, (-6.0)f
(-1.0)e, (-5.0)f
(-3.0)e, (-3.5)f
(-2.5)e, (-3.0)f
(-9.0)e, (-20.0)f
-
a The Tm was measured at a ratio of PNA/DNA or RNA = 1:1, concentration of PNA
strand = 2.5 m M, 10 mM phosphate buffer, pH 7.4, heating rate 0.5oC/min. All of these
oligomers can dissolve easily in this buffer.
b The values with triple mismatching DNA A9T3.
c The values with single mismatching DNA A5TA6.
d nd, Not detected.
e Compared to the Tm of PNA:DNA triplex for one monomer unit modification.
f Compared to the Tm of PNA:RNA triplex for one monomer unit modification.
PNA dodecamer 33 with a single isogaPNA (TS) unit at the C-terminus of the PNA
dodecamer gave Tm values of 61 and 67oC when hybridized to complementary dA12 and
rA12, respectively (Table 2, entry 9). While PNA dodecamer 34 with a single isogaPNA
(TS) unit at the N-terminus of the PNA dodecamer gave Tm values of 64 and 68
oC when
hybridized to complementary dA12 and rA12, respectively (Table 2, entry 10).  PNA
dodecamer 35 with three units of isogaPNA (TS) at the C-terminus of the PNA
dodecamer gave Tm values of 56 and 63oC when hybridized to dA12 and rA12,
respectively (Table 2, entry 11). While the PNA dodecamer 36 which contains three
units of isogaPNA (TS) at the N-terminus of the PNA dodecamer gave Tm values of 58
and 64oC when hybridized to dA12 and rA12, respectively (Table 2, entry 12).
Incorporation of a single isogaPNA (TS) unit in the middle of the PNA dodecamer, PNA
dodecamer 37 gave Tm values 46 and 53oC when hybridized to complementary dA12
and rA12, respectively (Table 2, entry 13). Unfortunately no thermal melting transition
was observed with the PNA dodecamer which consists mainly from 12 units of
isogaPNA (TS) 38 when hybridized either with the complementary dA12 and rA12,
respectively (Table 2, entry 14). The above data of the PNA dodecamers 33-38 imply
decreased Tm values of 4oC, 1oC, 3oC, 2.5  oC and 9oC for fragments 33, 34, 35, 36 and
37, respectively, calculated from the unmodified aegPNA dodecamer 25 complex with
DNA (see Table 2 enteries 9, 10, 11, 12, 13 vs. 1), and decreased Tm values of 6oC, 5oC,
3.5oC, 3oC and 20oC) for fragments 33, 34, 35, 36 and 37, respectively, calculated from
the unmodified aegPNA dodecamer 25 complex with RNA (see Table 2 enteries 3, 9, 10,
11, 12,13 vs. 1). Comparing to the corresponding Tm values measured between PNA
27-31 incorporated (TR) and DNA dA12, the complexes between 32-37 incorporated of
isogaPNA (TS) and dA12 showed decreased Tm values ( D Tm 1-7°C). Introduction of
mismatch base T to dA12 at the position to hybridize with isogaPNA (TR) and (TS)
resulted in decrease of the Tm ( D Tm 9oC for 30 and 31, D Tm 2oC and 7oC for 36 and 37,
28
respectively). These results show that the conformation of backbone of (TR) is more
effective sterically than that of (TS).
Furthermore, in order to determine the binding stoichiometry of these oligomers to
DNA and RNA, we used the (Job-plot) titration method(88a,b) for one of these oligomers
(fragment 31) with DNA. The total concentration which was used is 3.0 m M, heating
was carried out at 95oC for 10 minutes, then cooling to room temperature and keep
standing for 8 hours and measure the absorbance of different concentrations of 31 and
dA12 at 260 nm. The binding stoichiometry was found to be 2:1 (31 vs dA12) indicating a
PNA2-DNA triplex structure (Fig. 25).
The decreased Tm values compared to unmodified aegPNA oligomer indicate that the
glycyl- b -alanine backbone of isogaPNA may not be optimal length to hybridize with
DNA and RNA.
Fig. 25. Job plots of absorbance at 25oC for compound 31 and dA12 at 260 nm. The
 following extinction coefficients were used: T = 8.6 mL/mmol.cm for PNA, A
= 15.3 mL/mmol.cm, [31] and [dA12] = 3.0 _ M, 10 mM  phosphate buffer,
pH 7.4.
2.3.5. Solid-phase synthesis of adenine isogaPNA oligomers
By the same way to assess the hybridization properties of adenine isogaPNA monomer
15 to its complementary DNA and RNA, adenine PNA monomer 15 was individually
introduced into aegPNA sequences in different positions to form various adenine
octamers, in addition to another adenine octamer consists mainly from complete adenine
PNA monomers 15. The preparation of these oligomers was carried out using automated
synthesis by the same method as the preparation of thymine isogaPNA oligomers. The
crude products were characterized by Mass specteral analysis (matrix-assisted laser
desorption ionozation time-of-flight mass spectrometry) (MALDI-TOF)(87), which gave
a signal for the expected molecular weight (2347.2 (observed) vs. 2346.03 (calculated)).
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Table 3. Various oligomers of aegPNA and isogaPNA adenine monomers.
PNA sequences
39
40
41
42
H-A7-AX-Lys-NH2
H-AX-A7-Lys-NH2
H-A4-AX-A3-Lys-NH2
H-AX8-Lys-NH2
A = adenine aegPNA monomer, AX adenine isogaPNA monomer (15).
After the preparation of these adenine oligomers the crude products were identified by
MALDI-TOF mass spectral analysis, which gave a signal for the expected molecular
weight (2347.2 (observed) vs. 2346.03 (calculated)) for all of these adenine oligomers.
Unfortunately, despite several attempts to purify these oligomers using C18-reverse-
phase HPLC under various conditions of mobile phases, we could not obtain pure
oligomer to check its hybrdization properties with complementary DNA and RNA.
2.3.6. Synthesis and evaluation of isogaPNA derivatives tested as anti-HIV and anti-
HSV
Many antivirals are focused on the inhibition of viral polymerases and reverse
transcriptases, which are the key enzymes in the replicative cycle of any virus for
chemotherapy.(89a,b) Most available drugs such as acyclovir and AZT (Fig. 26) are
nucleoside analogues, and extensive research towards derivatisation on the sugar moiety
of natural nucleoside to enhance antiviral activity has been carried out in numerous
laboratories.(90a-d) On the other hand, aminoethylglycine peptide nucleic acids
(aegPNAs)(41), reported in 1991 by Nielsen, is a nucleic acid analogue in which the
sugar-phosphate backbone is replaced by peptide linkage. Many kinds of nucleotides
have been synthesized in order to improve the binding specificity to DNA and RNA,
solubility and uptake into cells.(91a-e) However there is no report on the derivatization of
30
peptide nucleic acid monomers, which are potent isosters of natural nucleoside, in order
to explore new antivirals. In this context, we examined the approach to antiviral agents
from some derivatives 44 and 48 with hydroxyl group in backbone, which is an
important group for the phosphorylation by cellular kinases in the activation mechanism
of antiviral nucleoside analogues, of isogaPNA(92) developed in our laboratory.
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NH
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Aciclovir AZT
aegPNA IsogaPNAB : Nucleobase
Fig. 26. Comparison between isogaPNA, aegPNA, aciclovir and AZT.
2.3.6.1.　Synthesis of isogaPNA derivatives tested as anti-HIV and anti-HSV
The synthesis of 3-hydroxy-1-(thymin-1-ylmethyl)propylamine 44, 48 proceeds through
benzyl ester compounds 3, 9(92) which are intermediates of isogaPNA monomers
(Scheme 1). Debenzylation of compounds 3, 9 was carried out by the use of H2 gas in
the presence of 10% Pd-C affording the corresponding acids 43, 47 in 60% yield for
each.  Reduction of the carboxylic acid compounds 43, 47 was carried out using ethyl
chloroformate and sodium borohydride provided the objective compounds 44, 48 in
60% yield for both.(76) Also the Boc-protected isogaPNA monomers 46, 50 were
prepared and used with the previously prepared Fmoc-protected isogaPNA monomers 6,
12 for the comparison with hydroxyl compounds 44, 48 . The Boc-protected isogaPNA
monomers 46, 50 were prepared from compounds 4, 10 which are intermediates of
isogaPNA monomers (Scheme 1). Coupling between compounds 4, 10  with equimolar
equivalent of Boc-glycine was carried out in the presence of TBTU, HOBt and DIEA in
DMF gave compounds 45, 49 in yield of 70% for each. Deprotection of the benzyl
group was carried out by the use of 1, 4-cyclohexadiene and 10% Pd-C afforded 46, 50
in yield of 70% for each.
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Scheme 4. Synthesis of various isogaPNA derivatives.
2.3.6.2. Evaluation of isogaPNA derivatives as anti-HIV and anti-HSV
Anti-HIV-1 and anti-HSV-1 activities of hydroxyl compounds 44, 48 isogaPNA
monomers 6, 12, 46 and 50 and the intermediate 4, 5, 10, 11, 43, 47 were examined by
the use of Lenti RT activity kit of CAViDiTECH and plaque reduction assay with HSV-
1 and VERO cells(93), respectively.　The Lenti RT activity kit is optimized for the
quantification of HIV RT activity in cell culture supernatants. The principle of the test
depend on Step 1: Poly-rA bound to the microtiter plate wells serves as template for the
reverse transcriptase enzyme. Oligo-dT serves as primer. Bromo-deoxyuridine-
triphosphate is the substrate used by the enzyme to build the new DNA strand. Step 2: A
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specific monoclonal anti-bromo-deoxyuridine-triphosphate antibody, conjugated to
alkaline phosphatase detects this strand of DNA. The alkaline phosphatase acts on the
chromogenic substrate para-nitrophenyl phosphate, and the colour change is measured
photometrically. The assay has been optimized for Lenti type virus reverse transcriptase
that depend on Mg2+. Unfortunately, the antiviral activities against HIV-1 and HSV-1
were not observed in these assays.(95-97) However, interestingly compound 12 (50 m g/ml)
derived from L-aspartic acid only showed potent cytotoxicity on VERO cells that was
not shown by compound 6 derived from D-aspartic acid. The chirality of the molecules
is one of the most important factors to show pharmacological activities. Therefore, it
seems to be a merit to develop new antiviral drugs that the construction of chiral
backbone of PNA monomers is relatively easy because of derivatization from chiral
amino acids.
33
III. Development of New Inhibitors
of Topoisomerases
34
3.1. Introduction
35
Developments in cancer treatment, although definite, have so far not resulted in a large
increase in survival, especially in solid tumors.(98) Drug resistance to cancer
chemotherapy is one of the causes of difficulty in the treatment of several cancer types.
Among the anticancer drugs, the DNA topoisomerase (topo) inhibitors represent an
important group of agents. Topoisomerases are essential nuclear enzymes that catalyze
the concerted breaking and rejoining of DNA strands, and the enzymes are involved in
producing the necessary topological and conformational changes in DNA which are
critical to many cellular processes such as replication, recombination and
transcription.(99a-c) There are two types of topoisomerases,  topoisomerase I(100) and
topoisomerase II(101) (topo I and topo II) which have been isolated from mammalian
cells. Topoisomerase I, which is ATP independent and introduces transient breaks (or
nick) on a single-strand of duplex DNA, catalyzes the passage of another DNA strand
through the nick. The level of topoisomerase I remains essentially constant through the
cell cycle. The mechanism of action of topoisomerase I is illustrated in Fig. 27. On the
other hand topoisomerase II which is ATP dependent and introduces double strand
breaks of the DNA, and catalyzes the passage of another DNA double strands through
this break. Topoisomerase II plays an important role in chromosome assembly,
condensation and segregation of chromosomes in anaphase as well as in the completion
of transcription.(102-106) The level of topoisomerase II reaches to its peak in S-phase and
then decline rapidly. The mechanism of action of topoisomerase II is illustrated in Fig.
28.  
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3.1.1. Mechanism of action of topoisomerase I
The mechanism of action of topoisomerase I enzyme is illustrated in Fig. 27.
Fig. 27. The reversible nicking reaction catalyzed by DNA topoisomerase I enzyme.
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3.1.2. Mechanism of action of topoisomerase II
The mechanism of action of topoisomerase I enzyme is illustrated in Fig. 28.
　　　　　　　　　　　　　　　　　
　　　　　　　　　　　　　　　　　　　Two circular DNA double helices 　　　
　　　　　　　　　　　 that　are interlocked.
A type II DNA topoisomerase makes a
reversible covalent attachment to both
DNA strands interrupting the green
double helix and forming a protein gate.
The topoisomerase gate opens and shuts
to let a second DNA helix pass.
Two circular DNA double helices that
are separated.
Reversal of the covalent attachment of
the topoisomerase restores an intact
double helix.
Fig. 28. Mechanism of action of topoisomerase II.
38
In addition to their normal cellular functions, both topoisomerase I and II enzymes have
recently emerged as important cellular targets for chemical intervention in the
development of antitumor drugs(107) and some drugs preventing the actions of the
enzymes are used clinically in the treatment of a variety of cancers. Many
topoisomerase inhibitors have been reported and these inhibitors are classified into three
types; the cleavable complex-forming types with and without DNA intercalation, and
the cleavable complex-nonforming type. The inhibitors of the first and second types
inhibit the DNA rejoining reaction of topoisomerase by holding together the tight
cleavable complex consisting of the enzyme and broken DNA.
3.1.3. Topoisomerase inhibitors that stabilize the cleavable complex and intercalate
into DNA
The first group of drugs intercalate into DNA, representative agents of this group are
doxorubicin(108),  amsacrine(109) and ellipticines(110) as topoisomerase II inhibitors and
saintopin(111) as topoisomerase I and II inhibitor (Fig. 29).
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Fig. 29. Examples of cleavable complex-forming types with DNA intercalation
topoisomerase inhibitors.
3.1.4. Topoisomerase inhibitors that stabilize the cleavable complex without
intercalation into DNA
The second group of drugs stabilize the cleavable complex without intercalating into
DNA. This group includes camptothecin(112) and its synthetic derivatives such as CPT-
11(113) and topotecans(114) as topoisomerase I inhibitor and epipodophyllotoxin
(etoposide)(115) as topoisomerase II inhibitor (Fig. 30). These antitumor drugs, referred to
as topoisomerase inhibitors, trap the enzyme in an intermediate complex with DNA,
termed cleavable complex which prevents the final rejoining step of the reaction and
result in increased DNA strands breaks. The inhibitors of the two types promote the
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accumulation of damaged DNA in the cells show strong cytotoxicity and therefore
arrest cell cycle progression.(116,117)
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Fig. 30. Examples of cleavable complex-forming types without DNA intercalation
topoisomerase inhibitors.
3.1.5. Cleavable complex-nonforming type topoisomerase inhibitors
The third group　are cleavable complex-nonforming type topoisomerases inhibitors, they
inhibit the DNA breaking and rejoining reactions of topoisomerases by a direct action
on the enzyme molecule without forming the cleavable complex. Inhibitors of this type
do not cause DNA damage. There are several examples of this group including synthetic
compounds and natural compounds. Representative agents of the synthetic one include;
bisdioxopiperazine family(118) (topoisomerase II inhibitor), 15-deoxy-_-12,14-
prostaglandin J2
(119) (topoisomerase II inhibitor), epigallocatechin-gallate(120)
(topoisomerase I and II inhibitor), and petroselinic acid(121) (topoisomerase I and II
inhibitor) (Fig. 31).
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3.1.5.1. Synthetic cleavable complex-nonforming type topoisomerase inhibitors
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Epigallocatechingallate
Fig. 31. Examples of synthetic cleavable complex-nonforming type topoisomerase
inhibitors.
Representative agents of the natural one include; natural products from actinomycetes
(low molecular compound) such as Isoaurostatin(122) (topoisomerase I inhibitor),
Topostatin(123-125) (topoisomerase I and II inhibitor), and 2070-DTI(126) (topoisomerase I
and II inhibitor) and natural products from actinomycetes (high molecular compound)
such as 2280-DTI (topoisomerase I inhibitor), 2890-DTI(127) (topoisomerase I and II
inhibitor) and Macrostatin(128) (topoisomerase I and II inhibitor) (Fig. 32)
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3.1.5.2. Natural cleavable complex-nonforming type topoisomerase inhibitors
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Fig. 32. Examples of natural cleavable complex-nonforming type topoisomerase
inhibitors.
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3.2. Scope of Investigation
43
In the second part of the thesis we explain the preparation of several compounds with
multi hydroxy groups on phenyl moiety aiming at inhibitory activities against
topoisomerases. Topoisomerases (topos) are DNA-associated enzymes that control and
modify DNA topology by causing transient single (topo I) or double (topo II) strand
DNA breaks during processes such as transcription, translation and chromatid
separation. Clinically potent anticancer agents, topo inhibitors like camptothecin,
etoposide, and doxorubicin bind to the cleavable complex formed between topo and
DNA, and keep it from going back the original DNA. This action is associated with
severe side effects as well as other anticancer agents targeted at DNA. Now agents
directly inhibiting topo are urgently being requested. Suzuki and co-workers reported
isoaurostatin A isolated from Thermomonospora alba showed topo I inhibition (IC50 =
307 m M), and they proved that this compound directly inhibited topo I. Isoaurostatin A
was modified to a lot of derivatives by chemical synthesis, including one that showed
potent activity 100 times than the original compound (IC50 = 3.0 m M). In the same time,
it was found that gallocatechin and epigallocatechin containing several hydroxy groups
on phenyl moiety have strong inhibitory activities against topoisomerases (Fig. 33).
From these results we tried to prepare compounds with polyhydroxy groups on phenyl
moiety aiming to improve the inhibitory activities against topoisomerases and also we
examine structure-activity relationship of the prepared compounds. Our objective
compounds consist from o-, m-, p-phenylenediamines and 2-aminobenzothiazole
coupled with either gallic acid, 3,4-dihydroxybenzoic acid, 4-hydroxybenzoic acid or
benzoic acid (Fig. 34). Thus the prepared compounds having hydroxy groups ranging
from 6 to zero would enable us to study the structure-activity relationship to identify the
essential parts of the structure which is responsible for the activity. Also the acetyl
derivatives of those compounds were tested for the inhibitory activities against
topoisomerases.
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Fig.　33. Various examples of polyhydroxyphenyl compounds which have strong
topoisomerases inhibitory activity.
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3.3. Results and Discussion
46
3.3.1. Synthesis of acetyl and acid chloride derivatives of gallic acid, 3,4-
dihydroxybenzoic acid and 4-hydroxybenzoic acid
The synthesis of acetyl derivatives 52a-c(129) were carried out by acetylation of gallic
acid, 3,4-dihydroxybenzoic acid and 4-hydroxybenzoic acid 51a-c, respectively using
acetic anhydride in the presence of few drops of concentrated H2SO4 and heating the
reaction mixture at 80oC for 10 minutes, the yields of these reactions were 77%, 77%
and 81.6%, respectively. Treatment of the acetyl derivatives 52a-c with thionyl chloride
in benzene gave the corresponding acid chlorides 53a-c in 82.1%, 82.6% and 79.6%
yields, respectively. The results were shown in (Scheme 5) and (Table 4).
COH
(HO) n
Conc. H 2SO 4
Ac 2O COH
(AcO) n
SOCl 2
Benzene
(AcO) n
51a-c 52a-c 53a-c
Cl
O
Scheme 5. Synthesis of various acetyl and acid chloride derivatives of gallic acid,
　3,4-dihydroxybenzoic acid and 4-hydroxybenzoic acid.
Table 4. Acetyl and acid chloride derivatives of gallic acid, 3,4-dihydroxybenzoic acid
and 4-hydroxybenzoic acid.
comp.
#
n position comp.
#
position yield
%
comp.
#
position yield 
%
51a
52b
53c
3
2
1
3, 4, 5-
3, 4-
4-
52a
52b
52c
3, 4, 5-
3, 4-
4-
77.0
77.0
81.6
53a
53b
53c
3, 4, 5-
3, 4-
4-
82.1
 
82.6
79.6
3.3.2. Synthesis of acetylgalloylbenzamide (AGBA) and galloylbenzamide (GBA)
derivatives
The preparation of AGBA derivatives 55a-l was carried out through coupling of various
acid chlorides 53a-c and benzoyl chloride 53d with o-phenylenediamine 54a, m-
phenylenediamine 54b and p-phenylenediamine 54c, respectively in the presence of
TEA either in CH2Cl2 in case of 53a-c or in dry benzene and THF in case of 53d
(Scheme 6). In order to examine the structure-activity relationship compound 55m was
similarly prepared in 81% yield by coupling of acid chloride 53a with aniline in the
presence of TEA in CH2Cl2. Treatment of AGBA 55a-m, respectively with hydrazine
monohydrate in CH3CN gave the corresponding GBA 56a-m in good yields (Table 5).
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(NH 2)n
O
(OAc) m
NH
O
(OH) m
NH
53a-d +
n
n
TEA
H 2NNH 2. H 2O
CH 3CN
54a-d 55a-m
56a-m
Scheme 6. Synthesis of various derivatives of AGBA and GBA.
Table 5. Various derivatives of AGBA and GBA.                                       
n comp.
#
m position yield
%
comp.
#
position yield 
%
54a 2
2
2
2
55a (ortho-)
55b (ortho-)
55c (ortho-)(131)
55d (ortho-)(132)
3
2
1
0
3, 4, 5-
3, 4-
4-
74.5
73.9
70.6
75.9
56a (ortho-)
56b (ortho-)(130)
56c (ortho-)
3, 4, 5-
3, 4-
4-
60.7
63.1
57.5
54b 2
2
2
2
55e (meta-)
55f (meta-)
55g (meta-)(131)
55h (meta-)(134)
3
2
1
0
3, 4, 5-
3, 4-
4-
75.3
75.7
81.0
76.0
56e (meta-)
56f (meta -)(130)
56g (meta -)(133)
3, 4, 5-
3, 4-
4-
60.7
71.0
66.6
54c 2
2
2
2
55i (para-)
55j (para-)
55k (para-)(131)
55l (para-)(137)
3
2
1
0
3, 4, 5-
3, 4-
4-
67.8
77.5
80.2
76.0
56i (para-)(135)
56j (para -)(130)
56k (para -)(136)
3, 4, 5-
3, 4-
4-
56.0
68.4
66.0
54d 1 55m(138) 3 3, 4, 5- 81.0 56m(139) 3, 4, 5- 73.5
3.3.3. Synthesis of acetylgalloyl-2-aminobenzothiazole (AGABT), galloyl-2-amino-
 benzothiazole (GABT), acetylgalloyl-2-aminothiazole (AGAT) and galloyl-2-  
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aminothiazole (GAT) derivatives
Coupling of compounds 53a-d with 2-aminobenzothiazole 57 (Scheme 7) was carried
out in the presence of TEA either in CH2Cl2 in case of 53a-c or in THF in case of 53d
affording the corresponding acetylgalloyl derivatives 58a-d in 77.3%, 78.6%, 77.1%
and 78.8% yields, respectively. In a similar way compound 61 was prepared in a good
yield for the comparison of the structure-activity relationship (Scheme 8) by direct
coupling of the acid chloride 53a with 2-aminothiazole 60 in the presence of TEA in
CH2Cl2. Complete deacetylation of compounds 58a-d and 61 using hydrazine
monohydrate in CH3CN gave the corresponding galloyl derivatives 59a-c and 62 in
66.2%, 59.4%, 66.7% and 67.4% yields, respectively (Scheme 7 and 8). The data of
these compounds were shown in Table 6.
N
S
NH 2
N
S
H
N
O
(AcO) n
N
S
H
N
O
(HO) n
CH 3CN
53a-d +
TEA
H 2NNH 2. H 2O
57
58a-d
59a-c
Scheme 7. Synthesis of various derivatives of AGABT and GABT.
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S
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N
S
H
N
O
N
S
H
N
O CH 3CN
CH 2Cl 2
AcO
OAc
OAc
HO
OH
OH
+
TEA
H 2NNH 2. H 2O
53a
60
61
62
Scheme 8. Synthesis of various derivatives of AGAT and GAT.
Table 6. Various derivatives of AGBAT, GBAT, AGAT and GAT.
comp.
#
n position yield
%
comp.
#
position yield
%
58a
58b
58c(140)
58d(141)
61
3
2
1
0
3
3, 4, 5-
3, 4-
4-
3, 4, 5-
77.30
78.60
77.10
78.77
74.10
59a
59b
59c
62
3, 4, 5-
3, 4-
4-
3, 4, 5-
66.20
59.40
66.67
67.40
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3.3.4.　Topoisomerases inhibitory activities
Inhibition against relaxation activity of topoisomerases I and II was measured by
detecting the conversion of supercoiled pBR322 DNA to its relaxed form.(101)
3.3.4.1.　Topoisomerase I inhibitory activities of AGBA derivatives
Several　derivatives of acetylgalloylbenzamide (AGBA) (Fig. 35) were prepared by
direct coupling of ortho-, meta- and para- phenylenediamine with either mono-, di-, and
tri- acetylbenzoyl chloride, and the prepared compounds were evaluated for their
inhibitory activities against topoisomerases I. Structure-activity relationship was
examined for the prepared compounds in order to identify the essential parts responsible
for the activity (Table 7).
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R 3
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R 1
R 3
R 2
R 1
H
N
O
OAc
OAc
OAc
Acetylgalloylbenzamide derivatives (AGBA)
55m
55a-k
Fig. 35. Various AGBA derivatives.
Table 7. Topoisomerase I inhibitory activities of AGBA derivatives.
AGBA
#
# of
OAc
R1 R2 R3 Topo I inhibitiory
activity (IC50, M)
55a
55b
55c
  6
  4
  2
OAc
OAc
H
OAc
OAc
OAc
OAc
  H
 H
4.7
88.0
> 100.0
55e
55f
55g
  6
  4
  2
OAc
OAc
H
OAc
OAc
OAc
OAc
  H
  H
11.2
43.2
> 100.0
55i
55j
55k
  6
  4
  2
OAc
OAc
  H
OAc
OAc
OAc
OAc  
  H
  H
8.6
         -
> 100.0
55m   3 OAc OAc OAc > 100.0
As shown in Table 7, compounds 55a, 55b and 55c which consist from o-
phenylenediamine coupled with either tri-, di- and mono- acetylbenzoyl chloride,
exhibited inhibitory activity against topoisomerase I with IC50 of 4.7, 88.0 and > 100
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m M, respectively. These results show that according as the number of acetyl moiety in
the AGBA derivatives increases, the inhibitory activity against topoisomerase I
increased, i.e., IC50 of 55a which contains six acetyl moieties was 4.7 m M while the IC50
of 55b which contains four acetyl moieties was 88 m M (55a is 19 folds potent activity
over 55b), and the IC50 of 55c which contains two acetyl moieties was > 100 m M. This
indicated that the acetyl moiety is essential for activity in such AGBA derivatives. On
the other hand, compounds 55e, 55f and 55g, which were prepared from m-
phenylenediamine and either tri-, di- and mono- acetylbenzoyl chloride, showed
inhibitory activity against topoisomerase I with IC50 of 11.2, 43.2 and > 100 m M,
respectively. These results suggest that by increasing the number of acetyl moiety in the
AGBA derivatives, the inhibitory activity against topoisomerase I was enhanced, i.e.,
IC50 of 55e which contains six acetyl moieties was 11.2 m M while the IC50 of 55f which
contains four acetyl moieties was 43.2 m M (55e is 4 folds potent activity over 55f), and
the IC50 of 55g which contains two acetyl moieties was > 100 m M. This also support that
the acetyl moiety is essential for activity of such AGBA derivatives. In contrast,
compounds 55i, 55k which were prepared from p-phenylenediamine with tri- and
mono- acetylbenzoyl chloride, respectively, showed inhibitory activity against
topoisomerase I with IC50 of 8.6 and > 100 m M, respectively, while compound 55j
which was prepared by coupling of p-phenylenediamine with diacetylbenzoyl chloride
did not show any inhibitory activity against topoisomerase I, this may be related to the
incomplete solubility of this compound in the reaction mixture during the assay. These
results indicated that by increasing the number of acetyl moiety in this type of AGBA
derivatives, the inhibitory activity against topoisomerase I was enhanced, i.e., IC50 of 55i
which contains six acetyl moieties was 8.6 m M while the IC50 of 55k which contains two
acetyl moieties was > 100 m M. This also support that the acetyl moiety is essential for
activity of such AGBA derivatives. It is also clear that if a comparison was made
between the most potent compounds of these groups 55a, 55e and 55i which contain six
acetyl moieties, the inhibitory activity against topoisomerase I will be in the following
order; 55a more potent than 55i which is more potent than 55e. In order to check the
effect of presence either one or two amino groups on phenylenediamine moiety on the
inhibitory activity against topoisomerase I, compound 55m was prepared from aniline
and triacetylbenzoyl chloride and it showed inhibitory activity against topoisomerase I
of IC50 > 100 m M. From these results of AGBA derivatives, it was apparent that the
presence of two amino groups for coupling with mono-, di- and tri- acetylbenzoyl
chloride is essential for the activity, and the presence of acetyl moiety is essential for
activity (at least 4 acetyl moieties required), enhancing the inhibitory activity against
topoisomerase I.
3.3.4.2. Topoisomerase I and topoisomerase II inhibitory activities of GBA derivatives
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The GBA derivatives (Fig. 36) were prepared by deacetylation of their corresponding
acetyl derivatives mentioned before using hydrazine monohydrate and evaluated of their
inhibitory activities against topoisomerase I and II. Structure-activity relationship was
examined for the prepared compounds in order to identify the essential parts responsible
for the activity (Table 8).  
 
H
N
O
R 3
R 2
NH
O
R 1
R 3
R 2
R 1
H
N
O
OH
OH
OH
Galloylbenzamide derivatives (GBA)
56m
56a-l
Fig. 36. Various GBA derivatives.
Table 8. Topoisomerase I and topoisomerase II Inhibitory activities of GBA derivatives.
GBA
#
# of
OH
R1 R2 R3 Topo I inhibitiory
activity (IC50, M)
Topo II inhibitiory
activity (IC50, M)
56a
56b
56c
55d
6
4
2
0
OH
OH
  H
  H
OH
OH
OH
H
OH
  H
 H
 H
0.9
6.4
> 100.0
> 100.0
0.09
nd
> 100.0
> 100.0   
56e
56f
56g
55h
6
4
2
0
OH
OH
  H
  H
OH
OH
OH
H
OH
  H
  H
  H
1.6
10.0
> 100.0  
> 100.0
0.08
nd
> 100.0  
> 100.0
56i
56j
56k
55l
6
4
2
0
OH
OH
  H
  H
OH
OH
OH
H
OH
  H
  H
  H
1.4
2.6
> 100.0   
> 100.0
0.08
0.14
nd   
> 100.0
56m 3 OH OH OH > 100.0 nd
nd, not determined
As shown in Table 8, compounds 56a, 56b, 56c, and 55d which represent the ortho-
forms of galloylbenzamide derivatives were prepared by deacetylation of their
corresponding acetyl derivatives, except for 55d which was prepared by direct coupling
of o-phenylenediamine with benzoyl chloride; these compounds exhibited inhibitory
activity against topoisomerase I with IC50 of 0.9, 6.4, > 100 and > 100 m M, respectively.
These results show that with increasing the number of hydroxy groups in ortho- form of
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GBA derivatives, enhancement of the inhibitory activity against topoisomerase I was
observed, i.e., IC50 of 56a which contains six hydroxy groups was 0.9 m M while the IC50
of 56b which contains four hydroxy groups was 6.4 m M (56a is 7 folds potent activity
over 56b) and both 56c which contains two hydroxy groups and 55d without any
hydroxy group showed IC50 > 100 m M. This indicates that the presence of hydroxy
moiety is essential for activity in such o-GBA derivatives. Compound 56a exhibited
inhibitory activity against topoisomerase II with IC50 of 0.09 m M, while compounds 56c
and 55d exhibited inhibitory activity against topoisomerase II with IC50 of > 100 m M.
The results indicated that compound 56a has topoisomerase II inhibitory activity 10
times more than topoisomerase I inhibitory activity. On the other side, compounds 56e,
56f, 56g, and 55h which represent the meta- derivatives of galloylbenzamide were
prepared by a similar method through deacetylation of the corresponding acetyl
derivatives, except for 55h which was prepared by coupling of m-phenylenediamine
with benzoyl chloride; these derivatives exhibited inhibitory activity against
topoisomerase I with IC50 of 1.6, 10.0, > 100 and > 100 m M, respectively. These results
show that with increasing the number of hydroxy groups in the meta- form of GBA
derivatives resulted in enhancement of the inhibitory activity against topoisomerases I
i.e., IC50 of 56e which contains six hydroxy groups was 1.6 m M while the IC50 of 56f
which contains four hydroxy groups was 10 m M (56e is 6 folds potent activity over 56f)
and both 56g which contains two hydroxy groups and 55h without any hydroxy group
indicated IC50 > 100 m M. This means that the presence of hydroxy moiety is essential
for activity in such m-GBA derivatives. Compound 56e exhibited inhibitory activity
against topoisomerase II with IC50 of 0.08 m M, while compounds 56g and 55h exhibited
inhibitory activity against topoisomerase II with IC50 of > 100 m M. The results indicated
that compound 56e has topoisomerase II inhibitory activity 20 times more than
topoisomerase I inhibitory activity. Compounds 56i, 56j, 56k , and 55l which represent
the para- derivatives of such galloylbenzamide and prepared by the same way through
deacetylation of their corresponding acetyl derivatives, except for 55l which was
prepared by direct reaction of p-phenylenediamine with benzoyl chloride, showed
inhibitory activity against topoisomerase I with IC50 of 1.4, 2.6, > 100 and > 100 m M,
respectively. These results show that with increasing the number of hydroxy groups in
these para- GBA derivatives, enhancement of the topo I inhibitory activity was observed,
i.e., IC50 of 56i which contains six hydroxy groups was 1.4 m M while the IC50 of 56j
which contains four hydroxy groups was 2.6 m M (56i is 1.8 folds potent activity over
than 56j) and the IC50 of both 56k which contains two hydroxy groups and 55l without
any hydroxy group was > 100 m M. This proves that the presence of hydroxy moiety in
such p-GBA derivatives is essential for the activity. Compound 56i exhibited inhibitory
activity against topoisomerase II with IC50 of 0.08 m M, while compound 56j indicated
inhibitory activity against topoisomerase II with IC50 of 0.14 m M (compound 56i is
about 1.7 folds potent activity over than 56j). On the other side, compound 55l
exhibited inhibitory activity against topoisomerase II with IC50 of > 100 m M. The results
indicated that compound 56i has topoisomerase II inhibitory activity 17.5 times more
than topoisomerase I inhibitory activity. If we compare the most potent compounds 56a,
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56e and 56i which contain six hydroxy groups, the topoisomerase I inhibitory activity
will be in the following order; 56a more potent than 56i which is slightly potent than
56e, the topoisomerase II inhibitory activity will be in the following order; 56e has the
same potency of 56i and slightly potent than 56a. Also these results indicated that at any
case the topoisomerase I inhibitory activity of the deacetylated forms (GBA) are more
potent than that of the corresponding acetyl derivatives (AGBA); 56a is 5.2 folds potent
over 55a while 56e is 7 folds potent over 55e and 56i is 6 folds potent over 55i. In order
to check the effect of presence either one or two amine groups on the phenylenediamine
on the topoisomerase I inhibitory activity in such GBA derivatives, compound 56m was
prepared by deacetylation of its corresponding acetyl derivative 55m. The results
showed that 56m exhibited inhibitory activity against topoisomerase I with IC50 > 100
m M. From these results of GBA derivatives, it was apparent that the presence of two
amino groups is essential for activity, by increasing the number of hydroxyl groups
which is essential for activity (at least 4 hydroxy groups required), the inhibitory
activity against topoisomerase I increased and the activity of the hydroxyl derivatives of
these compounds became more potent compared with the corresponding acetyl
derivatives.  
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3.3.4.3.　Topoisomerase I inhibitory activities of AGABT derivatives
AGABT derivatives (Fig. 37) were prepared by direct coupling of 2-aminobenzo-
thiazole with either tri-, di- and mono- acetylbenzoyl chloride. The prepared compounds
were evaluated for its inhibitory activities against topoisomerases I, structure- activity
relationship was examined for the prepared compounds in order to identify the essential
parts responsible for the activity (Table 9).
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Fig. 37. Various AGABT derivatives.
 
Table 9.  Topoisomerase I Inhibitory activities of AGABT derivatives.
AGABT
#
# of
OAc
R1 R2 R3 Topo I inhibitiory
activity (IC50, M)
58a 3 OAc OAc OAc 7.7
58b 2 OAc OAc
  
H > 100.0
58c 1
　
H OAc
  
H > 100.0
61 3 OAc OAc OAc > 100.0
As shown in Table 9, compound 58a which contains three acetyl moieties indicated
strong inhibitory activity against topoisomerase I with IC50 of 7.7 m M, while other
derivatives 58b (which contains two acetyl moieties) and 58c (which contains one
acetyl moiety) showed inhibitory activity against topoisomerase I with IC50 > 100.0 m M.
In order to check the effect of presence or absence of benzene ring on topoisomerase I
inhibitory activity of such derivatives, compound 61 was prepared by coupling of 2-
aminothiazole with triacetylbenzoyl chloride. Compound 61 showed inhibitory activity
against topoisomerase I with IC50 > 100.0 m M. From these results of AGABT derivatives
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it was apparent that, the presence of benzene ring is essential for inhibitory activity
against topoisomerase I and at least three acetyl moieties are required for the inhibitory
activity against topoisomerase I.  
3.3.4.4.　Topoisomerase I inhibitory activities of GABT derivatives
GABT derivatives (Fig. 38) were prepared by the same method through deacetylation of
its corresponding acetyl derivatives using hydrazine monohydrate except for 58d which
was prepared from 2-aminobenzothiazole with benzoyl chloride. The prepared
compounds were subjected for evaluation of its inhibitory activities against
topoisomerase I. Structure activity relationship was examined for the prepared
compounds in order to identify the essential parts responsible for the activity (Table 10).
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58d, 59a-c
Fig. 38. Various GABT derivatives.
Table 10. Topo I inhibitory activities of GABT derivatives.
AGABT
#
# of
OH
R1 R2 R3 Topo I inhibitiory
activity (IC50, M)
59a 3  OH OH OH 8.2
59b 2
 
OH OH H 16.9
59c 1 H OH H > 100.0  
58d 0 H H H > 100.0   
62 3 OH OH OH 34.4
As shown in Table 10, compounds 59a, 59b, 59c, and 58d showed inhibitory activity
against topoisomerase I with IC50 of 8.2, 16.9, > 100 and > 100 m M, respectively. These
results show that with increasing the number of hydroxy groups in these derivatives,
enhancement of the inhibitory activity against topoisomerase I was observed, i.e., IC50 of
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59a which contains three hydroxy groups was 8.2 m M while the IC50 of 59b which
contains two hydroxy groups was 16.9 m M (59a is 2 folds potent activity over 59b) and
the IC50 of both 59c which contains one hydroxy group and 58d without any hydroxy
group was > 100 m M. This indicates that the presence of hydroxy moiety is essential for
the activity in such GABT derivatives. In order to identify the effect of presence or
absence of benzene ring of 2-aminobenzothiazole on the inhibitory activity of
topoisomerase I, compound 62 was prepared by the same method of deaetylation from
its corresponding acetyl derivatives. The IC50 of 62 was 34.4 m M. From these results of
GABT it was apparent that the presence of hydroxy groups is essential for the activity
(at least two hydroxy groups required for the activity) as the enhancement of the
inhibitory activity against topoisomerase I was observed upon increasing the number of
hydroxy groups. The presence of benzene ring of 2-aminobenzothiazole is also essential
for the activity because compound 59a which includes benzene ring is about 4.2 folds
potent than 62 which did not contain benzene ring.
58
3.3.5. Inhibitory property
The inhibitory properties of o-GPD 56a were examined using these methods;
3.3.5.1. Inhibiton of topoisomerase I and II by o-GPD
As shown in Fig. 39, in the presence of increasing o-GPD, topoisomerase I and II
activities were inhibited in concentration dependence, and 0.9 m M and 0.09 m M of o-
GPD gave 50% inhibition (IC50) against topoisomerase I and II  activities, respectively.
The type of inhibition exhibited by o-GPD was determined by Lineweaver-Burk
plots(142) of substrate concentrations against the rate of relaxation of supercoiled pBR322
DNA by topoisomerase I and II in the presence and absence of o-GPD. As shown in Fig.
40, the relaxation activities of pBR322 DNA by topoisomerase I and II were inhibited in
a noncompetitive manner by o-GPD, and the Ki values were 0.4 m M and 74.1 nM,
respectively. The Michaelis constants (Km values) of relaxation by topoisomerase I and
II were 3.7 nM and 10.5 nM, respectively. In view of inhibitory potency (Ki / Km)
against DNA relaxation by topoisomerase I and II, o-GPD was 15-fold potent inhibitor
against topoisomerase II than topoisomerase I. From these results, o-GPD was found to
be highly potent inhibitor for topoisomerase I and II and it was considered to bind to a
different site from the binding site of the substrate DNA on the enzyme molecule.
                                                                                         
(A) Topoisomerase I                        (B) Topoisomerase II
 IC50 = 0.9 M    IC50 = 0.09 M
Fig. 39. Inhibitory activities of o-GPD against topoisomerase I (A) and
topoisomerase II (B).
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(B) Topoisomerase II
　　　　 Fig. 40.　Lineweaver-Burk plots of substrate (supercoiled pBR322 DNA)
concentrations against rate of relaxation by (A) topoisomerase I   
 　　　(B) topoisomerase II   with and without o-GPD.
3.3.5.2. Stabilization of topo-cleavable complex by o-GPD
Topoisomerase inhibitors of the cleavable complex-forming type, such as camptothecin
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and etoposide, stabilize the cleavable complex (topo-DNA reaction intermediate) and
inhibit the DNA rejoining reaction of topoisomerase; this inhibitory mechanism of the
inhibitors induces nicked or linearized DNA in the cleavage assay.(143, 144) To determine
whether o-GPD is an inhibitor of the cleavable complex-forming type or not, cleavage
assays were carried out. Camptothecin and etoposide were used as the controls for
cleavable complex-forming inhibitors against topoisomerase I and II, respectively. As
shown in Fig. 41, camptothecin induced nicked DNA with increasing concentrations.
Unlike camptothecin, o-GPD could not induce nicked DNA even at 100 m M. The results
for the stabilization of topoisomerase II-cleavable complex are shown in Fig. 41.
Etoposide induced the linearized DNA, but o-GPD failed to linearize DNA even at 1000
m M. These results suggest that o-GPD did not inhibit topoisomerase I and II by
stabilizing the cleavable complex and o-GPD is considered as an inhibitor of the
cleavable-nonforming type. The inhibition mechanism of o-GPD against topoisomerase
I and II differed from camptothecin and etoposide. o-GPD may directly act on
topoisomerase I and II molecules in an earlier step than the formation of the
topoisomerase-DNA complex and inhibit the DNA breaking and rejoining reactions by
the enzymes.
(A)　Topoisomerase I                         (B) Topoisomerase II
        
 Fig. 41. Stabilization of topoisomerase I and II cleavable complexes by o-GPD,
camptothecin and etoposide.
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3.3.5.3. DNA interaction by o-GPD          
Some topoisomerase inhibitors such as doxorubicin and amascarine are DNA
intercalators. To determine whether o-GPD has the ability to intercalate into DNA
strands, CD (circular dichroism) spectral change of DNA by addition of o-GPD was
measured, since the spectrum is sensitive to the conformation changes induced in DNA
by intercalators.(145,146) Doxorubicin was used as control of intercalator at the same
concentration. As shown in Fig. 42, the spectrum of DNA changed greatly with
increasing the concentrations of doxorubicin. On the other hand, there is no spectral
changes by o-GPD was noticed, therefore, it is clear that o-GPD has no ability to
intercalate into DNA. Thus, o-GPD is a selective inhibitor against topoisomerase I and
II, and it is different from inhibitors causing DNA damage such as cleavable complex-
forming inhibitors and DNA intercalators.     
 
Fig. 42. CD spectral changes of DNA by addition of o-GPD and doxorubicin.
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3.3.5.4. Effect of o-GPD on the growth and cell cycle of HeLa cells
The cell growth inhibition of o-GPD was determined in HeLa cell by Alamar blue
assay.(147)  As shown in Fig. 43, the values of cell growth inhibition (GI50) of o-GPD,
camptothecin and etoposide were 30, 0.6 and 40 m M, respectively. Camptothecin and
etoposide promote the accumulation of damaged DNA by stabilization of the cleavable
complex in the cells, thereby arresting cell cycle progression. The cell cycle progression
was analyzed with a flow cytometer. As shown in Fig. 44, HeLa cells were arrested at
the S phase and G2/M phase when cultured with 0.1 m M camptothecin and 2 m M
etoposide, respectively. On the other hand, o-GPD did not affect on the cell cycle even
at an extremely high concentration (100 m M). The results suggest that the cytotoxicity
of o-GPD is clearly different from that of　camptothecin and etoposide, and these results
are in a good agreement with the results of the cleavage assay of o-GPD. The results
suggest that o-GPD do not cause damage of DNA by cleavage complex formation in the
cells.
Fig. 43. Inhibitory effects of o-GPD, camptothecin and etoposide on cell growth.
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Fig. 44. Effects of o-GPD, camptothecin and etoposide on cell cycle of HeLa cells.
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IV. General Conclusion
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4.1. General conclusion of peptide nucleic acid chapter
This chapter was concentrated about peptide nucleic acids, which are very potent DNA
mimic capable of hybridization to complementary DNA, RNA or PNA.  Due to the
favorable RNA- and DNA-binding properties of PNA and the selective binding of 2’,5’-
isoDNA to RNA this have led us to design a novel type of 2’,5’-isoDNA mimic chiral
peptide nucleic acids (isoPNAs). The novel PNA was glycyl-b-alanine isoPNA
(isogaPNA) in R- and S- forms. They were prepared in high degree of purity through
several steps starting from D- and L- aspartic acids protected with Boc and benzyl
groups. In order to assess the hybridization properties of these monomers to
complementary DNA and RNA, the two monomers were individually introduced into
aegPNA sequences in different positions to form varied thymine dodecamers. The
hybridization properties of these PNA oligomers with complementary DNA and RNA
were investigated in UV-melting experiments (260 nm) and the results of these PNA
oligomers were compared to the dodecamer prepared totally from unmodified aegPNA.
The results indicted that most of these PNA oligomers have good binding affinity to
complementary DNA and RNA in the same time, and some of these oligomers show
similar Tm values to the unmodified aegPNA oligomer when hybridized to DNA. On
the other hand, decreased Tm values lower than that of the unmodified aegPNA
oligomer was observed upon binding of these oligomers to its complementary RNA.
Most of these oligomers did not show selectivity to either DNA or RNA. Unfortunately,
no hybridization was found for the complexes of complete isogaPNA TR or TS with DNA
or RNA, respectively. Introduction of mismatch base thymine to dA12 at the position to
hybridize with isogaPNA TR and TS resulted in decrease of the Tm. These results show
the conformation of backbone of TR is more effective sterically than that of TS.
Furthermore, the binding stoichiometry was found by UV titration (Job-Plot) to be 2:1,
indicating a PNA2-DNA triplex structure. The decreased Tm values compared to
unmodified aegPNA oligomer indicate that the length of the glycyl-b-alanine backbone
of isogaPNA may not be optimal to hybridize with DNA and RNA. This led us to think
and design of new type of PNA, glycyl-glycine isoPNA (isoggPNA) monomer which is
a lower homolog of the isogaPNA. This new isoggPNA was prepared starting from L-
serine after several trials and obtained in a high degree of purity. The work now is in
progress for the preparation of various oligomers containing isoggPNA monomer to
check its hybridization properties to complementary DNA and RNA. Also another PNA
monomer which is isogaPNA containing adenine as a nucleobase in stead of thymine
was prepared in high degree of purity starting from D-aspartic acid by the same
procedure as that for the preparation of isogaPNA thymine monomer. Several oligomers
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consisting of 8 monomers (octomers) were prepared by introducing isogaPNA adenine
monomer in different sequences of aegPNA adenine monomers. The prepared oligomers
were checked by MALDI-TOF mass spectrum analysis. Unfortunately, despite the
several trials to purify these oligomers using HPLC under various conditions, we could
not obtain pure oligomers to investigate the hybridization properties to complementary
DNA and RNA. On the other side there is no report on the derivatization of PNA
monomers, which are potent isosters of natural nucleosides, in order to develop new
antivirals. Several PNA monomers with a backbone containing a hydroxyl group, which
is important for the phosphorylation by cellular kinases in the activation mechanism of
antiviral nucleoside, were prepared through reduction of their corresponding carboxylic
acid derivatives. These monomers with hydroxyl group and other monomers with
carboxylic group in addition to some intermediates were investigated for the anti-HIV
and anti-HSV activities but unfortunately the antiviral activities against HIV-1 and
HSV-1 were not observed. However, interestingly the isogaPNA thymine monomer (S)
derived from L-aspartic acid (50 m g/ml) only showed potent cytotoxicity on VERO cells
whereas the other isogaPNA thymine monomer (R) derived from D-aspartic acid show
no activity. This proves that the chirality of the molecules is one of the important factors
to show pharmacological activities.
4.2. General conclusion for the topoisomerases inhibitors chapter
This chapter was focused on the topoisomerases inhibitors, topoisomerases are essential
nuclear enzymes involved in producing the necessary topological and conformational
changes in DNA which are critical to many cellular processes such as replication,
recombination and transcription. In addition to their normal cellular functions, both
topoisomerase I and II enzymes have emerged as important targets for chemical
intervention in the development of antitumor drugs. From this idea we begin to study
several polyhydroxyphenyl compounds prepared by the coupling of various acetylated
acid chlorides with o-, m-, p- phenylenediamine and 2-aminobenzothiazole. The formed
acetylated coupled compounds were completely deacetylated using hydrazine
monohydrate, and the obtained polyhydroxy derivatives in addition to the acetylated
ones were evaluated for their topoisomerases inhibitory activities. Structure-activity
relationship was examined in order to determine the essential parts for the activity of
these compounds. The results show that most of these compounds show strong
inhibitory activity against topoisomerase I and II, the polyhydroxyl form of the o-
phenylenediamine (o-GPD), indicating strong topoisomerase I inhibitory activity with
IC50 = 0.9 m M and very strong topoisomerase II inhibitory activity with IC50 = 0.09 m M.
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On the other hand, the polyhydroxyl form of the m-phenylenediamine indicating strong
topoisomerase I inhibitory activity with IC50 = 1.6 m M and very strong topoisomerase II
inhibitory activity with IC50 = 0.08 m M, while the polyhydroxyl form of the p-
phenylenediamine indicating strong topoisomerase I inhibitory activity with IC50 = 1.4
m M and very strong topoisomerase II inhibitory activity with IC50 = 0.08 m M.  Other
derivatives show good inhibitory activity against topoisomerase I and II. A study on the
inhibitory properties of o-GPD was carried out and the results indicated that, o-GPD is
highly potent inhibitor for topoisomerase I and II and it was consider to bind to a
different site from the binding site of the substrate DNA on the enzyme molecule.
Cleavage assays were carried out also on o-GPD to determine whether this compound is
an inhibitor of the cleavable complex-forming type or not. The results show that o-GPD
is considered as an inhibitor of the cleavable-nonforming type and the inhibition
mechanism of o-GPD against topoisomerase I and II differed from camptothecin and
etoposide, o-GPD may act directly on topoisomerase I and II molecules in an earlier
step than the formation of the topoisomerase-DNA complex and inhibit the DNA
breaking and rejoining reactions by the enzymes. CD spectral change of DNA by
addition of o-GPD was also measured, and there is no spectral changes noticed by o-
GPD, indicating that o-GPD has no ability to intercalate into DNA. Also the cell growth
inhibition of o-GPD was determined in HeLa cell by Alamar blue assay, and indicated
that the GI50 of o-GPD was 30 m M. o-GPD did not affect on the cell cycle even at an
extremely high concentration (100 m M), the results suggest that the cytotoxicity of o-
GPD is clearly different from that of camptothecin and etoposide.  
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V. Experimental
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5.1. Development of novel peptide nucleic acids
Materials
All reagents which used for the preparation of　PNA monomers and their intermediates
were purchased from Wako, Aldrich, Nacalai tesque, Tokyo Kasei and Novabiochem
and used without purification. Solvents were HPLC grade from Wako, Aldrich and
Sigma. Dry solvents were obtained by use of appropriate molecular sieves, except for
tetrahydrofuran was distilled from sodium/benzophenone. The water content in dry
solvents did not exceed 50 ppm as determined by Karl-Fischer titration. Reagents for
PNA synthesis were obtained from Applied Biosystems and other commercial sources.
General methods
TLC was performed on analytical Merck 9385 silica glass plates with F254 indicator.
TLCs were viewed either under 254 nm UV or by staining with phosphomolybdic acid
in ethanol or iodine crystals where appropriate. Column chromatography was performed
as flash chromatography on Merck 9385 silica gel 60 (0.040-0.063 mm). Reactions
were carried out under Argon gas. Accurate masses were obtained on Micromass LCT
mass spectrometer which was recorded in the positive ion mode with leucine enkephalin
as an internal lock mass standard. Elemental analysis was performed at the
microanalytical laboratory, Institute of Resource Development and Analysis,
Kumamoto University. Melting points were determined on electrothermal melting point
apparatus and were uncorrected. IR data were obtained on Jasco Fourier Transform-410
Infrared spectrometer as KBr discs for the crystalline products and on NaCl cell for the
oily products. NMR spectra were obtained on a 300 MHz AL spectrometer. d-Values are
in ppm relative to DMSO-d6 (2.50 for proton and 39.5 for carbon) or CDCl3 (7.29 for
proton and 76.9 for carbon). MALDI-TOF mass spectrometry measurements of PNA
oligomers were performed in a (Kratos) MALDI mass spectrometer using a-
cyanocinnamic acid as the matrix. The angle of optical rotation of different isogaPNA
monomers and its intermediates was measured on Jasco DIP-1000 KUY digital
polarimeter. Reversed-phaes HPLC chromatography was performed on a Shodex HPLC
system equipped with Wakosil-II 5C18-100, 7.5 mm x 300mm (W). For the purification
of different isogaPNA oligomers the following conditions were used. Buffer A: 0.1%
(v/v) trifluoroacetic acid in water (pH 2.0), buffer B: 0.1% (v/v) trifluoroacetic acid in
acetonitrile. Flow rate: 1 or 0.7 ml/min. Condition A) a 65 minutes linear gradient from
90 to 0% and B) from 10 to 100%, all runs were performed at 50oC. Fractions
containing the PNA were lyophilized. Pure isogaPNAs oligomers were stored frozen at -
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30oC) solutions in deionized water. Complementary DNA was purchased from Greiner-
Japan, RNA was purchased from Takara, Tokyo, Japan. DNA and RNA sequences were
purified by both cation exchange and reversed-phase HPLC, yielding chromato-
graphically pure materials. Synthesis of isogaPNA oligomers was carried out using
Expedite 8909 Synthesizer, all the reagents used for automated PNA synthesis including
aegPNA monomers (thymine and adenine), HATU, PNA base solution (0.2 M DIEA,
0.3M 2,6-lutidine), PNA deblocking solution (20% piperidine in DMF), PNA capping
solution (5% acetic anhydride, 6% 2,6-lutidine in DMF), PNA diluent (N-
methylpyrrolidone, NMP), Wash A (DMF), and Wash B (99.8% anhydrous DMF) were
purchased from Applied Biosystems, columns for solid phase synthesis containing
Fmoc-XAL PEG resin (GEN063053, Applied Biosystems) should be stored in a
desiccant box at –20oC and allowed to warm to room temperature prior to use. Powders
such as monomers, activators and lysine should be unpacked on arrival and placed in a
sealed container containing Drierite desiccant at –20oC and to ensure proper synthesis,
dry the powdered reagents in vacuo overnight prior to use. A PNA:DNA annealing
buffer and PNA:DNA melting temperature buffer was 0.1 M Na2HPO4, pH 7.4. Thermal
melting experiments including UV absorption spectra and melting curves (absorbance
versus temperature) were performed on 3-cm path-length cells using Jasco V-530 UV-
VIS spectrophotometer with Jasco ETC-505T temperature controller with a
programmed temperature increase of 0.5oC/min. Lenti RT activity kit for examination of
anti-HIV-1 was from CAViDiTECH, MEM (minimum essential medium) used for the
anti-HIV-1 and anti-HSV-1 assay was purchased from Gibco.
5.1.1. Synthesis of isogaPNA thymine monomer (R)
3-tert-Butoxycarbonylamino-4-hydroxybutyric acid benzyl ester (R) (2)(76)
To a stirred solution of 1 (1.94 g; 6.00 mmol) in distilled THF (30 ml) at –10oC, under
Argon atmosphere, N-methylmorpholine (0.61 g; 6.00 mmol) was added in a dropwise
manner followed by ethyl chloroformate (0.65 g; 6.00 mmol), after 10 minutes sodium
borohydride (0.68 g; 18.00 mmol) was added in one portion, methyl alcohol (30 ml)
was then added in a dropwise  manner to the mixture over a period of 10 minutes at
0oC. The solution is stirred for additional 10 minutes, and then neutralized with 1N HCl
or 1N H2SO4 (12 ml). The organic solvents were evaporated under reduced pressure and
the product was extracted with ethyl acetate (3 x 20 ml). The combined organic phase
was washed consecutively with 1N HCl or 1N H2SO4 (40 ml), H2O (50 ml), 5%
NaHCO3 (50 ml), H2O (2 x 50 ml), dried over MgSO4 or Na2SO4, and the solvent was
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evaporated under reduced pressure. The crude product was purified with silica gel
column chromatography using ethyl acetate: n-hexane (1:4) and then with ethyl acetate:
n-hexane (1:1) to give 2 as white crystals in yield of 1.12g (60.0%): mp 59.5-
60oC;_n max/cm
-1 3482 (OH), 3372 (NH), 1724, 1684 (C=O); 1H-NMR (300 MHz, CDCl3)
d  1.45 (9H, s, C(CH3)3), 2.69 (2H, d, J = 6.30 Hz, CH 2), 2.94 (1H, s, OH), 3.69 (2H, t, J
= 5.10 Hz, CH2), 3.96-4.08 (1H, m, CH), 5.14 (2H, s, CH2), 5.30 (1H, d, J = 12.00 Hz,
NH), 7.37 (5H, s, C6H5); 
13C-NMR (75 MHz, CDCl3) d  28.26 (CH3), 35.97 (CH2), 49.36
(CH), 64.19 (CH2), 66.52 (CH2), 79.73 (C), 128.15 (CH),128.24 (CH), 128.50 (CH),
135.52 (C), 155.74 (C), 171.55 (C), FAB-Mass: m/z  310 (M+1).
4-(3-Benzoyl-5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3-tert-butoxy-
carbonylaminobutyric acid benzyl ester (R) (3)(77,78)
 To a stirred suspension of 2 (0.31 g; 1.00 mmol), N3-Benzoylthymine (0.23 g; 1.00
mmol) and  triphenylphosphine (0.29 g; 1.10 mmol) in dry THF (10 ml) was added
diethyl azodicarboxylate (182 m l; 1.10 mmol) in a dropwise manner at –15oC. The
reaction mixture was stirred at room temperature for 24 hours, and then the clear
solution was evaporated to dryness. The residue was purified by silica gel column
chromatography using CH2Cl2: acetone (50:1) as a mobile phase a foamy product was
formed which was recrystallized from ethyl acetate: n-hexane to give 3 as white crystals
in yield of  0.24 g (45.0%): mp 76-77oC;_n max/cm
-1 3359 (NH), 1747, 1705,1654
(C=O); 1H-NMR (300 MHz, CDCl3) d  1.39 (9H, s, C(CH3)3), 1.86 (3H, s, CH3), 2.60
(2H, d, J = 5.40  Hz, CH2), 3.45-4.22 (2H, m, CH2), 4.25-4.37 (1H, m, CH), 5.10 (2H,
s, CH2), 5.55 (1H, d, J = 9.00 Hz, NH), 7.08 (1H, s, CH-6 of T), 7.32 (5H, s, C6H5), 7.45
(2H, t, J = 7.65 Hz, PhC=O), 7.60 (1H, t, J = 7.35 Hz, PhC=O), 8.07 (2H, d, J = 7.80 Hz,
PhC=O); 13C-NMR (125 MHz, CDCl3) d  12.22 (CH 3), 28.34 (CH3), 36.25 (CH2), 46.24
(CH), 52.04 (CH2), 66.83 (CH2), 79.94 (C), 110.07 (C), 128.30 (CH), 128.46 (CH),
128.65 (CH), 129.05 (CH), 130.71 (CH), 131.81 (C), 134.86 (CH), 135.41 (C),140.82
(CH), 150.20 (C), 155.42 (C), 163.22 (C), 169.19 (C), 170.88 (C); FAB-Mass: m/z 522
(M+1); (found C, 64.53; H, 5.74; N, 8.13. C28H31N3O7 requires C, 64.48; H, 5.99; N,
8.06).
3-Amino-4-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)butyric acid benzyl
ester (R) (4)(79)
A solution of 3N HCl in ethyl acetate (3 ml) was added to compound 3 (0.10 g; 0.20
mmol). After stirring of the reaction mixture for 30-45 minutes at room temperature, the
reaction was monitored by TLC and excess of the reagent was removed under reduced
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pressure. The obtained oily hydrochloride salt was dried for 2 hours in vacuo over
potassium hydroxide, neutralized with 5% sodium bicarbonate until pH (7-8) and then
extracted with ethyl acetate several times. The ethyl acetate extracts were washed with
saturated sodium chloride and then with distilled water, evaporation of the ethyl acetate
extracts gave 4 as an oily compound in yield of 0.04 g (70.0%): 1H-NMR (300 MHz,
CDCl3) d  1.88 (3H, s, CH3), 2.43 (1H, dd, J = 9.00 and 9.00 Hz, CHH), 2.62 (1H, dd, J
= 3.90 and 3.90 Hz, CHH), 3.57-3.67 (2H, b, NH2), 3.90-4.05 (2H, m, CH2), 4.17 (1H, q,
J = 7.20, CH), 5.12 (2H, s, CH2), 6.98 (1H, s, CH-6 of T), 7.34 (5H, s, C6H5); 
13C-NMR
(125 MHz, CDCl3) d  12.10 (CH 3), 36.10 (CH2), 45.47 (CH), 52.87 (CH2), 66.46 (CH2),
107.08 (C), 128.07 (CH), 128.14 (CH), 129.00 (CH), 135.98 (C), 136.11 (CH), 163.97
(C), 168.32 (C), 169.96 (C); FAB-Mass: m/z 318 (M+1), (found C, 60.48; H, 6.13; N,
13.18. C16H19N3O4 requires C, 60.56; H, 6.03; N, 13.24).
3-[2-(9H-Fluoren-9-ylmethoxycarbonylamino)acetylamino]-4-(5-methyl-2,4-dioxo-
3,4-dihydro-2H-pyrimidin-1-yl)butyric acid benzyl ester (R) (5)  
To a stirred solution of 4 (1.00 g; 3.15 mmol), Fmoc-glycine (0.94 g; 3.15 mmol) and
N-ethyldiisopropylamine (1.10 ml; 6.30 mmol) in DMF (20 ml) at 0oC under Argon gas,
HOBt.H2O (0.48 g, 3.15 mmol) was added followed by TBTU (1.01 g; 3.15 mmol). The
mixture was stirred at 0oC for 1 hour and then at room temperature for additional 4
hours. After evaporation of DMF completely, the residue was dissolved in ethyl acetate
(100 ml). The ethyl acetate was washed successively with 5% aqueous KHSO4 (20 ml),
water (20 ml), 5% NaHCO3 (20 ml) and water (20 ml). The solution was dried over
MgSO4 and then the solvent was evaporated under reduced pressure to give a crude
crystalline product, which was recrystallized from EtOAc: n-hexane to give 5 as a white
crystalline product in yield of  1.32 g (70.0%): mp 128-129oC; [ a ]D
25
 – 26.77
o (c 0.1,
methanol); n max/cm
-1 3329 (NH) 1724, 1645 (C=O); 1H-NMR (300 MHz, DMSO-d6)_d
1.74 (3H, s, CH3), 2.52-2.60 (2H, m, CH2), 3.48 (2H, t, J = 5.70 Hz, CH2), 3.90 (2H, d, J
= 6.60 Hz, CH2), 4.18-4.27 (3H, m, CH2, CH), 4.46-4.57 (1H, m, CH), 5.01 (2H, s, CH2),
7.24 (1H, s, CH-6 of T ), 7.30 (2H, d, J = 7.50 Hz, Ar-H), 7.33 (5H, s, C6H5), 7.40 (2H,
dd, J = 7.20  and 7.50 Hz, Ar-H), 7.70 (2H, d, J = 7.20 Hz, Ar-H), 7.87 (2H, d, J =
7.50 Hz, Ar-H), 10.83 (1H, b, NH); 13C-NMR (125 MHz, DMSO-d6) d _12.29 (CH3),
36.85 (CH2), 42.55 (CH2), 43.58 (CH2), 44.28 (CH), 44.51 (CH), 65.44 (CH2), 66.22
(CH2), 107.02 (C), 119.85 (CH), 121.20 (CH), 127.12 (CH), 127.74 (CH), 127.77 (CH),
128.22 (CH), 128.76 (CH), 136.24 (CH), 137.32 (C), 139.32 (C), 142.50 (C), 151.43
(C), 164.04 (C), 168.89 (C), 170.21 (C), 171.96 (C); FAB-Mass: m/z 597 (m+1); (found
C, 65.93; H, 5.51; N, 9.54. C33H32N4O7 requires C, 66.43; H, 5.41; N, 9.39).  
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3-[2-(9H-Fluoren-9-ylmethoxycarbonylamino)acetylamino]-4-(5-methyl-2,4-dioxo-
3,4-dihydro-2H-pyrimidin-1-yl)butyric acid (R) (6)(80)
To a stirred solution of 5 (0.60 g; 1.00 mmol) in ethanol (10 ml) under Argon gas 10 %
Pd/C (1.01 g) was added followed by 1,4-cyclohexadiene (1.64 g, 20.00 mmol). The
mixture was stirred over night and then filtered through celite. After washing several
times with hot ethanol, the combined organic solvent was evaporated and the residue
was dried in vacuum then 5 % NaHCO3 (10 ml) was added. The mixture was extracted
with ethyl acetate for the removal of byproduct. The sodium salt was neutralized with
10 % KHSO4 till pH (2-3) and then extracted with ethyl acetate (3 x 20 ml). The
combined ethyl acetate extracts were washed consequently with saturated sodium
chloride solution and  distilled water, dried over MgSO4 and evaporated under reduced
pressure to give a crude product, which was recrystallized from ethanol to give 6 as
white crystals in yield of  0.33 g (65.0%): mp 144oC; [ a ]D
25
 – 30.56
o (c 0.1, methanol);
n max/cm
-1 3311 (NH) 1714, 1638 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  1.75 (3H, s,
CH3), 2.35-2.46 (2H, m, CH2), 3.30 (1H, br, NH), 3.41-3.58 (2H, m, CH2), 3.84-3.98
(2H, m, CH2), 4.18-4.30 (3H, m, CH2, CH), 4.40-4.53 (1H, m, CH), 7.23 (1H, s, CH-6
of T), 7.32 (2H, dd, J  = 7.20 and 7.50 Hz, Ar-H), 7.40 (2H, dd, J = 7.20 and 7.50 Hz,
Ar-H), 7.71 (2H, d, J = 7.50, Ar-H), 7.87 (2H, d, J = 7.50 Hz, Ar-H), 10.81 (1H, br, NH),
12.14 (1H, br, COOH); 13C-NMR (75 MHz, DMSO-d6) d  12.48 (CH3), 37.03 (CH2),
42.72 (CH2), 43.39 (CH2), 44.55 (CH), 46.63 (CH), 65.74 (CH2), 107.13 (C), 120.06
(CH), 125.27 (CH), 127.06 (CH), 127.60 (CH), 136.28 (CH), 140.69 (C), 143.85 (C),
151.54 (C), 156.30 (C), 164.14(C), 168.48 (C), 171.94 (C); FAB-Mass: m/z 507 (M+1);
(found C, 61.21; H, 5.19; N, 10.94. C26H26N4O7 requires C, 61.65; H, 5.17; N, 11.06).
5.1.2. Synthesis of isogaPNA thymine monomer (S)
3-tert-Butoxycarbonylamino-4-hydroxybutyric acid benzyl ester (S) (8)(76)
To a stirred solution of 7 (1.94 g; 6.00 mmol) in distilled THF (30 ml) at –10oC, under
Argon atmosphere, N-methylmorpholine (0.61 g; 6.00 mmol) was added in a dropwise
manner followed by ethyl chloroformate (0.65 g; 6.00 mmol), after 10 minutes sodium
borohydride (0.68 g; 18.00 mmol) was added in one portion, methyl alcohol (30 ml)
was then added in a dropwise manner to the mixture over a period of 10 minutes at 0oC.
The solution is stirred for additional 10 minutes, and then neutralized with 1N HCl or
1N H2SO4 (12 ml). The organic solvents were evaporated under reduced pressure and
the product was extracted with ethyl acetate (3 x 20 ml). The combined organic phase
was washed consecutively with 1N HCl or 1N H2SO4 (40 ml), H2O (50 ml), 5%
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NaHCO3 (50 ml), H2O (2 x 50 ml), dried over MgSO4 or Na2SO4, and the solvent was
evaporated under reduced pressure. The crude product was purified with silica gel
column chromatography using ethyl acetate: n-hexane (1:4) and then with ethyl acetate:
n-hexane (1:1) to give 8 as white crystals in yield of 1.15g (62.0%): mp 62oC;_n max/cm
-1
3482 (OH), 3372 (NH), 1724, 1685 (C=O). 1H-NMR (300 MHz, CDCl3) d  1.42 (9H, s,
C(CH3)3), 2.65 (2H, d, J = 6.30 Hz, CH2), 3.09 (1H, br, NH), 3.63 (2H, d, J = 4.80 Hz,
CH2), 3.95-4.05 (1H, m, CH), 5.11 (2H, s, CH2), 7.34 (5H, s, C6H5); 
13C-NMR (125
MHz, CDCl3) d  28.28 (CH3), 36.07 (CH2), 49.49 (CH), 64.29 (CH2), 66.52 (CH2), 79.73
(C), 128.14 (CH), 128.24 (CH), 128.51 (CH), 135.62 (C), 155.73 (C), 171.49 (C); FAB-
Mass: m/z  310 (M+1).
4-(3-Benzoyl-5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3-tert-butoxy-
carbonylaminobutyric acid benzyl ester (S) (9)(77,78)
To a stirred suspension of 8 (0.31 g; 1.00 mmol), N3-Benzoylthymine (0.23 g; 1.00
mmol) and triphenylphosphine (0.29 g; 1.10 mmol) in dry THF (10 ml) under Argon gas
was added diethyl azodicarboxylate (182 m l; 1.10 mmol) in a dropwise manner at –15oC.
The reaction mixture was stirred at room temperature for 24 hours, and then the clear
solution was evaporated to dryness. The residue was purified by silica gel column
chromatography using CH2Cl2: acetone (50:1) as a mobile phase, gave a foamy product
which was recrystallized from ethyl acetate: n-hexane to give 9 as white crystals in yield
of  0.23 g (44.0%): mp 77oC; n max/cm
-1 3360 (NH) 1747, 1705, 1654 (C=O); 1H-NMR
(300 MHz, CDCl3) d  1.37 (9H, s, C(CH3)3), 2.02 (3H, s, CH3), 2.57 (1H, dd, J = 4.80
and 5.10  Hz, CHH), 2.66 (1H, dd, J = 4.80 and 5.10 Hz, CHH) 3.81 (1H, d, J = 9.60
Hz, NH), 4.11-4.30 (2H, m, CH2), 4.32-4.42 (1H, m, CH), 5.12 (2H, s, CH2), 7.11 (1H, s,
CH-6 of T), 7.33 (5H, s, C6H5), 7.47 (2H, t, J = 7.50 Hz, PhC=O), 7.88 (1H, d, J = 7.50
Hz, PhC=O), 8.11 (2H, d, J  = 7.20  Hz, PhC=O);  13C-NMR (125 MHz, CDCl3) d
12.06 (CH3),  28.19 (CH3), 36.10 (CH2), 46.07 (CH), 51.88 (CH2), 66.67 (CH2), 79.79
(C), 109.90 (C), 128.14 (CH), 128.31 (CH), 128.49 (CH), 128.91 (CH), 130.55 (CH),
131.64 (C), 134.73 (CH), 135.25 (C), 140.69 (CH), 150.04 (C), 155.27 (C), 163.08 (C),
169.04 (C), 170.71 (C), FAB-Mass: m/z  522.5 (M+1); (found C, 64.02; H, 5.95; N,
8.12. C28H31N3O7 requires C, 64.48; H, 5.99; N, 8.06); (found C, 64.38; H, 5.95; N, 8.03.
C28H31N3O7 requires C, 64.48; H, 5.99; N, 8.06).
3-Amino-4-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)butyric acid benzyl
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ester (S) (10)(79)
A solution of 3N HCl in ethyl acetate (3 ml) was added to compound 9 (0.10 g; 0.20
mmol). After stirring the reaction mixture was for 30-45 minutes at room temperature,
the reaction was monitored by TLC and excess of the reagent was removed under
reduced pressure. The obtained oily hydrochloride salt was dried for 2 hours in vacuo
over potassium hydroxide, neutralized with 5% sodium bicarbonate until pH (7-8) and
then extracted with ethyl acetate several times, the ethyl acetate extracts were washed
with saturated sodium chloride and then with distilled water, evaporation of the ethyl
acetate extracts gave 10 as an oily compound in yield of  0.04 g (75.0%): 1H-NMR
(300 MHz, CDCl3)_d  1.89 (3H, s, CH3), 2.43 (1H, dd, J = 8.98 and 8.98 Hz, CHH), 2.63
(1H, dd, J = 3.85 and 4.03, CHH) 3.63 (2H, b, NH2), 3.90-4.10 (2H, m, CH2), 4.15-4.22
(1H, m, CH), 5.1 (2H, s, CH2), 6.98 (1H, s, CH-6 of T), 7.34 (5H, s, C6H5), ); 
13C-NMR
(125 MHz, CDCl3) d  12.21 (CH3), 36.11 (CH2), 45.52 (CH), 52.82 (CH2), 66.53 (CH2),
107.10 (C), 128.03 (CH), 128.12 (CH), 129.10 (CH), 135.90 (C) 136.01 (CH), 164.11
(C), 168.38 (C), 169.98 (C); FAB-Mass: m/z 318 (m+1); (found C, 60.42; H, 6.03; N,
13.21. C16H19N3O4 requires C, 60.56; H, 6.03; N, 13.24).
3-[2-(9H-Fluoren-9-ylmethoxycarbonylamino)acetylamino]-4-(5-methyl-2,4-dioxo-
3,4-dihydro-2H-pyrimidin-1-yl)butyric acid benzyl ester (S) (11)
To a stirred solution of 10 (1.00 g; 3.15 mmol), Fmoc-glycine (0.94 g; 3.15 mmol) and
N-ethyldiisopropylamine (1.10 ml; 6.30 mmol) in DMF (20 ml) at 0oC under Argon gas,
HOBt.H2O (0.48 g, 3.15 mmol) was added followed by TBTU (1.01 g; 3.15 mmol). The
mixture was stirred at 0oC for 1 hour and then at room temperature for additional 4
hours. After evaporation of DMF completely, the residue was dissolved in ethyl acetate
(100 ml), the ethyl acetate was washed successively with 5% aqueous KHSO4 (20 ml),
water (20 ml), 5% NaHCO3 (20 ml) and water (20 ml). The solution was dried over
MgSO4 and then the solvent was evaporated under reduced pressure to give a crude
product which was recrystallized from EtOAc: n-hexane give 11 as a white crystalline
product in yield of 1.24 g (66.0%): mp 130-131oC; [ a ]D
25
 26.47
o (c 0.1, methanol);
n max/cm
-1 3330 (NH); 1736, 1668 (C=O), 1H-NMR (300 MHz, DMSO-d6)_d  1.74 (3H, s,
CH3), 2.53 (2H, d, J = 6.9 Hz, CH2), 3.48 (2H, t, J = 5.7 Hz, CH2), 3.90 (2H, d, J = 6.9
Hz, CH2), 4.19-4.26 (3H, m, CH2, CH), 4.45-4.59 (1H, m, CH), 5.01 (2H, s, CH2), 7.24
(1H, s, CH-6 of T), 7.32 (5H, s, C6H5), 7.28-7.44 (4H, m, Ar-H), 7.70 (2H, d, J = 7.2 Hz,
Ar-H), 7.87 (2H, d, J = 7.5 Hz, Ar-H), 10.82 (1H, b, NH); 13C-NMR (75 MHz, DMSO-
d6) d  12.45 (CH3), 36.92 (CH2), 42.65 (CH2), 43.37 (CH2), 44.53 (CH), 46.60 (CH),
65.57 (CH2), 65.72 (CH2), 107.11 (C), 120.06 (CH), 125.25 (CH), 127.05 (CH), 127.59
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(CH), 127.87 (CH), 127.89 (CH), 128.33 (CH), 135.99 (C), 136.36 (CH), 140.68 (C),
143.83 (C), 151.51 (C), 156.30 (C), 164.12 (C), 168.55 (C), 170.27 (C); FAB-Mass:
m/z 597 (m+1); (found C, 66.15; H, 5.54; N, 9.51. C33H32N4O7 requires C, 66.43; H,
5.41; N, 9.39).
3-[2-(9H-Fluoren-9-ylmethoxycarbonylamino)acetylamino]-4-(5-methyl-2,4-dioxo-
3,4-dihydro-2H-pyrimidin-1-yl)butyric acid (S) (12)(80)  
To a stirred solution of 11 (0.60 g; 1.00 mmol) in ethanol (10 ml) under Argon gas 10 %
Pd/C (1.01 g) was added followed by 1,4-cyclohexadiene (1.64 g, 20.00mmol). The
mixture was stirred over night and then filtered through celite. After washing several
times with hot ethanol, the combined organic solvent was evaporated and the residue
was dried in a vacuum then 5 % NaHCO3 (10 ml) was added. The mixture was extracted
with ethyl acetate for the removal of the byproduct. The sodium salt was neutralized
with 10 % KHSO4 till pH (2-3) and then extracted with ethyl acetate (3 x 20 ml). The
combined ethyl acetate extracts were washed  consequently with saturated sodium
chloride solution (20 ml) and  distilled water (2 x 20 ml), dried over MgSO4 and
evaporated under reduced pressure to give a crude product which was recrystallized
from ethanol to give 12 as a white crystalline product in yield of  0.31 g (62.0%): mp
145oC; [ a ]D
25
 30.15
o (c 0.1, methanol); n max/cm
-1 3310, 3295 (NH) 1715, 1635 (C=O);
1H-NMR (300 MHz, DMSO-d6) d _1.75 (3H, s, CH3), 2.39-2.44 (2H, m, CH2), 3.42-3.58
(2H, m, CH 2), 3.85-3.96 (2H, m, CH2), 4.18-4.28 (3H, m, CH2, CH), 4.41-4.52 (1H, m,
CH), 7.23 (1H, s, CH-6 of T), 7.31 (2H, t, J =  7.35 Hz, Ar-H), 7.40 (2H, t, J  = 7.20
Hz, Ar-H), 7.71 (2H, d, J  = 7.80 Hz, Ar-H), 7.87 (2H, d, J = 7.80 Hz, Ar-H), 10.81
(1H, br, NH), 12.14 (1H, br, COOH); 13C-NMR (75 MHz, DMSO-d6) d _12.48 (CH3),
37.03 (CH2), 42.72 (CH2), 43.39 (CH2), 44.55 (CH), 46.63 (CH), 65.73 (CH2), 107.13
(C), 120.06 (CH), 125.27 (CH), 127.06 (CH), 127.60 (CH), 136.28 (CH), 140.69 (C),
143.85 (C), 151.54 (C), 156.30 (C), 164.15 (C), 168.48 (C), 171.93 (C); FAB-Mass:
m/z 507 (M+1); (found C, 61.29; H, 5.01; N, 11.28. C26H26N4O7 requires C, 61.65; H,
5.17; N, 11.06).
5.1.3. Synthesis of isogaPNA adenine monomer
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4-(6-Benzoylaminopurin-9-yl)-3-tert-butoxycarbonylaminobutyric acid benzyl
ester (13)(77)
To a stirred suspension of 2 (5.57 g, 18.00 mmol), triphenylphosphine (5.19 g, 19.80
mmol) and N6-benzoyladenine (12.92 g, 54.00 mmol) in dry THF (150 ml) was added
N,N-diethyl azodicarboxylate (2.83 ml, 18.00 mmol) in a dropwise manner at 0oC. The
reaction mixture was stirred at 0oC for 2 hours followed by overnight stirring at room
temperature under stream of N2 gas. The insoluble products were filtered off and the
filtrate was evaporated till dryness. The crude product was purified with silica gel
column chromatography using dichloromethane: acetone (50:1) as a mobile phase to
give 13 as white crystals in yield of  4.30 g (45.0%): mp 127-129oC, n max/cm
-1 3296
(NH) 1725, 1644 (C=O)), 1H-NMR (300 MHz, DMSO-d6) d  1.22 (9H, s, C(CH3)3),
2.49-2.76 (2H, m, CH2), 4.22-4.45 (3H, m, CH, CH2), 5.07 (2H, s, CH2), 7.01 (1H, d,
J = 7.8 Hz, NH), 7.35 (5H, s, C6H5), 7.53 (2H, t, J = 7.35 Hz, PhC=O), 7.62 (1H, d, J =
7.2 Hz, PhC=O), 8.02 (2H, d, J = 7.2 Hz, PhC=O), 8.27 (1H, s, CH), 8.70 (1H, s, CH),
11.10 (1H, s, NH); 13C-NMR (75 MHz, DMSO-d6) d  27.88 (CH3), 36.69 (CH2), 46.41
(CH2), 47.41 (CH), 65.68 (CH2), 77.96 (C), 127.83 (CH), 127.95 (CH), 128.36 (CH),
128.41 (CH), 128.66 (CH), 128.80 (CH), 132.32 (CH), 133.56 (C), 135.99 (C), 144.84
(CH), 149.96 (C), 151.26 (C), 154.73 (C), 170.11 (C); FAB-Mass: m/z 531 (M+1);
(found C, 63.05; H, 5.71; N, 15.36. C26H30N6O5 requires C, 63.38; H, 5.70; N, 15.84).
4-(6-Benzoylaminopurin-9-yl)-3-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-
acetylamino]butyric acid benzyl ester (14)(81,82)
To a stirred solution of 13 (1.06 g, 2.00 mmol) in dichloromethane (8 ml) at 0oC and
under stream of Argon gas was added trifluoroacetic acid (8 ml). The mixture was
stirred at room temperature for 24 hours, once the TLC analysis indicated complete
acidolysis of the Boc group, the solvents were completely evaporated. The residue was
dried under reduced pressure then dissolved in water (20 ml). The aqueous solution was
extracted with dichloromethane (3 x 20 ml) to remove byproduct. The aqueous phase
was neutralized with 5% NaHCO3 until pH 7 and then extracted with ethyl acetate. The
combined ethyl acetate extracts were washed with saturated NaCl (30 ml) and H2O (2 x
30 ml), dried over MgSO4 and then evaporated till dryness to give crude white crystals
which was used for the next step without purification. To a stirred solution of the crude
product (1.12 g, 2.60 mmol), Fmoc-glycine (0.71 g, 2.40 mmol) and TEA (0.35 ml, 2.50
mmol) in acetonitrile (30 ml) at 0oC under argon gas, TBTU (0.83 g, 2.60 mmol) was
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added. The mixture was stirred at 0oC for 1 hour then at room temperature for 24 hours.
The reaction was quenched by the addition of saturated NaCl (30 ml), the resulting
mixture was extracted with ethyl acetate (4 x 30 ml). The combined ethyl acetate
extracts were washed consequently with 2N HCl (20 ml), H2O (20 ml), 5% NaHCO3 (20
ml) and H2O (2 x 20 ml). The solution was dried over MgSO4, and then the solvent was
completely evaporated under reduced pressure to give a crude oily product, which was
purified using silica gel column chromatography eluted with CH2Cl2: MeOH (10:1) as a
mobile phase to give 14 as a white crystalline product in yield of  1.4 g (75.8 %): mp
133-135oC; n max/cm
-1 ; 1H-NMR (300 MHz, DMSO-d6) d  2.74 (2H, dd, J = 5.70 and 5.70
Hz, CH2), 3.5 (2H, d, J = 5.86 Hz, CH2), 4.22 (1H, d, J = 6.23  Hz, CH), 4.28 (2H, d, J
= 6.23 Hz, CH2), 4.32-4.48 (2H, m, CH2), 4.52-4.64 (1H, m, CH), 5.07 (2H, s, CH2),
7.29-7.43 (4H, m, Ar-H), 7.34 (5H, s, C6H5), 7.53 (2H, t, J = 6.70  Hz, Ar-H), 7.61 (1H,
d, J = 7.33  Hz, Ar-H), 7.70 (2H, d, J  = 7.51 Hz, Ar-H), 7.87 (2H, d, J  = 7.51 Hz,
Ar-H), 8.03 (2H, d, J = 7.51 Hz, Ar-H), 8.33 (1H, s, CH), 8.70 (1H, s, CH), 11.12 (1H, s,
NH); 13C-NMR (75 MHz, DMSO-d6) d  36.23 (CH2), 43.44 (CH2), 45.76 (CH2), 46.08
(CH), 46.59 (CH), 65.75 (CH2, CH2), 120.04 (CH), 125.07 (C), 125.21 (CH), 127.02
(CH), 127.57 (CH), 127.94 (CH), 128.36 (CH), 128.39 (CH), 132.31 (CH), 133.47 (C),
135.91 (C), 140.67 (C), 143.80 (C), 144.98 (CH), 149.99 (C), 151.37 (CH), 152.81 (C),
156.44 (C), 165.49 (C), 168.99 (C), 169.99 (C); FAB-Mass: m/z 710 (m+1); (found C,
67.11; H, 5.14; N, 13.49. C40H35N7O6 requires C, 67.69; H, 4.97; N, 13.81).  
        
4-(6-Benzoylamino-purin-9-yl)-3-[2-(9H-fluoren-9-ylmethoxycarbonylamino)
acetylamino]butyric acid (15)(83)
To a stirred solution of 14 (0.71 g, 1.00 mmol) in methanol (10 ml) under Argon gas
10% Pd-C (0.70 g) was added. The mixture was stirred under stream of hydrogen gas
for 24 hours and then the mixture was filtered through celite. After washing several
times with hot methanol, the combined methanol solution was completely evaporated in
vacuum then 5 % NaHCO3 (10 ml) was added. The mixture was extracted with ethyl
acetate for the removal of byproduct. The sodium salt was neutralized with 10 %
KHSO4 till pH (2-3) and then extracted with ethyl acetate (3 x 20 ml). The combined
ethyl acetate extracts were washed  consequently with saturated NaCl (30 ml),
distilled water (2 x 30 ml), dried over MgSO4 and then completely evaporated under
reduced pressure to give a crude product, which was recrystallized from ethanol to give
15 as a white crystalline product in yield of  0.30 g (50.0%): mp 213-215oC; n max/cm
-1
3309 (OH), 1697, 1646 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  2.42-2.62 (2H, m,
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CH2), 3.49 (2H, d, J = 5.2 Hz, CH2), 4.13-4.56 (4H, m, CH2, CH, CH), 7.10 (1H, s, NH),
7.31 (2H, d, J = 7.50 Hz, Ar-H), 7.39 (2H, t, J = 7.20 Hz, Ar-H), 7.54 (2H, d, J = 7.2 Hz,
Ar-H), 7.61 (1H, d, J = 8.1 Hz, Ar-H), 7.70 (2H, d, J = 7.2 Hz, Ar-H), 7.87 (2H, d, J =
7.2 Hz, Ar-H), 8.03 (2H, d, J = 7.8 Hz, Ar-H), 8.32 (1H, s, CH), 8.71 (1H, s, CH), 11.13
(1H, s, NH); 13C-NMR (75 MHz, DMSO-d6) d _36.45 (CH2), 43.42 (CH2), 45.80 (CH2),
46.13 (CH), 46.58 (CH), 65.73 (CH2), 120.02 (CH), 125.05 (C), 125.21 (CH), 127.01
(CH), 127.54 (CH), 128.37 (CH), 132.28 (C), 133.52 (CH), 140.66 (C), 143.80 (C),
144.96 (CH), 149.94 (C), 151.24 (CH), 152.76 (C), 156.40 (C), 165.58 (C), 168.88 (C),
171.73 (C); FAB-Mass: m/z 620 (m+1); (found C, 63.87; H, 4.81; N, 15.61. C33H29N7O6
requires C, 63.97; H, 4.72; N, 15.82).       
5.1.4. Synthesis of isoggPNA thymine monomer
2-tert-Butoxycarbonylamino-3-hydroxypropionic acid dicyclohexylamine salt (17)
To a stirred solution of 16 (24.62 g, 0.12 mol) in a mixture of dichloromethane-
methanol (100:50 ml) was added dicyclohexylamine (24.30 ml, 0.12 mol) in a dropwise
manner.  The mixture was stirred at 0oC for 30 minutes followed by overnight stirring
at room temperature. The solvents were completely evaporated under reduced pressure
and the resulting oily product was recrystallized from ethyl acetate: n-hexane to give 17
as a white crystalline substance in yield of 34.00 g (73.3%).
2-tert-Butoxycarbonylamino-3-hydroxypropionic acid benzyl ester (18)
To a stirred solution of 17 (44.84 g, 0.12 mol) in DMF (200 ml) was added benzyl
bromide (13.85 ml, 0.12 mol). The mixture was stirred at room temperature for 24 hours
and then The DMF was completely evaporated under reduced pressure. Water (200 ml)
and ethyl acetate (100 ml) were added, and the aqueous layer was extracted with ethyl
acetate (4 x 30 ml). The combined ethyl acetate extracts were washed consequently with
saturated NaCl (30 ml) and water (2 x 30 ml), dried over MgSO4. The ethyl acetate
extracts were completely evaporated to give a crude oily product which was
recrystallized  from ethyl acetate: n-hexane to give 18 as a white crystalline product in
yield of  28.20 g (82.3%): mp 70-71oC; n max/cm
-1 3420 (OH), 3365 (NH), 1760, 1670
(C=O); 1H-NMR (300 MHz, CDCl3) d  1.44 (9H, s, C(CH3)3), 2.1 (1H, br, OH), 3.90 (1H,
dd, J = 11.30 and 3.5 Hz, CHH), 3.98 (1H, dd, J = 11.20 and 4 Hz, CHH), 4.42 (1H, br,
CH), 5.21 (2H, s, CH2Ph), 5.4 (1H, br, NH), 7.35 (5H, s, C6H5); 
13C-NMR (75 MHz,
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CDCl3) d  28.08 (CH3), 55.80 (CH), 66.60 (CH2), 71.80 (CH2), 79.42 (C), 127.81 (CH),
128.06 (CH), 128.35 (CH), 135.62 (C), 155.30 (C), 169.17 (C); FAB-Mass: M/z 296
(M+1).       
2-tert-Butoxycarbonylamino-3-(toluene-4-sulfonyloxy)propionic acid benzyl ester
(19)(85)
To a stirred solution of 18 (6.91 g, 23.42 mmol) in dry pyridine (40 ml) was added tosyl
chloride (4.91 g, 25.76 mmol). The resulting solution was stirred at –10oC under stream
of N2 gas for 2 hours followed by stirring at room temperature for 18 hours. The
resulting mixture was poured into a beaker of ice-water (200 ml) with continued stirring,
a white solid was formed. The resulting solid was filtered and washed with distilled
water, dried in a vacuum desicator over phosphorus pentoxide. The obtained crude
product was recrystallized from ethanol to give 19 as a white crystalline solid  in yield
of  8.86 g (84.2%): mp 95-96oC; n max/cm
-1 3374 (NH), 1753, 1694 (C=O); 1H-NMR
(300 MHz, CDCl3) d  1.41 (9H, s, C(CH3)3), 2.42 (3H, s, CH3), 4.27-4.33 (1H, m, CHH),
4.38-4.44 (1H, m, CHH), 4.51-4.57 (1H, m, CH), 5.08 (1H, d, J = 12.00  Hz, PhCHH),
5.17 (1H, d, J = 12.3 Hz, PhCHH), 5.34 (1H, d, J = 8.10 Hz, NH), 7.29-7.37 (2H, m,
Ar-H), 7.34 (5H, s, C6H5), 7.71 (2H, d, J = 8.10 Hz, Ar-H); 
13C-NMR (75 MHz,
CDCl3)_d  21.61 (CH3), 28.15 (CH3), 53.02 (CH), 67.79 (CH2), 69.46(CH2), 80.43 (C),
127.92 (CH), 128.23 (CH), 128.52 (CH), 128.58 (CH), 129.88 (CH), 132.25 (C), 134.72
(C), 145.08 (C), 154.89 (C), 168.39 (C); FAB-Mass: M/z 450 (M+1).   
2-tert-Butoxycarbonylamino-3-iodopropionic acid benzyl ester (20)(85)
A solution of sodium iodide (3.90 g, 26.06 mmol) in dry acetone (20 ml) was added in a
dropwise manner to a stirred solution of 19 (7.81 g, 17.37 mmol) in dry acetone (20 ml)
under N2 gas. The resulting yellow solution was stirred in the dark at ambient
temperature for 24 hours and then filtered and concentrated under reduced pressure. The
residue was dissolved in chloroform (100 ml), washed sequentially with distilled water
(2 x 50 ml), sodium thiosulfate (50 ml, 1M), and distilled water (3 x 50 ml), and then
dried over anhydrous sodium sulfate. Concentration under reduced pressure gave a
light-sensitive colorless oil which solidified on standing. Recrystallization from a
minimum amount of hot ethanol, followed by filtration and trituration with light
petroleum ether to give the iodide 20 as a white crystalline solid in yield of  5.66 g
(80.4%): mp 79-80oC; n max/cm
-1 3362 (NH), 1759, 1685 (C=O); 1H-NMR (300 MHz,
CDCl3) d _1.37 (9H, s, C(CH3)3), 3.29-3.38 (1H, m, CHH), 3.47-3.55 (1H, m, CHH),
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4.22-4.31 (1H, m, CH), 5.13 (2H, s, CH2), 7.35 (5H, s, C6H5), 7.45 (1H, d, J = 8.10 Hz,
NH); 13C-NMR (75 MHz, CDCl3)_d _4.42 (CH2), 28.08 (CH3), 55.55 (CH), 66.43 (CH2),
78.67 (C), 127.78 (CH), 128.06 (CH), 128.35 (CH), 135.59 (C), 155.10 (C), 169.13 (C);
FAB-Mass: M/z 406 (M+1).   
3-(3-Benzoyl-5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2-tert-butoxy-
carbonylaminopropionic acid benzyl ester (21) and 2-tert-Butoxycarbonylamino-
3-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)propionic acid benzyl ester
(22)
To a stirred solution of iodide compound 20 (4.05 g, 10.00 mmol), N3-Benzoylthymine
(4.60 g, 20.00 mmol) in DMF (30 ml) was added anhydrous K2CO3 (2.76 g, 20.00
mmol). The mixture was stirred at room temperature for 12 hours, the solvent was
evaporated completely to dryness. The resulting residue was dissolved in ethyl acetate
(200 ml), washed with water (200 ml), and then dried over MgSO4. The ethyl acetate
was completely evaporated under reduced pressure and the resulting crude products
were purified by flash chromatography on silica gel using ethyl acetate: n-hexane (1:2)
as a mobile phase to give 21 as a white crystalline substance in 3.45 g (68.0% yield) and
22 as a white crystalline substance in yield of  0.45g (11.2%). Analytical samples were
further purified by recrystallization from ethyl acetate: n-hexane. 21: mp 133-134oC;
n max/cm
-13361 (NH) 1746, 1703, 1655 (C=O); 1H-NMR (300 MHz, CDCl3) d  1.43 (9H, s,
C(CH3)3), 1.90 (3H, s, CH3), 3.70-3.85 (1H, m, CHH), 4.34-4.42 (1H, m, CHH), 4.59-
4.70 ( 1H, m, CH), 5.07 (1H, d, J = 12.00 Hz, PhCHCH), 5.19 (1H, d, J = 12.00 Hz,
PhCHCH), 5.47 (1H, d, J = 6.60 Hz, NH), 7.02 (1H, s, CH-6 of T), 7.33 (5H, s, C6H5),
7.48 (2H, dd, J = 7.80 and 7.80, PHC=O), 7.63 (1H, dd, J = 7.80 and 7.80 Hz, PhC＝O),
8.04 (2H, d, J = 7.80 Hz, PhC＝O); 13C-NMR (75 MHz, CDCl3)_d  12.30 (CH3), 28.21
(CH3), 50.47 (CH2), 52.26 (CH), 68.08 (CH2), 80.68 (C), 110.41 (C), 128.53 (CH),
128.63 (CH), 129.01 (CH), 130.68 (CH), 131.59 (C), 134.68 (C), 134.89 (CH), 140.46
(CH), 150.06 (C), 155.22 (C), 163.04 (C), 168.86 (C), 169.39 (C); FAB-Mass: M/z 508
(M+1); (found: C, 63.98; H, 5.73; N, 8.30. C27H29N3O7 requires: C, 63.89; H, 5.76; N,
8.28).
22: mp 191-192oC; n max/cm
-1 3358 (NH) 1745, 1703, 1653 (C=O); 1H-NMR (300 MHz,
CDCl3)_d  1.41 (9H, s, C(CH3)3), 1.85 (3H, s, CH3), 4.02 (1H, dd, J = 14.20 and 6.80 Hz,
CHH), 4.20 (1H, dd, J = 14.20 and 5.60 Hz, CHH), 4.52 (1H, dd, J = 6.80 and 5.60 Hz,
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CH), 5.16 (1H, d, J = 12.00 Hz, PhCHH), 5.22 (1H, d, J = 12.00 Hz, PhCHH), 5.46 (1H,
br, NH), 6.92 (1H, s, CH-6 of T), 7.34 (5H, s, C6H5), 8.25 (1H, brs, NH);
 13C-NMR (75
MHz, CDCl3)_d  11.95 (CH3), 27.98 (CH3), 48.12 (CH2), 51.70 (CH), 66.38 (CH2), 78.72
(C), 108.03 (C), 127.89 (CH), 128.11 (CH), 128.39 (CH), 135.58 (C), 141.80 (CH),
150.87 (C), 155.26 (C), 164.20 (C), 169.76 (C); FAB-Mass: M/z 404 (M+1); (found: C,
59.65; H, 5.95; N, 10.23. C27H29N3O7 requires: C, 59.54; H, 6.25; N, 10.42).
              
3-(3-Benzoyl-5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2-[2-(9H-fluoren-
9-ylmethoxycarbonylamino)acetylamino]propionic acid benzyl ester (23)(86)
To a stirred solution of 21 (0.51 g, 1.00 mmol) in 1,4-dioxane (10 ml) was added
concentrated HCl (8 ml). The reaction was continued stirring until the TLC analysis
indicated complete acidolysis of the Boc group. The solvents were completely
evaporated under reduced pressure and the residue was neutralized with saturated
NaHCO3. The solution was extracted with CH2Cl2 (3 x 100 ml), the combined CH2Cl2
extracts washed with saturated NaCl (20 ml) and water (2 x 30 ml) then dried over
MgSO4. The organic solvent was completely evaporated till dryness to give a crude
deprotected compound from Boc as an oily product. After dryness under reduced
pressure for 24 hours, the oily compound was used in the next coupling without
purification. N-Ethyldiisopropylamine (0.35 ml, 2.00 mmol) was added to a stirred
solution of the crude oily compound, Fmoc-glycine (0.30 g, 1.00 mmol), HOBt.H2O
(0.15g, 1.00 mmol), and TBTU (0.32 g, 1.00 mmol) in DMF (6 ml) under argon gas at
room temperature. After stirring for 1.5 hour, the solvent was evaporated under reduced
pressure. The resulting residue was dissolved in CH2Cl2 (100 ml) and the solution was
washed consecutively with H2O (80 ml), 4% NaHCO3 (3 x 80 ml), 5% aqueous KHSO4
(3 x 80 ml) and H2O (2 x 80 ml), dried over MgSO4. The organic solvent was
evaporated completely under reduced pressure, and the resulting residue was purified by
flash chromatography on silica gel with ethyl acetate: n-hexane (3:1) to give an oily
compound. The resulting oily compound was recrystallized from ethyl alcohol-diethyl
ether to give 23 as a white crystalline solid in yield of  0.51 g (74.0% from 21): mp
194-195oC; [ a ]D
25
 5.00
o (c 0.1, methanol); n max/cm
-1 3330 (NH) 1726, 1645 (C=O); 1H-
NMR (300 MHz, CDCl3) d  1.87 (3H, s, CH3), 3.78-3.85 (2H, m, CH2), 4.13-4.28 (2H, m,
CH2), 4.39 (2H, d, J = 6.90 Hz, CH2), 4.82-4.91 (1H, , m, CH), 5.08 (1H, d, J = 12.00
Hz, PhCHH), 5.17 (1H, d, J = 12.00 Hz, PhCHH), 5.30-5.38 (1H, m, CH), 7.02(1H, d, J
= 5.20 Hz, NH), 7.28-7.48 (7H, m, Ar-H), 7.33 (5H, s, C6H5), 7.52-7.62 (5H, m, Ar-H
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and NH), 7.76 (2H, d, J = 7.40 Hz, Ar-H), 7.93 (2H, d, J = 7.40, Ar-H); 13C-NMR (75
MHz, CDCl3)_d _12.24 (CH3), 44.54 (CH2), 47.04 (CH), 49.51 (CH2), 52.11 (CH), 67.33
(CH2), 68.28 (CH2), 111.37 (C), 120.00 (CH), 125.05 (CH), 127.08 (CH), 127.76 (CH),
128.63 (CH), 128.72 (CH), 128.81 (CH), 129.10 (CH), 130.60 (CH), 131.44 (C), 134.58
(C), 135.07 (CH), 140.21 (CH), 141.29 (C), 143.67 (C), 150.52 (C), 156.67 (C), 162.88
(C), 168.77 (C), 169.49 (C); FAB-Mass: M/z 687 (M+1); (found: C, 67.92; H, 4.95; N,
8.18. C39H34N4O8 requires: C, 68.21; H, 4.99; N, 8.16).
  
3-(3-Benzoyl-5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2-[2-(9H-fluoren-
9-ylmethoxycarbonylamino)acetylamino]propionic acid (24)(83)
To a stirred solution of 23 (0.85 g, 1.20 mmol) in methyl alcohol (20 ml) was added
10 % Palladium on carbon (0.60 g), under Argon gas. After stirring for 0.5-1 hour under
atmospheric pressure of hydrogen gas, the solvent was filtered through celite. After
washing several times with hot methanol, the solvent was evaporated under reduced
pressure. The resulting residue was purified by flash chromatography on silica gel (ethyl
acetate: methyl alcohol gradient) to give 24 as a white crystalline solid in yield of 0.64 g
(87.0%). Analytical sample was purified by recrystallization from dichloromethane: n-
hexane: mp 183-184oC; [ a ]D
25
 -9.44
o (c 0.1, methanol); n max/cm
-1 3328 (NH) 1713, 1645
(C=O); 1H-NMR (300 MHz, CDCl3)_d  1.78 (3H, s, CH3), 3.55-3.70 (2H, m, CH2), 4.18-
4.28 (4H, m, CH2, CH2), 4.37-4.45 (2H, m, CH, CH), 7.27 (1H, s, CH-6 of T), 7.32 (1H,
d, J = 7.5 Hz, Ar-H), 7.39 (2H, t, J = 7.35 Hz, Ar-H), 7.45-7.50 (1H, m, Ar-H), 7.53 (2H,
d, J = 7.80 Hz, Ar-H), 7.62-7.73 (4H, m, Ar-H and NH), 7.80 (1H, d, J = 7.50 Hz, Ar-H),
7.87 (2H, d, J = 7.50 Hz, Ar-H), 8.04 (2H, d, J = 7.50 Hz, Ar-H); 13C-NMR (75 MHz,
DMSO-d6)_d  11.74 (CH3), 43.67 (CH2), 46.60 (CH), 51.27 (CH2), 52.28 (CH), 65.80
(CH2), 107.63 (C), 120.09 (CH), 125.21 (CH), 127.09 (CH), 127.61 (CH), 129.24 (CH),
130.56 (CH), 131.32 (C), 135.13 (CH), 140.69 (C), 142.78 (CH), 143.80 (C), 149.45
(C), 156.47 (C), 163.03 (C), 168.94 (C), 170.01 (C), 171.12 (C); FAB-Mass: M/z 597
(M+1); (found: C, 64.44; H, 4.88; N, 9.12. C32H28N4O8 requires: C, 64.42; H, 4.73; N,
9.39).
5.1.5. Synthesis of some derivatives of isogaPNA thymine monomer (R)
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3-tert-Butoxycarbonylamino-4-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-
yl)butyric acid (R) (43)(83)
To a stirred solution of 3 (1.01 g, 2.00 mmol) in methyl alcohol (20 ml) under Argon
gas was added 10 % Palladium on carbon (0.50 g). The mixture was stirred for 0.5-1
hour under atmospheric pressure of hydrogen gas, the solvent was filtered through celite.
After washing several times with hot methanol, the solvent was evaporated under
reduced pressure. The residue was purified by flash chromatography on silica gel
(dichloromethane-methanol 5:1 gradient) to give 43 as a white crystalline solid in yield
of 0.39 g (60.0%). Analytical sample was purified by recrystallization from ethanol: n-
hexane: mp170-171oC; [ a ]D
25
 – 26.56
o (c 0.1, methanol); n max/cm
-1 3365 (OH), 1720,
1708 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  1.27 (9H, s, C(CH3)3), 1.74 (3H, s, CH3),
2.35 (2H, d, J = 6.60 Hz, CH2), 3.64-4.02 (2H, m, CH2), 4.12-4.25 (1H, m, CH), 6.48
(1H, d, J = 9.00 Hz, NH), 7.22 (1H,s, CH-6 of T), 10.78 (1H, br, NH), 12.10 (1H, br,
COOH); 13C-NMR (125 MHz, DMSO-d6) d  12.32 (CH3), 27.95 (CH3), 37.00 (CH2),
43.33 (CH2), 45.52 (CH), 77.35 (C), 106.98 (C), 135.94 (CH), 151.38 (C), 154.83
(C),163.93(C), 172.02(C); FAB-Mass: M/z 328 (M+1); (found: C, 51.41; H, 6.44; N,
12.96. C14H21N3O6 requires: C, 51.37; H, 6.47; N, 12.84).
[3-Hydroxy-1-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl)propyl]
carbamic acid-tert-butyl ester  (R) (44)(76)
To a stirred solution of 43 (1.96 g; 6.00 mmol) in distilled THF (30 ml) at –10oC, under
Argon atmosphere, N-methylmorpholine (0.61 g; 6.00 mmol) was added in a dropwise
manner followed by ethyl chloroformate (0.65 g; 6.00 mmol). After 10 minutes stirring
sodium borohydride (0.68 g; 18.00 mmol) was added in one portion, and then methyl
alcohol (30 ml) was added in a dropwise manner to the reaction mixture over a period of
10 minutes at 0oC. The reaction mixture was stirred for additional 10 minutes at 0oC,
and then neutralized with 1N HCl or 1N H2SO4 (12 ml). The organic solvents were
evaporated under reduced pressure and the product was extracted with ethyl acetate (3 x
20 ml). The combined ethyl acetate was washed consecutively with 1N HCl or 1N
H2SO4 (40 ml), H2O (50 ml), 5% NaHCO3 (50 ml) and H2O (2 x 50 ml), dried over
MgSO4 or Na2SO4, and then the solvent was evaporated under reduced pressure. The
crude product was purified with silica gel column chromatography using
dichloromethane: methanol (15:1) then dichloromethane: methanol (5:1) as mobile
phases to give an oily compound. The resulting oily product was recrystallized from
ethyl acetate: n-hexane to give 44 as white crystals in yield of  1.30 g (69.0%): mp
85
180oC; [ a ]D
25 +8.47o (c 0.1, methanol); n max/cm
-1 3356 (OH), 1720, 1687, 1645 (C=O);
1H-NMR (300 MHz, DMSO-d6) d  1.27 (9H, s, C(CH3)3), 1.49-1.51 (2H, m, CH2), 1.74
(3H, s, CH3), 3.59-3.62 (2H, m, CH2), 3.89-3.92 (2H, m, CH2), 4.35-4.37 (1H, m, CH),
6.39 (1H, d, J = 7.80 Hz, NH), 7.22 (1H,s, CH-6 of T), 10.76 (1H, br, OH); 13C-NMR
(125 MHz, DMSO-d6) d  12.32 (CH3), 27.98 (CH3), 34.96 (CH2), 44.04 (CH2), 45.72
(CH), 57.72 (CH2), 77.12 (C), 106.96 (C), 135.85 (CH), 151.37(C), 155.28 (C),
163.93(C); FAB-Mass: m/z 314 (M+1); (found C, 53.59; H, 7.51; N, 13.44. C14H23N3O5
requires C, 53.66; H, 7.40; N, 13.41).
3-[(2-tert-Butoxycarbonylamino)acetylamino]-4-(5-methyl-2,4-dioxo-3,4-dihydro-
2H-pyrimidin-1-yl)butyric acid benzyl ester (R) (45)
To a stirred solution of 4 (1.00 g; 3.15 mmol), Boc-glycine (0.55 g; 3.15 mmol) and N-
Ethyldiisopropylamine (1.10 ml; 6.30 mmol) in DMF (20 ml) at 0oC under Argon gas
was added HOBt.H2O (0.48 g, 3.15 mmol) followed by TBTU (1.01 g; 3.15 mmol). The
mixture was stirred at 0oC for 1 hour and then at room temperature for additional 4
hours. After completele evaporation of DMF under reduced pressure, the formed residue
was dissolved in ethyl acetate (100 ml). The ethyl acetate was washed successively with
5%KHSO4 (20 ml), water (20 ml), 5% NaHCO3 (20 ml) and water (20 ml). The solution
was dried over MgSO4 and then the solvent was completely evaporated under reduced
pressure to give a crude crystalline product which was recrystallized from ethyl acetate:
n-hexane to give 45 as white crystals in yield of 1.00 g (70.0%): mp 103oC; n max/cm
-1
3332 (NH), 1715, 1650 (C=O); 1H-NMR (300 MHz, DMSO-d6)_d _1.36 (9H, s, C(CH3)3),
1.75 (3H, s, CH3), 2.54 (2H, d, J = 6.00  Hz, CH2), 3.36-3.40 (2H, m, CH2), 3.89 (2H,
d, J = 7.20 Hz, CH2), 4.45-4.55 (1H, m, CH), 5.01 (2H, s, CH2), 6.70-6.73 (1H, m, NH),
7.24 (1H, s, CH-6 of T), 7.33 (5H, s, C6H5), 7.72 (1H, d, J = 8.70 Hz, NH), 10.82 (1H, s,
NH);_13C-NMR (125 MHz, DMSO-d6) d  12.27 (CH3), 28.06 (CH3), 36.80 (CH2), 42.55
(CH2), 43.14 (CH2), 44.45 (CH), 65.44 (CH2), 77.88 (C), 107.02 (C), 127.74 (CH),
127.77 (CH), 128.22 (CH), 135.93 (C), 136.21 (CH), 151.40 (C), 155.45 (C), 164.04
(C), 168.67 (C), 170.15 (C); FAB-Mass: m/z 475 (M+1).
3-[(2-tert-Butoxycarbonylamino)acetylamino]-4-(5-methyl-2,4-dioxo-3,4-dihydro-
2H-pyrimidin-1-yl)butyric acid (R) (46)(80)
To a stirred solution of 45 (0.47 g, 1.00 mmol) in methyl alcohol (20 ml) under Argon
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gas was added 10 % Palladium on carbon (0.20 g) followed by 1,4-cyclohexadiene
(1.64 g, 20.00 mmol). The mixture was stirred for 24 hours and then filtered through
celite. After washing several times with hot methanol, the combined solvents were
evaporated under reduced pressure. The obtained residue was purified by silica gel
column chromatography using dichloromethane: methanol 5:1 as a mobile phase to give
an oily compound which was recrystallized from ethanol: ether gave 46 as a white
crystalline substance in yield of  0.25 g (65.0%): mp 115-117oC; n max/cm
-1 3324 (OH),
1713, (C=O); 1H-NMR (300 MHz, DMSO-d6)_d  1.36 (9H, s, C(CH3)3), 1.75 (3H, s,
CH3), 2.37 (2H, d, J = 5.4 Hz, CH2), 3.35-3.40 (2H, m, CH2), 3.82-3.95 (2H, m, CH2),
4.35-4.50 (1H, m, CH), 6.70-6.80 (1H, m, NH), 7.23 (1H,s, CH-6 of T), 7.64 (1H, d, J =
8.40 Hz, NH), 10.81 (1H, br, NH), 12.15 (1H, br, COOH); 13C-NMR (125 MHz,
DMSO-d6) d  12.32 (CH3), 28.07 (CH3), 36.83 (CH2), 42.60 (CH2), 43.16 (CH2), 44.40
(CH), 77.89 (C), 107.02 (C), 136.13(CH), 151.42(C), 155.45(C),164.04(C), 168.60(C),
171.77(C); FAB-Mass: m/z 385 (M+1).
5.1.6. Synthesis of some derivatives of isogaPNA thymine monomer (S)
3-tert-Butoxycarbonylamino-4-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-
yl)butyric acid (S) (47)(83)
To a stirred solution of 9 (1.01 g, 2.00 mmol) in methyl alcohol (20 ml) under Argon
gas was added 10 % Palladium on carbon (0.50 g). After stirring for 0.5-1 hour under
atmospheric pressure of hydrogen gas, the solvent was filtered through celite. After
washing several times with hot methanol, the combined methanol solution was
evaporated under reduced pressure. The resulting residue was purified by silica gel
column chromatography using dichloromethane: methanol 5:1 as a mobile phase to give
47 as a white crystalline solid in yield of 0.39 g (60.0%). Analytical sample was
purified by recrystallization from ethanol: n-hexane: mp 170-171oC; [ a ]D
25
  27.23
o (c
0.1, methanol); n max/cm
-1 3365 (OH), 1716, 1708 (C=O); 1H-NMR (300 MHz, DMSO-
d6) d  1.26 (9H, s, C(CH3)3), 1.73 (3H, s, CH3), 2.36 (2H, d, J = 6.60 Hz, CH2),  3.60-
4.00 (2H, m, CH2), 4.15-4.25 (1H, m, CH), 6.48 (1H, d, J = 9.00 Hz, NH), 7.22 (1H,s,
CH-6 of T), 10.77 (1H, br, NH), 12.11 (1H, br, COOH); 13C-NMR (125 MHz, DMSO-
d6) d  12.35 (CH3), 27.98 (CH3), 37.00 (CH2), 43.35 (CH2), 45.56 (CH), 77.41 (C),
107.04 (C), 135.97 (CH), 151.43 (C), 154.87 (C),163.97(C), 172.01(C); FAB-Mass:
M/z 328 (M+1); (found: C, 51.09; H, 6.47; N, 12.93. C14H21N3O6 requires: C, 51.37; H,
6.47; N, 12.84).
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[3-Hydroxy-1-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl)propyl]
carbamic acid-tert-butyl ester (S) (48)(76)
To a stirred solution of 47 (1.96 g; 6.00 mmol) in distilled THF (30 ml) at –10oC, under
Argon atmosphere, N-methyl morpholine (0.61 g; 6.00 mmol) was added in a dropwise
manner followed by ethyl chloroformate (0.65 g; 6.00 mmol). After 10 minutes stirring
sodium borohydride (0.68 g; 18.00 mmol) was added in one portion and then methyl
alcohol (30 ml) was added in a dropwise manner to the reaction mixture over a period of
10 minutes at 0oC. The solution was stirred for additional 10 minutes at 0oC, and then
neutralized with 1N HCl or 1N H2SO4 (12 ml). The organic solvents were evaporated
under reduced pressure and the product was extracted with ethyl acetate (3 x 20 ml).
The ethyl acetate extracts were washed consecutively with 1N HCl or 1N H2SO4 (40 ml),
H2O (50 ml), 5% NaHCO3 (50 ml) and H2O (2 x 50 ml), dried over MgSO4 or Na2SO4.
The solvents were evaporated completely under reduced pressure to give the crude
product which was purified with silica gel column chromatography using
dichloromethane: methanol 15:1 then dichloromethane: methanol 5:1. the resulting oily
product was recrystallized from ethyl acetate: n-hexane gave 48 as white crystals in
yield of 1.41 g (69.0%):  mp 179oC; [ a ]D
25 -7.96 (c 0.1, methanol); n max/cm
-1 3356
(OH), 1720, 1687, 1645 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  1.27 (9H, s,
C(CH3)3), 1.50-1.52 (2H, m, CH2), 1.74 (3H, s, CH3), 3.59-3.62 (2H, m, CH2),  3.89-
3.92 (2H, m, CH2), 4.34-4.38 (1H, m, CH), 6.41 (1H, d, J = 8.40 Hz, NH), 7.23 (1H,s,
CH-6 of T), 10.75 (1H, br, OH); 13C-NMR (125 MHz, DMSO-d6) d  12.32 (CH 3), 27.98
(CH3), 34.96 (CH2), 44.04 (CH2), 45.72 (CH), 57.72 (CH2), 77.12 (C), 106.96 (C),
135.85 (CH), 151.37(C), 155.28 (C),163.93(C); FAB-Mass: m/z 314 (M+1); (found C,
53.50; H, 7.48; N, 13.29. C14H23N3O5 requires C, 53.66; H, 7.40; N, 13.41).
3-[(2-tert-Butoxycarbonylaminoyacetylamino]-4-(5-methy-2,4-dioxo-3,4-dihydro-
2H-pyrimidin-1-y)butyric acid benzyl ester (S) (49)
To a stirred solution of 10 (1.00 g; 3.15 mmol), Boc-glycine (0.55 g; 3.15 mmol) and N-
Ethyldiisopropylamine (1.10 ml; 6.30 mmol) in DMF (20 ml) at 0oC under Argon gas
was added HOBt.H2O (0.48 g, 3.15 mmol) followed by TBTU (1.01 g; 3.15 mmol). The
mixture was stirred at 0oC for 1 hour and then at room temperature  for additional 4
hours. After complete evaporation of DMF under reduced pressure, the formed residue
was dissolved in ethyl acetate (100 ml). The ethyl acetate was washed successively with
5%KHSO4 (20 ml), water (20 ml), 5% NaHCO3 (20 ml) and water (20 ml). The solution
was dried over MgSO4 and then the solvent was evaporated completely under reduced
88
pressure to give a crude crystalline product which was recrystallized from ethyl acetate:
n-hexane to give 49 as white crystals in yield of 1.00 g (70.0%): mp 102-103oC; n max
/cm-1; 1H-NMR (300 MHz, DMSO-d6)_d  1.37 (9H, s, C(CH3)3), 1.74 (3H, s, CH3), 2.54
(2H, d, J = 6.00  Hz, CH2), 3.36-3.40 (2H, m, CH2), 3.89 (2H, d, J = 7.20 Hz, CH2),
4.46-4.56 (1H, m, CH), 5.01 (2H, s, CH2), 6.70-6.73 (1H, m, NH), 7.24 (1H, s, CH-6 of
T), 7.33 (5H, s, C6H5), 7.72 (1H, d, J = 8.70 Hz, NH), 10.81 (1H, s, NH);_
13C-NMR (125
MHz, DMSO-d6) d  12.28 (CH3), 28.04 (CH3), 36.78 (CH2), 42.53 (CH2), 43.12 (CH2),
44.45 (CH), 65.42 (CH2), 77.87 (C), 107.02 (C), 127.73 (CH), 127.75 (CH), 128.22
(CH), 135.92 (C), 136.22 (CH), 151.42 (C), 155.47 (C), 163.98 (C), 168.65 (C), 170.13
(C); FAB-Mass: m/z 475 (M+1).   
3-[(2-tert-Butoxycarbonylamino)acetylamino]-4-(5-methyl-2,4-dioxo-3,4-dihydro-
2H-pyrimidin-1-yl)butyric acid (S) (50)(80)
To a stirred solution of 49 (0.47 g, 1.00 mmol) in methyl alcohol (20 ml) under Argon
gas was added 10 % Palladium on carbon (0.20 g) followed by 1,4-cyclohexadiene
(1.64 g, 20.00 mmol). The mixture was stirred for 24 hours and then filtered through
celite. After washing several times with hot methanol, the combined solvents were
evaporated under reduced pressure. The obtained residue was purified by silica gel
column chromatography using dichloromethane: methanol 5:1 as a mobile phase to give
an oily product which was recrystallized from ethanol: ether to give 50 as a white
crystalline substance in yield of  0.27 g (70.0%): mp 114-116oC; n max/cm
-1 3323 (OH),
1713, 1655 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  1.36 (9H, s, C(CH3)3), 1.75 (3H, s,
CH3), 2.37 (2H, d, J = 6.00 Hz, CH2), 3.32-3.41 (2H, m, CH2), 3.85-3.91 (2H, m, CH2),
4.35-4.48 (1H, m, CH), 6.70-6.80 (1H, m, NH), 7.22 (1H,s, CH-6 of T), 7.63 (1H, d, J =
8.70 Hz, NH), 10.80 (1H, d, J = 5.10 Hz, NH), 12.16 (1H, br, COOH); 13C-NMR (125
MHz, DMSO-d6) d  12.32 (CH3), 28.07 (CH3), 36.83 (CH2), 42.60 (CH2), 43.17 (CH2),
44.42 (CH), 77.91 (C), 107.04 (C), 136.14(CH), 151.43(C), 155.46(C),164.05(C),
168.61(C), 171.77(C); FAB-Mass: m/z 385 (M+1).
 
5.1.7. Synthesis of PNA oligomers
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Several PNA oligomers were prepared using automated peptide synthesizer on an
Expedite 8909 (Applied Biosystems, Foster City, CA) uses Fmoc PNA monomers and
offers a routine method for producing PNAs on a relatively small (2 m M) scale, five
oligomers 27-31 were prepared each of which consists from 12 units by introducing
thymine monomer 6 (TR) (either one unit or three units) into aegPNA thymine oligomer
in different positions either toward the C-terminal, N-terminal or in the middle of the
12-mer oligomer. In addition to another oligomer 32 which consists mainly from 12
units of thymine monomer 6 (TR). Another five oligomers 33-37 were prepared each of
which consists from 12 units by introducing thymine monomer 12 (TS) (either one unit
or three units) into aegPNA thymine oligomer in different positions either toward the C-
terminal, N-terminal or in the middle of the 12-mer oligomer. In addition to another
oligomer 38 which consists from 12 units of thymine monomer 12 (TS). Also another
four oligomers 39-41 were prepared each of which consists from 8 units by introducing
adenine monomer 15 (Ax) (one unit) into aegPNA adenine oligomer in different
positions either toward the C-terminal, N-terminal or in the middle of the 8 mer
oligomer. In addition to another oligomer 42 which consists from 8 units of adenine
monomer 15 (Ax). Lysine was introduced at the C-terminus of the PNAs to reduce their
self-aggregation and to ensure adequate solubility in UV-melting experiments.(41) aeg
PNA thymine and aegPNA adenine monomers should be warmed to room temperature
prior to solubilization to prevent water from condensing inside the container, aegT PNA
and aegPNA adenine monomers were dissolved in diluent (N-methylpyrrolidone
(NMP)) (3.25 ml) and attached directly to the amber bottle in which monomer was
shipped and allow the mixture to sit undisturbed for 10 minutes. In the same way
monomers 6, 12 and 15 dissolved in NMP and then introduced into the amber bottle in
which monomer was shipped, PNA activator (HATU is dissolved in anhydrous DMF
13.5 ml, PNA base solution (0.2 M DIEA, 0.3M 2,6-lutidine in DMF), PNA deblocking
solution (20% piperidine in DMF), PNA capping solution (5% acetic anhydride, 6% 2,6-
lutidine in DMF) and wash B (99.8% anhydrous DMF), wash A (DMF). Columns for
solid-phase synthesis containing Fmoc-XAL PEG resin should be stored in a desiccant
box at –20oC and allowed to warm to room temperature prior to use. After finishing the
preparation of these PNAs oligomers according to the protocol of Applied Biosystems
for the preparation of PNA oligomers, the columns were removed and washed from both
sides with DMF (3 ml) and then with CH2Cl2 (3 ml) and leave to dryness using vacuum
pump. Cleavage from the resin was carried out using 20% (v/v) m-cresol in TFA (200
m l) for 90 minutes. Centrifugation of the tubes containing the samples was carried out at
4000 rpm for 5 minutes and then allow filtration and keep the filtrate in ice bath for 5
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minutes.  Precipitation for the PNAs oligomers was carried out using anhydrous dry
ether (800 m l), keep cool in ice bath for 10 minutes and fortex for 1 minute.
Centrifugation again at 4000 rpm for 5 minutes and then decantation of the solvents, the
obtained precipitate was washed with anhydrous dry ether (3 x 300 m l), and then drying
in vacuo. In the case of Adenine oligomers 39-42 the removal of the benzoyl protected
the amino group of adenine was carried out using (TFMSA/ TFA/DMS/m-cresol
(1/10/6/2, v/v/v/v)(94), leaving for 3.5 hours). Analysis and purification of crude PNAs
was carried out using reversed-phase HPLC, using C18 column and maintain the water
jacket around column at 50oC to reduce aggregation and sharpen peaks, flow rate was
ranged from 0.7 to 1 ml/min. using the mobile phase previously described, after
identification of the objective PNAs using MALDI-TOF mass spectrometry using a -
cyanocinnamic acid as the matrix, which gave the expected molecular weight.
5.1.7.1. Synthesis of thymine PNA oligomers
H-T11-TR-Lys-NH2 (27)
Oligomer 27 was prepared as described above, (Rt 25.6 minutes, flow rate was 0.9
ml/min). MS (MALDI-TOF): calculated for C138H183N51O49 m/z = 3338.34, observed
3339.3 [M+H]+, 3361.31 [M+Na]+ and 3377.32 [M+K]+.
H- TR -T11- Lys-NH2 (28)
Oligomer 28 was prepared as described above, (Rt 27.1 minutes, flow rate was 0.8
ml/min). MS (MALDI-TOF): calculated for C138H183N51O49 m/z = 3338.34, observed
3339.3 [M+H]+, 3361.31 [M+Na]+ and 3377.32 [M+K]+.
H- T9- TR TR TR - Lys-NH2 (29)
Oligomer 29 was prepared as described above, (Rt 29.6 minutes, flow rate was 0.8
ml/min). MS (MALDI-TOF): calculated for C138H183N51O49 m/z = 3338.34, observed
3340.3 [M+H]+, 3362.31 [M+Na]+ and 3378.32 [M+K]+.
H- TR TR TR -T9-Lys-NH2 (30)
Oligomer 30 was prepared as described above, (Rt 29.4 minutes, flow rate was 0.8
ml/min). MS (MALDI-TOF): calculated for C138H183N51O49 m/z = 3338.34, observed
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3339.3 [M+H]+, 3361.31 [M+Na]+ and 3377.32 [M+K]+.
H-T6-TR-T5-Lys-NH2 (31)
Oligomer 31 was prepared as described above, (Rt 28 minutes, flow rate was 1 ml/min).
MS (MALDI-TOF): calculated for C138H183N51O49 m/z = 3338.34, observed 3339.3
[M+H]+ and 3361.31 [M+Na]+.
H-TR12-Lys-NH2 (32)
Oligomer 32 was prepared as described above, (Rt 37 minutes, flow rate was 0.9
ml/min). MS (MALDI-TOF): calculated for C138H183N51O49 m/z = 3338.34, observed
3339.3 [M+H]+.
H-T11-TS-Lys-NH2 (33)
oligomer 33 was prepared as described above, (Rt 25.3 minutes, flow rate was 0.9
ml/min). MS (MALDI-TOF): calculated for C138H183N51O49 m/z = 3338.34, observed
3339.3 [M+H]+, 3361.31 [M+Na]+.
H- TS -T11- Lys-NH2 (34)
Oligomer 34 was prepared as described above, (Rt 27.6 minutes, flow rate was 0.8
ml/min). MS (MALDI-TOF): calculated for C138H183N51O49 m/z = 3338.34, observed
3339.3 [M+H]+, 3361.31 [M+Na]+ and 3377.32 [M+K]+.
H- T9- TS TS TS - Lys-NH2 (35)
Oligomer 35 was prepared as described above, (Rt 29.6 minutes, flow rate was 0.8
ml/min). MS (MALDI-TOF): calculated for c138H183N51O49 m/z = 3338.34, observed
3340.3 [M+H]+, 3362.31 [M+Na]+.
H- TS TS TS -T9-Lys-NH2 (36)
Oligomer 36 was prepared as described above, (Rt 29.1 minutes, flow rate was 0.8
ml/min). MS (MALDI-TOF): calculated for C138H183N51O49 m/z = 3338.34, observed
3339.3 [M+H]+, 3361.31 [M+Na]+ and 3377.32 [M+K]+.
H-T6-TS-T5-Lys-NH2 (37)
Oligomer 37 was prepared as described above, (Rt 27.4 minutes, flow rate was 1
ml/min). MS (MALDI-TOF): calculated for C138H183N51O49 m/z = 3338.34, observed
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3340.3 [M+H]+ and 3362.31 [M+Na]+.
H-TS12-Lys-NH2 (38)
Oligomer 38 was prepared as described above, (Rt 40.2 minutes, flow rate was 0.8
ml/min). MS (MALDI-TOF): calculated for C138H183N51O49 m/z = 3338.34, observed
3339.3 [m+H]+ and 3361.31 [M+Na]+.
After complete dryness of the collective samples using lyophillizer the samples were
kept in the refrigerator until Tm measurements.
5.1.7.2. Synthesis of adenine PNA oligomers
H-A7-AX-Lys-NH2 (39)
Oligomer 39 was prepared as described above, (Rt 14.5 minutes, flow rate was 1
ml/min). MS (MALDI-TOF): calculated for C94H119N59O17 m/z = 2346.03, observed
2347.2 [M+H]+ and 2369.1 [M+Na]+ in addition to many peaks of  byproducts.
H- AX -A7-Lys-NH2 (40)
Oligomer 40 was prepared as described above (Rt 14.3 minutes, flow rate was 1 ml/min).
MS (MALDI-TOF): calculated for C94H119N59O17 m/z = 2346.03, observed 2347.2
[M+H]+ in addition to many peaks of byproducts.
H- A4- AX –A3-Lys-NH2 (41)
Oligomer 41 was prepared as described above, (Rt 15 minutes, flow rate was 1 ml/min).
MS (MALDI-TOF): calculated for C94H119N59O17 m/z = 2346.03, observed 2347.2
[M+H]+ in addition to many peaks of byproducts.
H- AX8-Lys-NH2 (42)
Oligomer 42 was prepared as described above, (Rt 28 minutes, flow rate was 1 ml/min).
MS (MALDI-TOF): calculated for C94H119N59O17 m/z = 2346.03, observed 2347.2
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[M+H]+ in addition to many peaks of byproducts.
5.1.8. Melting experiments  
Melting experiments between different PNAs oligomers (25-38) with its complementary
DNA or RNA were carried out using a 1:1 molar mixtures of PNA and the
corresponding target DNA or RNA (amounts determined by the UV absorption at 260
nm), each at a concentration of 2.5 m M in 10 mM phosphate buffer, pH 7.4, containing
100 mM sodium chloride, and 0.1 mM EDTA. Prior to the measurement of the melting
profiles, the solutions were heated to 95oC for 5 minutes at a fast rate, then cooled to
0.5oC over 90 minutes and equilibrated at this temperature for 45 minutes subsequently,
the absorbance A260 was recorded versus temperature for both dissociation and
annealing at the rates 0.5oC/min. and 0.2oC, respectively. In (Job-plot) titration method
for determination the binding stoichiometry between PNA and DNA, the total
concentration used was 3 m M (20 m M DNA, 20 m M PNA), the mixture of PNA and
DNA allowed for heating at 95oC for 10 minutes and then cooled to room temperature
and then allowed to stay for 8 hours in dark place and then the absorbance was
measured at 260 nm.
5.1.9. Biological procedures for anti-HSV (93)
Monolayer cultures of VERO cells were prepared in plastic petri dishes 6.0 cm in
diameter at 37oC in a 5% CO2 incubator in Eagle’s minimum essential medium (MEM)
with 10% calf serum and 0.03% L-glutamine. After the medium was discarded and
washed with phosphate buffer saline once, 0.2 ml of the PH strain of HSV, type 1, at 5 x
102 plaque forming units/ml was inoculated over the VERO cells. One hour later the cell
sheets were overlaid with a solution of the test compounds at various concentrations,
prepared in MEM with 0.5% methyl cellulose and 1% calf serum. The cultures were
incubated at 37oC in a 5% CO2 incubator for 2 days and then the cells were stained with
crystal violet and the plaques were counted. Petri dishes without an added compound
served as controls, and the percentage inhibition of plaque development by test
compounds was calculated. Adenine arabinoside (and acyclovir) served as a positive
control for comparison.
5.1.10. HIV cytopathic effect inhibition assay(95-97)
MT2 cells or ATH8 cells (2 x 105), which are sensitive to the cytopathic effect of
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HTLV-III, exposed to a high multiplicity of infectious HTLV-IIIB virus (2000 virus
particles per cell) for 45 minutes, resuspended in 2 ml of 15% (v/v) fresh culture
medium [the culture medium supplemented with 15 % heat inactivated fetal calf serum,
4mM L-glutamine, Penicillin (50 unit/ml), and streptomycin (50 m g/ml)], and cultured in
the presence or absence of various concentrations of the tested compounds in culture
tubes. The culture tubes were incubated in at 37oC in 5% CO2-containing humidified air.
Control cells were treated similarly but were not exposed to the virus. The assays were
all performed in duplicate. On days 6, 8, and 10 the total viable cells were counted in a
hemocytometer under the microscope by the trypan blue dye exclusion method.
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5.2. Development of novel topoisomerases inhibitors
Materials
All reagents which used for the preparation of final compounds and their intermediates
were purchased from Wako, Aldrich, Nacalai tesque, Tokyo Kasei and Novabiochem
and used without purification. Solvents were HPLC grade from Wako, Aldrich and
Sigma. Dry solvents were obtained by use of appropriate molecular sieves, except for
tetrahydrofuran was distilled from sodium/benzophenone. The water content in dry
solvents did not exceed 50 ppm as determined by Karl-Fischer titration.
General methods
TLC was performed on analytical Merck 9385 silica glass plates with F254 indicator.
TLCs were viewed either under 254 nm UV or by staining with phosphomolybdic acid
in ethanol or iodine crystals where appropriate. Column chromatography was performed
as flash chromatography on Merck 9385 silica gel 60 (0.040-0.063 mm). Reactions
were carried out under Argon gas. Accurate masses were obtained on Micromass LCT
mass spectrometer which was recorded in the positive ion mode with leucine enkephalin
as an internal lock mass standard. Elemental analysis was performed at the
microanalytical laboratory, Institute of Resource Development and Analysis,
Kumamoto University. Melting points were determined on electrothermal melting point
apparatus and were uncorrected. IR data were obtained on Jasco fourier transform-410
infrared spectrometer as KBr discs. NMR spectra were obtained on a 300 MHz AL
spectrometer. d -Values are in ppm relative to DMSO-d6 (2.50 for proton and 39.5 for
carbon) or CDCl3 (7.29 for proton and 76.9 for carbon).
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5.2.1. Synthesis of acetyl and acid chlorides of gallic acid, 3,4-dihydroxy-　benzoic acid
and 4-hydroxybenzoic acid
3,4,5-Triacetoxybenzoic acid (52a)(129)
To a stirred suspension of gallic acid 51a (30.00 g; 0.17 mol) in acetic anhydride (120
ml) was added concentrated sulfuric acid (10 drops). The resulting solution was heated
at 80oC for 10 minutes, then left to cool to room temperature. The solution was
decomposed with caution by adding it to ice water (300 ml). After two hours leaving at
room temperature the formed white precipitate was filtered off and dried to give 52a as
white crystals in yield of 40.00 g (77.0%): mp 163oC; n max/cm
-1 3546 (OH), 1789, 1696
(C=O); 1H-NMR (300 MHz, CD3OD) d  2.17 (6H, s, CH3 x 2), 2.18 (3H, s, CH3), 7.67
(2H, s, Ar-H); 13C-NMR (75 MHz, CD3OD) d  19.91 (CH3), 20.32 (CH3), 123.21 (CH),
130.04 (C), 139.95 (C), 144.82 (C), 167.32 (C), 168.21 (C), 169.41 (C); FAB-Mass:
m/z 297 (M+1).
3,4-Diacetoxybenzoic acid (52b)(129)
Compound 52b was prepared as described above for compound 52a, starting from 3,4-
dihydroxybenzoic acid 51b (26.20 g; 0.17 mol) to give 52b as white crystals in yield of
31.20 g (77.0%): mp 155-156oC; n max/cm
-1 3540 (OH), 1774, 1686 (C=O); 1H- NMR
(300 MHz, CD3OD) d  2.28 (6H, s, CH3 x 2), 7.32 (1H, d, J = 8.40 Hz, Ar-H), 7.84 (1H,
d, J = 2.10 Hz, Ar-H), 7.93 (1H, dd, J = 8.40 and 2.10 Hz, Ar-H) 13C-NMR (75 MHz,
CD3OD) d  20.36 (CH3), 20.41 (CH3), 124.70 (CH), 126.08 (CH), 129.05 (CH), 130.56
(C), 143.61 (C), 147.47 (C), 168.13 (C), 169.43 (C), 169.75 (C); FAB-Mass: m/z 239
(M+1).
4-Acetoxybenzoic acid (52c)(129)
Compound 52c was prepared as described above for compound 52a, starting from 4-
hydroxybenzoic acid 51c (23.48 g; 0.17 mol) to give 52c as white crystals in yield of
25.00 g (81.6%): mp 195-197oC; n max/cm
-1 3512 (OH), 1755, 1682 (C=O); 1H-NMR
(300 MHz, CDCl3) d  2.33 (3H, s, CH3), 7.21 (2H, d, J = 8.40 Hz, Ar-H), 8.15 (2H, d, J
= 8.40 Hz, Ar-H); 13C-NMR (75 MHz, CDCl3) d  21.01 (CH3), 121.65 (CH), 126.85 (C),
131.78 (CH), 155.08 (C), 168.68 (C), 171.12 (C); FAB-Mass: m/z 181 (M+1).
2,3-Diacetoxy-5-chlorocarbonylacetic acid phenyl ester (53a)(129)
To a suspension of 52a (7.00 g; 23.6 mmol) in dry benzene (50 ml) was added thionyl
chloride (5 ml; 70.0 mmol) in a dropwise manner. The mixture was refluxed for 1.5
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hours then leave to cool to room temperature, and then the solvent was completely
evaporated using vacuum pump. A crude white precipitate formed which was washed
several times with ether and dried using vacuum pump to give 53a as a white precipitate
in yield of 6.10 g (82.1%).
2-Acetoxy-5-chlorocarbonylacetic acid phenyl ester (53b)(129)
Compound 53b was prepared as described above for compound 53a, starting from 52b
(5.62 g; 23.6 mmol) to give 53b as an oily compound in yield of 5.00 g (82.6%).
4-Chlorocarbonylacetic acid phenyl ester (53c)(129)
Compound 53c was prepared as described above for compound 53a, starting from 52c
(4.25 g; 23.6 mmol) to give 53c as a white crystalline substance in yield of 3.73 g
(79.6%): mp 169-170oC.
  
5.2.2. Synthesis of AGBA derivatives
2,3-Diacetoxy-5-[2-(3,4,5-triacetoxybenzoylamino)phenylcarbamoyl]acetic acid 　
phenyl ester (55a)
To a stirred solution of o-phenylenediamine 54a (0.11 g; 1.0 mmol) in CH2Cl2 (20 ml)
was added 53a (0.63 g; 2.0 mmol) followed by triethylamine (0.31 ml; 2.2 mmol). The
mixture was stirred for 1 hour at room temperature, the reaction was quenched by the
addition of saturated NaCl (20 ml) and EtOAc (20 ml). The aqueous layer was extracted
with EtOAc (2 x 20 ml), the combined EtOAc extracts were washed subsequently with
1 N HCl (10 ml), H2O (2 x 10 ml), NaHCO3 (10 ml), H2O (2 x 10 ml) and saturated
NaCl (10 ml), and dried over MgSO4. After complete evaporation of the organic
solvents using vacuum pump an oily crude product was formed which was purified by
silica gel column chromatography using CH2Cl2: acetone 10:1 as a mobile phase. The
obtained oily product was then recrystallized from CH2Cl2: n-hexane to give 55a as
white crystals in yield of 0.99 g (74.5%): mp 114-115oC; n max/cm
-1 3423 (NH), 1780,
1659 (C=O); 1H-NMR (300 MHz, CDCl3) d  2.26 (12H, s, CH3 x 4), 2.27 (6H, s, CH3 x
2), 6.99 (2H, q, J = 3.60 Hz, Ar-H), 7.36 (2H, q, J = 3.60 Hz, Ar-H), 7.70 (4H, s, Ar-H),
9.64 (2H, s, NH x 2); 13C-NMR (75 MHz, CDCl3) d  20.07 (CH3), 20.45 (CH3) 120.61
(CH), 125.61 (CH), 126.67 (CH), 130.08 (C), 132.06 (C), 137.83 (C), 143.49 (C),
164.14 (C), 166.54 (C), 167.79 (C); FAB-Mass: m/z 665 (M+1); (found C, 57.79; H,
4.22; N, 4.17. C32H28N2O14 requires C, 57.83; H, 4.25; N, 4.22).
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2-Acetoxy-4-[2-(3,4-diacetoxybenzoylamino)phenylcarbamoyl]acetic acid phenyl
ester (55b)
Compound 55b was prepared as described above for compound 55a, starting from 53b
(0.51 g; 2.0 mmol) to give a crude product which was purified by silica gel column
chromatography using CH2Cl2: acetone 15:1 as a mobile phase. The oily product which
was obtained was then recrystallized from EtOAc: n-hexane to give 55b as white
crystals in yield of 0.81 g (73.9%): mp 219-220oC; n max/cm
-1 3273 (NH), 1770, 1678,
1653 (C=O); 1H-NMR (300 MHz, CDCl3) d  2.31 (6H, s, CH3 x 2), 2.33 (6H, s, CH3 x 2),
6.87 (2H, q, J = 3.60 Hz, Ar-H), 7.25-7.34 (4H, m, Ar-H), 7.83 (2H, d, J = 2.10 Hz,
Ar-H), 7.86 (2H, s, Ar-H) 9.49 (2H, s, NH x 2); 13C-NMR (75 MHz, CDCl3) d  18.75
(CH3), 18.85 (CH3) 121.81 (CH), 121.90 (CH), 124.01 (CH), 124.09 (CH), 124.83 (CH),
130.40 (C), 132.09 (C), 142.29 (C), 145.32 (C), 164.81 (C),  167.64 (C), 167.89 (C);
FAB-Mass: m/z 549 (M+1); (found C, 61.27; H, 4.38; N, 4.95. C28H24N2O10 requires C,
61.31; H, 4.41; N, 5.11).
4-[2-(4-Acetoxybenzoylamino)phenylcarbamoyl]acetic acid phenyl ester (55c)(131)
Compound 55c was prepared as described above for compound 55a, starting from 53c
(0.40 g; 2.0 mmol) to give a crude product which was purified by recrystallization from
EtOH to give 55c as white crystals in yield of 0.61 g (70.6%): mp 200oC; n max/cm
-1 3277
(NH), 1755, 1648 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  2.28 (6H, s, CH3 x 2), 7.26-
7.30 (6H, m, Ar-H), 7.66 (2H, q, J = 3.60 Hz, Ar-H), 7.98 (4H, d, J = 8.40 Hz,　Ar-H),
10.04 (2H, s, NH x 2); 13C-NMR (75 MHz, DMSO-d6) d  20.85 (CH3), 121.99 (CH),
125.56 (CH), 125.88 (CH), 129.08 (CH), 131.30 (C), 131.79 (C), 153.08 (C), 164.75
(C), 168.94 (C); FAB-Mass: m/z 433 (M+1).
N-[2-(Benzoylamino)phenyl]benzamide (55d)(132)
Compound 55d was prepared as described above for compound 55a, starting from
benzoyl chloride 53d (0.28 g; 2.0 mmol) the reaction was carried out in dry benzene and
stirred for 5 hours to give a crude product which was purified by recrystallization from
EtOH to give 55d as a brownish white precipitate in yield of 0.48 g (75.9%): mp >
300oC; n max/cm
-1 3272 (NH), 1655 (C=O); 1H-NMR (300 MHz, DMSO-d6) d _7.30-7.35
(4H, m, Ar-H), 7.50-7.63 (6H, m, Ar-H), 7.93 (4H, d, J = 7.20, Ar-H), 10.05 (2H, s, NH
x 2); 13C-NMR (75 MHz, DMSO-d6) d  125.34 (CH), 125.57 (CH), 127.24 (CH), 128.33
99
(CH), 131.15 (C), 131.58 (CH), 134.07 (C), 165.31 (C); FAB-Mass: m/z 317 (M+1).
2, 3-Diacetoxy-5-[3-(3,4,5-triacetoxybenzoylamino)phenylcarbamoyl]acetic acid
phenyl ester (55e)
Compound 55e was prepared as described above for compound 55a, starting from m-
phenylenediamine 54b (0.11 g; 1.0 mmol) to give a crude product which was purified
by silica gel column chromatography using CH2Cl2: acetone 5:1 as a mobile phase. The
resulting oily compound was recrystallized from CH2Cl2: n-hexane to give 55e as white
crystals in yield of 1.00 g (75.3%): mp 252-253oC; n max/cm
-1 3382 (NH), 1779, 1675
(C=O); 1H-NMR (300 MHz, DMSO-d6) d  2.32 (12H, s, CH3 x 4), 2.33 (6H, s, CH3 x 2),
7.34 (1H, t, J = 8.40 Hz, Ar-H), 7.48 (2H, d, J = 8.40 Hz, Ar-H) 7.83 (4H, s, Ar-H), 8.27
(1H, s, Ar-H) 10.40 (2H, s, NH x 2); 13C-NMR (75 MHz, DMSO-d6) d  19.7 (CH3),
20.15 (CH3) 112.92 (CH), 116.33 (CH), 120.39 (CH), 128.56 (CH), 132.75 (C), 137.17
(C), 138.87 (C), 143.00 (C), 162.97 (C), 166.75 (C), 167.80 (C); FAB-Mass: m/z 665
(M+1); (found C, 57.67; H, 4.08; N, 4.17. C32H28N2O14 requires C, 57.83; H, 4.25; N,
4.22).
2-Acetoxy-4-[3-(3,4-diacetoxybenzoylamino)phenylcarbamoyl]acetic acid phenyl
ester (55f)
Compound 55f was prepared as described above for compound 55e, starting from 53b
(0.51 g; 2.0 mmol) to give a crude product which was purified by silica gel column
chromatography using CH2Cl2: Acetone 15:1 as a mobile phase. The obtained oily
compound was then recrystallized from EtOAc: n-hexane to give 55f as white crystals
in yield of 0.83g (75.7%): mp 211-212oC; n max/cm
-1 3366 (NH), 1771, 1654 (C=O); 1H-
NMR (300 MHz, DMSO-d6) d  2.31 (6H, s, CH3 x 2), 2.32 (6H, s, CH3 x 2), 7.32 (1H, t,
J = 8.00 Hz, Ar-H), 7.44 (2H, d, J = 8.70 Hz, Ar-H), 7.49 (2H, dd, J = 9.60 and 1.46 Hz,
Ar-H) 7.87 (2H, s, Ar-H), 7.92 (2H, dd, J = 8.40 and 1.83 Hz, Ar-H), 8.30 (1H, s, Ar-H),
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10.38 (2H, s, NH x 2); 13C-NMR (75 MHz, DMSO-d6) d  20.30 (CH3), 20.38 (CH3),
112.87 (CH), 116.22 (CH), 123.21 (CH), 123.70 (CH), 126.22 (CH), 128.68 (CH),
133.39 (C), 139.15 (C), 141.83 (C), 144.59 (C), 163.90 (C), 168.03 (C), 168.23 (C);
FAB-Mass: m/z 549 (M+1); (found C, 61.52; H, 4.42; N, 5.05. C28H24N2O10 requires C,
61.31; H, 4.41; N, 5.11).
4-[3-(4-Acetoxybenzoylamino)phenylcarbamoyl]acetic acid phenyl ester (55g)(131)
Compound 55g was prepared as described above for compound 55e, starting from 53c
(0.40 g; 2.0 mmol) to give a crude product which was purified by recrystallization from
EtOH to give 55g as a white crystalline in yield of 0.70 g (81.0%): mp 280-281oC;
n max/cm
-1 3330 (NH), 1754, 1645 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  2.30 (6H, s,
CH3 x 2), 7.28 (4H, d, J = 8.70 Hz, Ar-H), 7.32-7.35 (1H, m, Ar-H), 7.49 (2H, d, J =
8.10 Hz, Ar-H) 8.00 (4H, d, J = 8.70 Hz, Ar-H), 8.30 (1H, s, Ar-H) 10.31 (2H, s, NH x
2); 13C-NMR (75 MHz, DMSO-d6) d  20.86 (CH3), 112.81 (CH), 116.04 (CH), 121.79
(CH), 128.59 (CH), 129.21 (CH), 132.47 (C), 139.30 (C), 152.88 (C), 164.79 (C),
168.99 (C); FAB-Mass: m/z 433 (M+1).
N-[(3-Benzoylamino)phenyl]benzamide (55h)(134)
Compound 55h was prepared as described above for compound 55e, starting from 53d
(0.28 g; 2.0 mmol), the reaction was carried out in dry THF and stirred for 24 hours.
The obtained crude product washed several times with ether and dried under reduced
pressure, and purified by recrystallization from EtOH to give 55h as a white precipitate
in yield of 0.48 g (75.9%): mp 245oC; n max/cm
-1 3268 (NH), 1648 (C=O); 1H-NMR (300
MHz, DMSO-d6) d  7.31 (1H, t, J = 8.10 Hz, Ar-H), 7.48-7.58 (8H, m, Ar-H), 7.96 (4H,
d, J = 6.90 Hz, Ar-H), 8.33 (1H, s, Ar-H) 10.30 (2H, s, NH x 2); 13C-NMR (75 MHz,
DMSO-d6) d  112.95 (CH), 116.08 (CH), 127.67 (CH), 128.34 (CH), 128.55 (CH),
131.52 (CH), 134.94 (C), 139.34 (C), 165.54 (C); FAB-Mass: m/z 317 (M+1).
2,3-Diacetoxy-5-[4-(3,4,5-triacetoxybenzoylamino)phenylcarbamoyl]acetic acid 　
phenyl ester　(55i)
Compound 55i was prepared as described above for compound 55a, starting from p-
phenylenediamine 54c (0.11 g; 1.0 mmol) to give a crude product which was purified by
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silica gel column chromatography using CH2Cl2: acetone 10:1 as a mobile phase. The
obtained oily product was then recrystallized from CH2Cl2: n-hexane to give 55i as
white crystals in yield of 0.90 g (67.8%): mp 280-281oC; n max/cm
-1 3284 (NH), 1774,
1649 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  2.32 (12H, s, CH3 x 4), 2.33 (6H, s, CH3
x 2), 7.73 (4H, s, Ar-H), 7.82 (4H, s, Ar-H), 10.36 (2H, s, NH x 2); 13C-NMR (75 MHz,
DMSO-d6) d  20.27 (CH3), 20.72 (CH3) 120.86 (CH), 121.27 (CH), 133.33 (C), 135.27
(C), 137.69 (C), 143.58 (C), 163.32 (C), 167.32 (C), 168.37 (C); FAB-Mass: m/z 665
(M+1); (found C, 57.75; H, 4.15; N, 4.26. C32H28N2O14 requires C, 57.83; H, 4.25; N,
4.22).
2-Acetoxy-4-[4-(3,4-diacetoxybenzoylamino)phenylcarbamoyl]acetic acid phenyl
ester (55j)
Compound 55j was prepared as described above for compound 55i, starting from 53b
(0.51 g; 2.0 mmol) to give a crude product which was purified by silica gel column
chromatography using CH2Cl2: acetone 10:1 as a mobile phase. The obtained oily
product was then recrystallized from CH2Cl2: n-hexane to give 55j as a white crystalline
product in yield of 0.85g (77.5%): mp 288-290oC; n max/cm
-1 3347 (NH), 1770, 1649
(C=O); 1H-NMR (300 MHz, DMSO-d6) d  2.31 (6H, s, CH3 x 2), 2.32 (6H, s, CH3 x 2),
7.44 (2H, d, J = 8.40 Hz, Ar-H), 7.74 (4H, s, Ar-H), 7.86 (2H, s, Ar-H), 7.92 (2H,d, J =
8.10 Hz, Ar-H), 10.32 (2H, s, NH x 2); 13C-NMR (75 MHz, DMSO-d6) d  20.29 (CH3),
20.35 (CH3), 120.60 (CH), 120.70 (CH), 123.13 (CH), 123.68 (CH), 126.08 (CH),
133.40 (C), 134.86 (C), 141.83 (C), 144.51 (C), 163.64 (C), 168.00 (C), 168.19 (C);
FAB-Mass: m/z 549 (M+1); (found C, 61.37; H, 4.39; N, 5.11. C28H24N2O10 requires C,
61.31; H, 4.41; N, 5.11).
4-[4-(4-Aceoxybenzoylamino)phenylcarbamoyl]acetic acid phenyl ester (55k)(131)
Compound 55k was prepared as described above for compound 55i, starting from 53c
(0.40 g; 2.0 mmol) to give a crude product which was purified by silica gel column
chromatography using CH2Cl2: acetone 10:1 as a mobile phase. The obtained oily
product was then recrystallized from CH2Cl2: n-hexane to give 55k as white crystals in
yield of 0.69 g (80.2%): mp > 300oC; n max/cm
-1 3315 (NH), 1756, 1644 (C=O); 1H-
NMR (300 MHz, DMSO-d6) d  2.30 (6H, s, CH3 x 2), 7.28 (4H, d, J = 8.40 Hz, Ar-H),
7.74 (4H, s, Ar-H), 8.00 (4H, d, J = 8.40 Hz, Ar-H), 10.25 (2H, s, NH x 2); 13C-NMR
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(75 MHz, DMSO-d6) d  20.85 (CH3), 120.49 (CH), 120.59 (CH), 121.79 (CH), 129.11
(CH), 132.48 (C), 134.92 (C), 152.83 (C), 164.53 (C), 168.96 (C); FAB-Mass: m/z 433
(M+1).
N-[(4-Benzoylamino)phenyl]benzamide (55l)(137)
Compound 55l was prepared as described above for compound 55i, starting from 53d
(0.28 g; 2.0 mmol), the reaction was carried out in dry THF and stirred for 24 hours.
The formed crude product was washed several times with ether and dried under pressure
and purified by recrystallization from EtOH to give 55l as a white precipitate in yield of
0.48 g (75.9%): mp > 300oC; n max/cm
-1 3332 (NH), 1649 (C=O); 1H-NMR (300 MHz,
DMSO-d6) d  7.49-7.58 (6H, m, Ar-H), 7.75 (4H, s, Ar-H), 7.94-7.96 (4H, m, Ar-H),
10.23 (2H, s, NH x 2); 13C-NMR (75 MHz, DMSO-d6) d  120.64 (CH), 127.57 (CH),
128.35 (CH), 131.46 (CH), 134.94 (C), 134.97 (C), 165.30 (C); FAB-Mass: m/z 317
(M+1).
2, 3-Diacetoxy-5-phenylcarbamoylacetic acid phenyl ester (55m)(138)
Compound 55m was prepared as described above for compound 55a, starting from
aniline 54d (0.09 ml; 1.0 mmol), 53c (0.40 g; 2.0 mmol) and triethylamine (0.15 ml; 1.1
mmol). And stirring for 2 hours to give a crude product which was purified by
recrystallization from EtOH to give 55m as white crystals in yield of 0.30 g (81.0%):
mp 162-163oC; n max/cm
-1 3330 (NH), 1782, 1764, 1652 (C=O);  1H-NMR (300 MHz,
CD3OD) d  2.29 (6H, s, CH3 x 2), 2.30 (3H, s, CH3) 7.12-7.20 (1H, m, Ar-H), 7.32-7.40
(2H, m, Ar-H), 7.64-7.70 (2H, m, Ar-H), 7.74 (2H, s, Ar-H); 13C-NMR (75 MHz,
CD3OD) d  19.96 (CH3), 20.36 (CH3), 108.28 (CH) 121.38 (CH), 122.32 (CH), 122.37
(CH), 125.84 (CH), 129.80 (CH), 134.39 (C), 139.57 (C), 145.04 (C), 146.74 (C),
166.03 (C), 168.34 (C), 169.52 (C); FAB-Mass: m/z 372 (M+1).
5.2.3. Synthesis of GBA derivatives
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3,4,5-Trihydroxy-N-[2-(3,4,5-trihydroxbenzoylamino)phenyl]benzamide(56a)
To a stirred solution of 55a (0.66 g; 1.0 mmol) in acetonitrile (20 ml) was added
hydrazine monohydrate (0.29 ml; 6.0 mmol). The mixture was stirred for 30 minutes at
room temperature, then 10% aqueous KHSO4 was added until pH = 3. The total mixture
was extracted with EtOAc (3 x 20 ml), the combined EtOAc extracts were washed with
saturated NaCl solution (10 ml) and H2O (2 x 10 ml) and then dried over MgSO4.
Complete evaporation of the EtOAc was carried out using vacuum pump to give a crude
product which was recrystallized from water to give 56a as yellowish white crystals in
yield of 0.25 g (60.7%): mp 261oC; n max/cm
-1 3479 (OH), 3400 (NH), 1591 (C=O); 1H-
NMR (300 MHz, CD3OD) d  6.87 (4H, s, Ar-H), 7.18 (2H, q, J = 3.60 Hz, Ar-H), 7.47
(2H, q, J = 3.60 Hz, Ar-H); 13C-NMR (75 MHz, CD3OD) d  108.34 (CH), 125.78 (C),
126.87 (CH), 127.18 (CH), 132.85 (C), 138.85 (C), 146.84 (C), 169.04 (C); FAB-Mass:
m/z 413 (M+1); (found C, 58.01; H, 4.11; N, 6.66. C20H16N2O8 requires C, 58.25; H,
3.91; N, 6.79).
3,4-Dihydroxy-N-[2-(3,4-dihydroxbenzoylamino)phenyl]benzamide (56b)(130)
Compound 56b was prepared as described above for compound 56a, starting from 55b
(0.55 g; 1.0 mmol) and hydrazine monohydrate (0.19 ml; 4.0 mmol). A crude product
was formed which was purified by recrystallization from water to give 56b as white
crystals in yield of 0.24 g (63.1%): mp 269-270oC; n max/cm
-1 3295 (OH), 3218 (NH),
1635 (C=O); 1H-NMR (300 MHz, CD3OD) d  6.73 (2H, d, J = 8.40 Hz, Ar-H), 7.16-7.24
(4H, m, Ar-H), 7.31 (2H, d, J = 2.40 Hz, Ar-H), 7.48 (2H, q, J = 3.30 Hz, Ar-H); 13C-
NMR (75 MHz, CD3OD) d  116.06 (CH), 116.12 (CH), 121.04 (CH), 126.63 (C), 126.88
(CH), 127.21 (CH), 132.85 (C), 146.54 (C), 150.82 (C), 168.68 (C); FAB-Mass: m/z
381 (M+1).
4-Hydroxy-N-[2-(4-hydroxbenzoylamino)phenyl]benzamide (56c)
Compound 56c was prepared as described above for compound 56a, starting from 55c
(0.43 g; 1.0 mmol) and hydrazine monohydrate (0.1 ml; 2.0 mmol). A crude product
was formed which was recrystallized from methanol to give 56c as white crystals in
yield of 0.20 g (57.5%) mp >  300oC; n max/cm
-1 3342 (OH), 3233 (NH), 1646 (C=O); 1H-
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NMR (300 MHz, DMSO-d6) d  6.84 (4H, d, J = 8.70 Hz, Ar-H), 7.24 (2H, q, J = 3.45 Hz,
Ar-H), 7.60 (2H, q, J = 3.60 Hz, Ar-H), 7.81 (4H, d, J = 8.40 Hz, Ar-H), 9.87 (2H, s,
OH x 2), 10.14 (2H, s, NH x 2); 13C-NMR (75 MHz, DMSO-d6) d  114.45 (CH), 124.47
(CH), 124.83 (CH), 125.18 (C), 128.74 (CH), 131.05 (C), 160.38 (C), 164.61 (C); FAB-
Mass: m/z 349 (M+1); (found C, 68.68; H, 4.59; N, 7.89. C20H16N2O4 requires C, 68.96;
H, 4.63; N, 8.04).
3,4,5-Trihydroxy-N-[3-(3,4,5-trihydroxbenzoylamino)phenyl]benzamide (56e)
Compound 56e was prepared as described above for compound 56a, starting from 55e
(0.66 g; 1.0 mmol) and hydrazine monohydrate (0.29 ml, 6.0 mmol). A crude  product
was formed which was recrystallized from EtOH: n-hexane to give 56e as white crystals
in yield of 0.25 g (60.7%): mp > 300oC; n max/cm
-1 3377 (OH), 3325 (NH), 1656 (C=O);
1H-NMR (300 MHz, CD3OD) d  6.87 (4H, s, Ar-H), 7.20 (1H, q, J = 7.20 Hz, Ar-H),
7.29-7.33 (2H, m, Ar-H), 7.83 (1H, t, J = 1.95 Hz, Ar-H); 13C-NMR (75 MHz, CD3OD)
d  108.20 (CH), 115.37 (CH), 118.33 (CH), 126.62 (C), 129.89 (CH), 138.44 (C), 140.39
(C), 146.72 (C), 169.15 (C); FAB-Mass: m/z 413 (M+1); (found C, 57.93; H, 3.99; N,
6.50. C20H16N2O8 requires C, 58.25; H, 3.91; N, 6.79).
 
3,4-Dihydroxy-N-[3-(3,4-dihydroxbenzoylamino)phenyl]benzamide (56f)(130)
Compound 56f was prepared as described above for compound 56a, starting from 55f
(0.55 g; 1.0 mmol) and hydrazine monohydrate (0.19 ml; 4.0 mmol). A crude product
was formed which was purified by recrystallization from EtOH: n-hexane to give 56f as
a white crystalline product in yield of 0.27 g (71.0%): mp 280-281oC; n max/cm
-1 3490
(OH), 3348 (NH), 1646 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  6.81 (2H, d, J = 8.10
Hz, Ar-H), 7.23 (1H, t, J = 7.95 Hz, Ar-H), 7.33-7.42 (6H, m, Ar-H), 8.22 (1H, s, Ar-H),
9.41 (2H, s, OH x 2), 9.93 (2H, s, NH x 2); 13C-NMR (75 MHz, DMSO-d6) d  112.94
(CH), 114.87 (CH), 115.49 (CH), 115.67 (CH), 119.66 (CH), 125.98 (C), 128.29 (CH),
139.57 (C), 144.92 (C), 148.82 (C), 165.21 (C); FAB-Mass: m/z 381 (M+1).
4-Hydroxy-N-[3-(4-hydroxybenzoylamino)phenyl]benzamide (56g)(133)
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Compound 56g was prepared as described above for compound 56a, starting from 55g
(0.43 g; 1.0 mmol) and hydrazine monohydrate (0.10 ml; 2 mmol). A crude product was
formed which was purified by recrystallization from EtOH: n-hexane to give 56g as
white crystals in yield of 0.23 g (66.0%): mp >  300oC; n max/cm
-1 3410 (OH), 1643
(C=O); 1H-NMR (300 MHz, DMSO-d6) d  6.86 (4H, d, J = 8.40 Hz, Ar-H), 7.26 (1H, t, J
= 8.10 Hz, Ar-H), 7.44 (2H, d, J = 9.90 Hz, Ar-H), 7.87 (4H, d, J = 8.70 Hz, Ar-H), 8.25
(1H, s, Ar-H), 10.00 (2H, s, OH x 2), 10.10 (2H, s, NH x 2); 13C-NMR (75 MHz,
DMSO-d6) d  112.95 (CH), 114.90 (CH), 115.76 (CH) 125.46 (C), 128.39 (CH), 129.76
(CH), 139.57 (C), 160.53 (C), 165.09 (C); FAB-Mass: m/z 349(M+1).
3,4,5-Trihydroxy-N-[4-(3,4,5-trihydroxybenzoylamino)phenyl]benzamide (56i)(135)
Compound 56i was prepared as described above for compound 56a, starting from 55i
(0.66 g; 1.0 mmol) and hydrazine monohydrate (0.29 ml, 6.0 mmol). A crude product
was formed which was recrystallized from EtOH: n-hexane to give 56i as white crystals
in yield of 0.23 g (56.0%): mp > 300oC; n max/cm
-1 3380 (OH), 3204 (NH), 1649 (C=O);
1H-NMR (300 MHz, DMSO-d6) d  6.94 (4H, s, Ar-H), 7.65 (4H, s, Ar-H); 
13C-NMR (75
MHz, DMSO-d6) d  106.90 (CH), 119.95 (CH), 120.05 (CH), 124.86 (C), 134.50 (C),
136.14 (C), 144.99 (C), 164.76 (C); FAB-Mass: m/z 413 (M+1).
3,4-Dihydroxy-N-[4-(3,4,-dihydroxybenzoylamino)phenyl]benzamide (56j)(130)
Compound 56j was prepared as described above for compound 56a, starting from 55j
(0.55 g; 1.0 mmol) and hydrazine monohydrate (0.19 ml; 4.0 mmol). A crude product
was formed which was purified by recrystallization from EtOH: n-hexane to give 56j as
a white crystalline product in yield of 0.26 g (68.4%): mp > 300oC; n max/cm
-1 3450 (OH),
3311 (NH), 1642 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  6.81 (2H, d, J = 8.40 Hz,
Ar-H), 7.32 (2H, d, J = 2.25 Hz, Ar-H), 7.37 (2H, s, Ar-H), 7.66 (4H, s, Ar-H), 9.25 (2H,
s, OH x 2), 9.87 (2H, s, NH x 2); 13C-NMR (75 MHz, DMSO-d6) d  114.87 (CH), 115.38
(CH), 119.52 (CH), 120.43 (CH), 125.99 (C), 134.93 (C), 144.92 (C), 148.73 (C),
164.99 (C); FAB-Mass: m/z 381 (M+1).
4-Hydroxy-N-[4-(4-hydroxybenzoylamino)phenyl]benzamide (56k)(136)
Compound 56k was prepared as described above for compound 56a, starting from 55k
(0.43 g; 1.0 mmol) and hydrazine monohydrate (0.10 ml; 2 mmol). A crude product was
formed which was purified by silica gel column chromatography using CH2Cl2: MeOH
106
10:1. The obtained oily product was recrystallized from EtOAc: n-hexane to give 56k as
a white crystalline substance in yield of 0.23 g (66.0%): mp >  300oC; n max/cm
-1 3422
(OH), 3324 (NH), 1647 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  6.85 (4H, d, J = 8.70
Hz, Ar-H), 7.68 (4H, s, Ar-H), 7.84 (4H, d, J = 8.70 Hz, Ar-H), 9.93 (2H, s, OH x 2),
10.07 (2H, s, NH x 2); 13C-NMR (75 MHz, DMSO-d6) d  114.88 (CH), 120.51 (CH),
125.46 (C), 129.61 (CH), 134.94 (C), 160.44 (C), 164.85 (C); FAB-Mass: m/z 349
(M+1).
3,4,5-Trihydroxy-N-phenylbenzamide (56m)(139)
Compound 56m was prepared as described above for compound 56a, starting from 55m
(0.37 g; 1.0 mmol) and (0.14 ml; 3.0 mmol). A crude product was formed which was
purified by recrystallization from water to give 56m as white crystals in yield of 0.18 g
(73.5%): mp 211-212oC; n max/cm
-1 3356 (OH), 3276 (NH) 1652 (C=O); 1H-NMR (300
MHz, CD3OD) d  6.96 (2H, s, Ar-H) 7.08-7.12 (1H, m, Ar-H), 7.28-7.34 (2H, m, Ar-H),
7.61 (2H, d, J = 7.50 Hz, Ar-H); 13C-NMR (75 MHz, CD3OD) d _108.28 (CH), 122.34
(CH), 125.32 (CH), 126.79 (C), 129.69 (CH), 138.40 (C), 139.98 (C), 146.73 (C),
169.10 (C); FAB-Mass: m/z 246 (M+1).
5.2.4. Synthesis of AGABT and AGAT derivatives
2,3-Diacetoxy-5-(benzothiazol-2-ylcarbamoyl)acetic acid phenyl ester (58a)
Compound 58a was prepared as described above for compound 55a, starting from 2-
aminobenzothiazole 7 (0.15 g; 1.0 mmol) to give a crude product which was purified by
silica gel column chromatography using CH2Cl2: acetone 25:1 as a mobile phase. The
obtained oily product was recrystallized from EtOAc: n-hexane to give 58a as white
crystals in yield of 0.33 g (77.3%): mp 132-134oC; n max/cm
-1 3286 (NH), 1779, 1754,
1677 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  2.33 (6H, s, CH3 x 2), 2.34 (3H, s, CH3),
7.31-7.36 (1H, m, Ar-H), 7.44-7.49 (1H, m, Ar-H), 7.74-7.79 (1H, m, Ar-H), 7.99-8.05
(1H, m, Ar-H), 8.03 (2H, s, Ar-H); 13C-NMR (75 MHz, DMSO-d6) d  19.86 (CH3), 20.31
(CH3) 121.31 (CH), 121.91 (CH), 123.84 (CH), 126.36 (CH), 130.16 (C), 138.21 (C),
143.28 (C), 166.94 (C), 167.98 (C); FAB-Mass: m/z 429 (M+1); (found C, 56.07; H,
3.81; N, 6.52. C20H16N2O7S requires C, 56.07; H, 3.76; N, 6.54).
2-Acetoxy-4-(benzothiazol-2-ylcarbamoyl)acetic acid phenyl ester (58b)
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Compound 58b was prepared as described above for compound 58a, starting from 53b
(0.25 g; 1.0 mmol) to give a crude product which was purified by silica gel column
chromatography using CH2Cl2: acetone 15:1 as a mobile phase. The obtained oily
product was recrystallized from EtOAc: n-hexane to give 58b as a white crystalline
product in yield of 0.29g (78.6%): mp 182-183oC; n max/cm
-1 3175 (NH), 1775, 1675
(C=O); 1H-NMR (300 MHz, DMSO-d6) d  2.31 (3H, s, CH3), 2.34 (3H, s, CH3), 7.18-
7.52 (3H, m, Ar-H), 7.73 (1H, d, J = 8.1 Hz, Ar-H), 7.99-8.12 (3H, m, Ar-H), 12.98 (1H,
s, NH); 13C-NMR (75 MHz, DMSO-d6) d  20.24 (CH3), 20.32 (CH3), 114.13 (CH),
121.75 (CH), 123.71 (CH), 123.92 (CH), 123.98 (CH), 126.20 (CH), 126.82 (CH),
141.77 (C), 142.02 (C), 145.33 (C), 145.55 (C), 167.84 (C), 168.04 (C), 168.14 (C);
FAB-Mass: m/z 371 (M+1); (found C, 58.32; H, 3.81; N, 7.18. C18H14N2O5S requires C,
58.37; H, 3.81; N, 7.56).
4-(Benzothiazol-2-ylcarbamoyl)acetic acid phenyl ester (58c)(140)
Compound 58c was prepared as described above for compound 58a, starting from 53c
(0.20 g; 1.0 mmol) to give a crude product which was purified by recrystallization from
EtOH to give 58c as white crystals in yield of 0.24g (77.1%): mp 212-213oC; n max/cm
-1
3311 (NH), 1745, 1674 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  2.30 (3H, s, CH3),
7.06-7.48 (4H, m, Ar-H), 7.76-7.78 (1H, d, J = 7.89 Hz, Ar-H), 7.99-8.02 (1H, d, J =
7.89 Hz, Ar-H), 8.06-8.09 (1H, d, J = 8.80 Hz, Ar-H), 8.16-8.19 (1H, m, Ar-H), 12.91
(1H, s, NH); 13C-NMR (75 MHz, DMSO-d6) d  20.74 (CH3), 121.58 (CH), 121.85 (CH),
121.93 (CH) 122.70 (CH), 123.55 (CH), 126.03 (CH), 129.85 (CH),130.69 (CH),
132.22 (C), 132.67 (C), 153.79 (C), 155.42 (C), 168.66 (C); FAB-Mass: m/z 313
(M+1).
N-Benzothiazol-2-yl-benzamide (58d)(141)
Compound 58d was prepared as described above for compound 58a, starting from 53d
(0.14 g; 1.0 mmol), the reaction was carried out in dry THF and was stirred for 6 hours
to give a crude product which was washed several times with ether and dried under
pressure to give 58d as a white precipitate in yield of 0.20 g (78.8%): mp 130oC;
n max/cm
-1 3156 (NH), 1673 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  7.28 (1H, t, J =
7.80 Hz, Ar-H), 7.44-7.63 (5H, m, Ar-H), 7.77 (1H, t, J = 7.05 Hz, Ar-H) 7.96-8.01 (2H,
m, Ar-H); FAB-Mass: m/z 255 (M+1).
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2,3-Diacetoxy-5-(thiazol-2-ylcarbamoyl)acetic acid phenyl ester (61)
Compound 61 was prepared as described above for compound 58a, starting from 2-
aminothiazole 60 (0.10 g; 1.0mmol) to give a crude product which was purified by
recrystallization from EtOH to give 61 as white crystals in yield of 0.28 g (74.1%): mp
205-206oC; n max/cm
-1 3340 (NH), 1774, 1676 (C=O); 1H-NMR (300 MHz, DMSO-d6) d
2.32 (6H, s, CH3 x 2), 2.33 (3H, s, CH3), 7.28 (1H, d, J = 3.90 Hz, Ar-H), 7.556 (1H, d,
J = 3.90 Hz, Ar-H), 7.98 (2H, s, Ar-H); 13C-NMR (75 MHz, DMSO-d6) d  19.77 (CH3),
20.21 (CH3), 113.94 (CH), 121.08 (CH), 130.50 (C), 137.93 (C), 143.23 (C), 166.93 (C),
167.97 (C); FAB-Mass: m/z 379 (M+1); (found C, 50.78; H, 3.71; N, 7.28. C16H14N2O7S
requires C, 50.79; H, 3.73; N, 7.40).
5.2.5. Synthesis of GABT and GAT derivatives
N-Benzothiazol-2-yl-3,4,5-trihydroxybenzamide (59a)
Compound 59a was prepared as described above for compound 56a, starting from 58a
(0.43 g; 1.0 mmol) and hydrazine monohydrate (0.14 ml; 3.0 mmol). A crude product
was formed which was purified by recrystallization from EtOH: n-hexane to give 59a as
white crystals in yield of 0.2 g (66.2%): mp > 300oC; n max/cm
-1 3505 (OH), 3368 (NH),
1673 (C=O); 1H-NMR (300 MHz, DMSO-d6) d _7.07 (2H, s, Ar-H), 7.24 (1H, t, J = 7.60
Hz, Ar-H), 7.37 (1H, t, J = 7.65 Hz, Ar-H), 7.68 (1H, d, J = 8.10 Hz, Ar-H), 7.91 (1H, d,
J = 7.80 Hz, Ar-H); 13C-NMR (75 MHz, DMSO-d6) d  108.00 (CH), 120.26 (CH),
121.61 (CH), 123.45 (CH), 126.07 (CH), 131.54 (C), 138.39 (C), 145.64 (C); FAB-
Mass: m/z 303 (M+1); (found C, 55.37; H, 3.32; N, 9.17. C14H10N2O4S requires C,
55.62; H, 3.33; N, 9.27).
N-Benzothiazol-2-yl-3,4-dihydroxybenzamide (59b)
Compound 59b was prepared as described above for compound 56a, starting from 58b
(0.37 g; 1.0 mmol) and hydrazine monohydrate (0.10 ml; 2.0 mmol). A crude product
was formed which was purified by recrystallization from EtOH to give 59b as a white
crystalline substance in yield of 0.17 g (59.4%): mp 266-267oC; n max/cm
-1 3303 (OH),
3175 (NH), 1648 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  6.84 (1H, d, J = 8.10 Hz,
Ar-H), 7.27-7.32 (1H, m, Ar-H), 7.40-7.46 (1H, m, Ar-H), 7.53 (1H, d, J = 2.40 Hz, Ar-
H), 7.58 (1H,d, J = 2.25 Hz, Ar-H), 7.74 (1H, d, J = 8.10 Hz, Ar-H), 7.97 (1H, d, J =
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7.20 Hz, Ar-H); 13C-NMR (75 MHz, DMSO-d6) d  114.90 (CH), 115.72 (CH), 120.51
(CH), 121.30 (CH), 122.55 (C), 123.16 (CH), 125.75 (CH), 130.54 (C), 144.96 (C),
150.04 (C); FAB-Mass: m/z 287 (M+1).
N-Benzothiazol-2-yl-4-hydroxybenzamide (59c)
Compound 59c was prepared as described above for compound 56a, starting from 58c
(0.31 g; 1.0 mmol) and hydrazine monohydrate (0.05 ml; 1.0 mmol). A crude product
was formed which was purified by silica gel column chromatography using CH2Cl2:
acetone 5:1. The obtained oily product was then recrystallized from EtOAc: n-hexane to
give 59c as a white crystalline substance in yield of 0.18 g (66.7%): mp 258oC; n max/cm
-1
3352 (OH), 3146 (NH), 1675 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  6.83 (2H, d, J =
8.7 Hz, Ar-H), 7.2-7.28 (1H, m, Ar-H), 7.36-7.41 (1H, m, Ar-H), 7.70 (1H, d, J = 7.80
Hz, Ar-H), 7.93 (1H,d, J = 7.20 Hz, Ar-H), 7.99 (2H, d, J = 8.70 Hz, Ar-H), 10.35 (2H,
s, OH x 2), 12.57 (2H, s, NH x 2); 13C-NMR (75 MHz, DMSO-d6) d  115.03 (CH),
121.31 (CH), 122.15(C), 123.20 (CH), 125.77 (CH), 130.34 (CH), 161.49 (C); FAB-
Mass: m/z 271 (M+1); (found C, 62.07; H, 3.76; N, 10.30. C14H10N2O2S requires C,
62.21; H, 3.73; N, 10.36).
3,4,5-Trihydroxy-N-thiazol-2-yl-benzamide (62)
Compound 62 was prepared as described above for compound 56a, starting from 61
(0.38 g; 1.1 mmol) and hydrazine monohydrate (0.14 ml; 3.0 mmol). A crude product
was formed which was purified by recrystallization from EtOH: n-hexane to give 62 as
a white crystalline substance in yield of 0.17 g (67.4%): mp 282-283oC; n max/cm
-1 3339
(OH), 3226 (NH), 1654 (C=O); 1H-NMR (300 MHz, DMSO-d6) d  7.06 (2H, s, Ar-H),
7.19 (1H, d, J = 3.60 Hz, Ar-H), 7.49 (1H, d, J = 3.60 Hz, Ar-H), 9.20 (3H, s, OH x 3),
12.16 (3H, s, NH x 3); 13C-NMR (75 MHz, DMSO-d6) d  107.72 (CH), 113.20 (CH),
122.03 (C), 137.79 (C), 145.64 (C), 164.92 (C); FAB-Mass: m/z 253 (M+1); (found C,
47.40; H, 3.23; N, 10.75. C10H8N2O4S requires C, 47.61; H, 3.20; N, 11.11).
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5.2.6. Biological evaluation of topoisomerases inhibitors
Materials
Topoisomerase I (EC 5.99.1.2) from calf thymus gland and topoisomerase II (EC
5.99.1.3) from human placenta were purchased from TopoGEN. Propidium iodide,
RNase A and calf thymus DNA were purchased from Sigma. Proteinase K, pBR322
DNA and HeLa cell were purchased from Boehringer Mannheim GmbH, MBI
fermentas and from ATCC, respectively. MEM (minimum essential medium), Alamar
Blue reagent were purchased from Gibco and Biosource, respectively. Camptothecin,
etoposide and doxorubicin hydrochloride were obtained from Aldrich, Calbiochem and
Sigma, respectively.
5.2.6.1. DNA relaxation and cleavage assays of topoisomerase I
Relaxation activity of topoisomerase I was determined by detecting the conversion of
supercoiled pBR322 DNA to its relaxed form.(148) Topoisomerase I reaction was
performed in 20 m l of reaction mixture containing 50 mM　Tris-HCl　(pH 7.5), 120 mM
KCl, 10 mM MgCl2, 0.5 mM EDTA, 0.5 mM dithiothreitol, 0.6 m g bovine serum
albumin, tested compound solution in 10% DMSO/MeOH, 1 unit topoisomerase I (20
units for DNA cleavage assay) and 0.15 m g supercoiled pBR322 DNA. Enzyme reaction
proceeded for 40 minutes at 37oC and terminated by adding 5 m l loading buffer
consisting of 200 mM Tris (pH 7.5), 200 mM boric acid, 5 mM EDTA, 50% glycerine
and 10 % bromophenol blue. Fifteen m l of the mixture was subjected to 1.0% agarose
gel electrophoresis at 50V for 60 minutes in 100 mM Tris-borate buffer (pH 8.5)
containing 2.5 mM EDTA. The agarose gel was stained with ethidium bromide and
washed thoroughly with deionized water, and the remaining supercoiled pBR322 DNA
on the gel was measured by a densitometer (Atto Co., AE-6900M). One unit of
inhibitory activity (IC50) was defined as the amount of inhibitor inhibited 50% of the
relaxation of supercoiled pBR322 DNA by 1 unit of topoisomerase I under the above
assay conditions. For DNA cleavage reaction(143), the reaction mixture was terminated
by the addition of 5 m l of  a solution containing 5% SDS and 12.5 mg proteinase K and
incubated for additional 30 minutes at 37oC. Loading buffer was added and the mixture
was run into 1.0% agarose gel containing 0.1% SDS and ethidium bromide (0.5　m g/ml)
at 50V for 2 hours. After agarose gel electrophoresis, the nicked pBR322 DNA on the
gel was measured by a densitometer. The increase of nicked pBR322 DNA
(topoisomerase I-mediated DNA cleavage) was estimated as the stabilization of
cleavable complex by an inhibitor.
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5.2.6.2. DNA relaxation and cleavage assays of topoisomerase II
DNA topoisomerase II reaction was performed(101) in 20 m l of reaction buffer
supplemented with 50 mM Tris-HCl buffer (pH 8.0), 100 mM KCl, 10 mM MgCl2, 0.5
mM ATP, 0.5 mM dithiothreitol, 0.06 m g bovine serum albumin, 0.15 m g supercoiled
pBR322 DNA, tested compound solution in 10% DMSO/MeOH, 1 unit topoisomerase
II. Incubation for 60 minutes at 37oC, followed by the addition of loading buffer (4 m l).
The mixture was electrophoresed in 1% agarose gel in 100 mM Tris-borate buffer (pH
8.5) containing 2.5 mM EDTA and reaction products were quantitated by densitometric
analysis. One unit of inhibition was defined as the amount that inhibits 50% of the
relaxation of supercoiled pBR322 DNA by 1 unit of topoisomerase II under the above
assay conditions. For DNA cleavage activity(144), the same procedure for topoisomerase I
but 10 units topoisomerase II were used. After agarose gel electrophoresis, the increase
of linearized pBR322 DNA (topoisomerase II-mediated DNA cleavage) was estimated
as the stabilizing of cleavable complex by an inhibitor.
5.2.6.3. Cell cycle and cell growth analysis
HeLa cells were grown at 37oC in a humidified atmosphere containing 5% CO2 in MEM
medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 unit/ ml
penicillin and 100 m g/ ml streptomycin. For cell cycle analysis by flow cytometry, HeLa
cells (1 x 106 cells) in exponential growth were treated with inhibitor at several
concentrations for 24 hr. After treatment, the cells were washed with phosphate buffer
saline (PBS; 8.4 mM Na2HPO4.12H2O, 1.5 mM KH2PO4, 136.9 mM NaCl, 2.7 mM KCl,
pH 7.2) and fixed in cold 70% MeOH and stored at -20oC. The cell pellet was incubated
with PBS containing 0.1% RNase A for 40 minutes at 37oC and then 100 m l of
propidium iodide at 500 m g/ ml was added. The cells were analyzed with a flow
cytometer (Becton Dickinson FACS Calibur) using the ModFit LT which is software for
determining the percentage of cells in G0/G1, S and G2/M phases.(126)
HeLa cells (1 x 104 cells/well) were grown for 21 hours in 12-well plate on the same
conditions as the cell cycle analysis. Aliquots of 100 m l of Alamar Blue reagent were
added to each well containing 1 ml of medium. After incubation for 3 hours at 37oC, the
absorbance was read on the plate reader (System Instrument Co., Immuno Mini NJ-
2300) at 560 and 620 nm. Cell growth was calculated from the substracting value of the
dual wavelength (OD560 to OD620).
112
5.2.6.4. DNA Intercalation
CD (circular dichroism) spectral change of DNA was obtained by substracting of the
CD of inhibitor from the CD of DNA with inhibitor. CD spectra was recorded in 50 mM
Tris-HCl buffer (pH 8.0) containing 100 mM KCl, 1 mM MgCl2 and salmon sperm
DNA (25 mg/ml) by a spectropolarimeter (JASCO J-720).
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